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Abstract 
Neovascular diseases of the posterior eye like age-related macular degeneration, 
proliferative diabetic retinopathy or retinopathy of prematurity carry a tremendous 
burden for patient and health care system alike. Although intravitreal injections of anti-
VEGF based therapeutics have significantly improved the visual outcome for many 
patients, current therapeutic options still show significant drawbacks such as the 
injection-related risk of contracting an infection. Due to their ability to encapsulate drugs 
with otherwise poor bioavailability, accumulate in areas of increased vascular 
permeability and control the release of active ingredients over time, nanoparticle systems 
have been widely researched to enhance current therapeutic strategies and expand the 
therapeutic arsenal. In this review, emphasis is placed both on the possibilities and 
drawbacks that a systemic nanoparticle-based therapy could have in the context of 
neovascular posterior eye diseases. Recent investigations into intravenous and intravitreal 
administration of nanomaterials and their potential to deliver potent drugs and genes to 
pathologic lesions will also be presented. Furthermore, we will focus on the exceptional 
anti-oxidative and anti-angiogenic properties of selected nanoscale systems that carve out 
new paths for the treatment of these severe posterior eye diseases. 
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1 Introduction 
Proliferative diseases of blood vessels in the posterior eye are responsible for many cases 
of vision loss every year [1]. The three most common ophthalmologic neovascular 
diseases - exudative age-related macular degeneration (wet AMD), proliferative diabetic 
retinopathy (PDR) and retinopathy of prematurity (ROP) - are among the main causes of 
blindness and severe impairment of visual acuity in children (ROP), working-age adults 
(PDR) and elderly patients (wet AMD) [2–4]. They share pathophysiological mechanisms 
of neovascularization, leading first to fluid accumulation and hemorrhage in the retina 
and finally to retinal detachment and photoreceptor death/degeneration (Fig. 1) [5–7].  
In the healthy eye, a sophisticated balance between pro-angiogenic and anti-angiogenic 
factors tightly controls the formation of new blood vessels [8]. Usually, because anti-
angiogenic factors such as pigment epithelium-derived factor (PEDF) prevail, this 
complex balance is biased to an anti-angiogenic state. Thus, excessive and pathologic 
neovascularizations are normally suppressed. PEDF has potent anti-vascular endothelial 
growth factor (VEGF) activity and is expressed by the retinal pigment epithelium 
(RPE) [9], a cell layer located between the outer segments of the photoreceptors and the 
major underlying blood vessels, the choriocapillaris.  
One strong factor that can push this delicate equilibrium towards pro-angiogenesis is 
hypoxia. Over a prolonged period of time, retinal ischemia leads to hypoxia. 
Concomitantly, expression of hypoxia-inducible factor 1α (HIF-1α) initiates a complex 
signaling cascade that ultimately results in the upregulation of several pro-angiogenic 
factors [10], with VEGF being the most prominent and crucial one (Fig. 1). VEGF, which 
exists in several isoforms, has been shown to be one of the key regulator for pathological 
angiogenesis [11].  
The development of intravitreal therapies targeting VEGF like ranibizumab (Lucentis®), 
bevacizumab (Avastin®), pegaptanib (Macugen®) and aflibercept (Eylea®) were a major 
breakthrough in the treatment of neovascular eye diseases. However, these therapies also 
have drawbacks. Besides the risk related intravitreal injection of the formulation into the 
eye, there are also relevant systemic risks that stem from antibodies which exit the eye and 
enter into systemic circulation [12]. The small but prolonged suppression of the plasma 
VEGF level which may result is postulated to lead to an increased risk of cardiovascular 
diseases like stroke and thromboembolic events [12,13].  
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Figure 1: Simplified schematic representation of hypoxia as one key event in the formation of 
neovascular lesions. Hypoxic conditions lead to the upregulation of HIF-1α, which in turn 
increases expression of VEGF tilting the angiogenic balance towards pro-angiogenesis. This 
results in pathological neovascularizations. AGEs - Advanced glycosylation end products, 
FGF – Fibroblast growth factor, HIF-1α - Hypoxia-inducible factor 1α, PEDF – pigment 
epithelium-derived factor, PDGF – Platelet-derived growth factor, VEGF - Vascular endo-
thelial growth factor, CNV - choroidal neovascularization; RNV - retinal neovascularization. 
Furthermore, because VEGF also plays an important protective role in the retinal tissue 
itself [14], broad and rigorous VEGF knockout in the retina can lead to severe side effects: 
defects in the RPE-choroid complex or the loss of interaction between the RPE and 
photoreceptors’ outer segments [15]. Additionally, VEGF deprivation results in a 
reduction of endothelial cell fenestrations in the choriocapillaris [16], which can in turn 
induce endothelial wall thickening and lead to decreased nutritional support for the 
photoreceptors and RPE [15]. This is also the reason why the therapy with anti-VEGF 
antibodies increased the development of foveal and non-foveal geographic atrophy in a 
number of patients with neovascular AMD [17].  
Therefore, alternative therapeutic concepts would be highly desirable. Unfortunately, the 
eye as a target organ possesses several important superficial and internal barriers that 
Introduction 
15 
impede both direct and systemic drug access [18]. The outer and inner blood-retinal 
barriers (BRB), which consist of tight junctions between neighboring RPE cells and retinal 
endothelial cells, respectively, strictly limit the transport of unwanted molecules from the 
blood stream to the retina. On the other hand, the blood-aqueous barrier (BAB), located 
in the anterior eye segment and formed by the ciliary epithelium and the uveal capillaries, 
prevents drugs from diffusing into the anterior eye from the systemic circulation. In the 
pathogenesis of neovascular diseases of the posterior eye, newly formed vessels sprout 
into the retina or vitreous, infiltrate the ocular tissue and break down the BRBs. In this 
case, the drug’s target tissue is directly accessible from the circulation, circumventing the 
need to cross challenging biological barriers. However, compared to intravitreal injection, 
a substantially higher dose is needed to maintain therapeutic concentrations in the 
pathologic lesions [19]. For instance, just 2.5 mg of bevacizumab are required to achieve 
therapeutic drug levels in the eye with an intravitreal injection, whereas 5 mg/kg 
bevacizumab are needed to achieve the same therapeutic effect after intravenous 
injection [20]. The systemic side effects and elevated cost that result mean that systemic 
therapies with free drug are often unfavorable in comparison. 
In cancer therapy, we find an instructive case study for how encapsulation of therapeutics 
in nanoparticles (NPs) may significantly advance the therapy of neovascular posterior eye 
disease. In both cases, systemic administration of free drug leads to dose-limiting 
toxicities. The physiology is also quite similar; abnormal tumor vasculature and 
pathologic neovascular eye lesions both exhibit enhanced permeability to and retention of 
macromolecules and NPs. In other words, both sets of disease experience the same 
limitations on conventional systemic treatments and are characterized by highly similar 
physiological architectures, where drug delivery is concerned. Thus, we believe that the 
therapeutic index of intravenously injected drugs could be vastly improved by 
encapsulation within NPs. 
Nanoparticle formulations are also of great interest for intravitreally administered drugs, 
with intravitreal injections of drug containing solutions remaining the gold standard for 
therapy of the posterior eye. In this regard, intravitreal delivery is also highly interesting 
for nanomedical applications: The eye’s highly compartmentalised anatomy leads to slow 
elimination of colloidal systems, which may be found in the eye several months after 
application [21]. In addition, since the eye is an immune-privileged organ, some severe 
drawbacks of systemic NP application, such as clearance by the mononuclear phagocyte 
system, can be avoided.  
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This review is a comprehensive systematic overview of nanoparticle systems that were 
investigated for the treatment of retinal and choroidal neovascularization for the therapy 
of AMD, PDR and ROP. Along with drug and gene delivery applications, use of the 
inherent anti-angiogenic and anti-oxidative properties of nanomaterials in the context of 
neovascular ocular diseases is highlighted. Furthermore, this review focuses on the 
opportunities, pitfalls and challenges related to developing systemic nanoscale therapies of 
the previously mentioned neovascular eye diseases. 
2 Ocular diseases related to neovascularizations 
Neovascularizations are a hallmark of a small number of severe eye diseases. Due to its 
enormous metabolic activity, the eye (and particularly, the retina) has the highest oxygen 
consumption of any tissue in the human body [22]. When small capillaries are damaged, 
e.g. through hyperglycemia in diabetes, the retina can rapidly suffer from hypoxic 
conditions; neovascularization sets in to compensate for the lack of oxygen. 
Unfortunately, the newly built blood vessels are often leaky and cause more problems 
than they solve. Below, the epidemiology and current treatment options for the three most 
common neovascular posterior eye diseases will briefly be presented. 
2.1 Age-related macular degeneration 
AMD is the most common cause of vision loss in the elderly [23]. In 2011, it was 
estimated that 6.5 % of the population of the United States over the age of 40 years had 
signs of AMD [24]. Furthermore, it is predicted that the total number of people with 
AMD worldwide will rise to 196 million in 2020 and further to 288 million in 2040 [25]. 
The disease occurs via two processes, either through exudative neovascularizations (called 
“wet” AMD) or by a non-exudative geographic atrophy (often referred to as “dry” 
AMD) [12]. Wet AMD is characterized by pathological neovascularizations that originate 
in the choriocapillaris and break through Bruch’s membrane as well as the RPE. These 
neovascular vessels leak into the subretinal space and often lead to sudden vision loss [26]. 
Although just 10 to 15 % of all patients with AMD suffer from the wet form, this 
exudation and hemorrhage into the retina is primarily responsible for the occurrence of 
rapid vision loss in the entire AMD population. In contrast to wet AMD, dry AMD 
progresses more slowly and is characterized by the appearance of drusen: small, yellowish 
deposits that ultimately lead to atrophy and thinning of the RPE, the choriocapillaris and 
the photoreceptors in the macula. Although vision loss is less aggressive for dry AMD 
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patients, a certain percentage of patients with dry AMD can develop wet AMD [27]. 
Before anti-VEGF therapy was introduced into clinical practice, the neovascular form of 
AMD was mainly treated by laser photocoagulation and photodynamic therapy (PDT) of 
the pathologic lesions, both of which have mediocre therapeutic outcomes [12]. 
Consequently, the development of anti-VEGF treatments represented an enormous 
breakthrough in the standard of care for wet AMD. Besides anti-VEGF antibodies, the 
current palette of anti-VEGF molecules additionally consists of pegaptanib, a VEGF 
binding aptamer and aflibercept, which is a soluble decoy receptor fusion protein [28].  
2.2 Diabetic retinopathy 
DR is the most prevalent microvascular complication of diabetes mellitus [29], a disease 
currently affecting more than 285 million worldwide [30]. Nearly all patients that suffer 
from diabetes for more than 20 years will have at least some symptoms of diabetic 
retinopathy [29]. In 2010, it was estimated that 93 milion people worldwide are affected 
by diabetic retinopathy [31] and that in the United States alone 10,000 people are going 
blind due to diabetic retinopathy every year. Similar to AMD, DR can also be divided into 
proliferating and non-proliferating disease forms. Proliferative diabetic retinopathy 
(PDR) is characterized by pathological neovascularizations that originate in the venous 
side of the retinal circulation and subsequently penetrate through the inner limiting 
membrane into the vitreous cavity [29]. This can result in vitreous hemorrhage, the 
proliferation of fibrous tissue and ultimately, retinal detachment. By comparison, non-
proliferative diabetic retinopathy (NPDR) often occurs in early stages of diabetic 
retinopathy and is characterized by microaneurysms and retinal hemorrhages that are a 
consequence of sustained hyperglycemia in diabetic patients. Until recently, the standard 
of care treatment for PDR has been pan-retinal photocoagulation (PRP) [32], in which 
peripheral VEGF-releasing retinal cells are destroyed. Moreover, because the overall 
retinal oxygen demand by the outer retina is reduced, more oxygen is available for the 
macula, preserving the important central vision. Based on the results of the RISE and 
RIDE phase 3 trials [33], the US Food and Drug Administration (FDA) approved 
Lucentis® Breakthrough Therapy for the treatment of diabetic macular edema. Both trials 
impressively showed that patients under anti-VEGF therapy were less likely to develop the 
proliferative form of DR. However, for therapy of PDR, all anti-VEGF therapies were 
beneficial and effective but only in the short-term. Compared to the gold standard PRP, 
whose therapeutic effects are remarkably long-lasting [32], the anti-VEGF substances did 
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not have a similarly sustained impact. Furthermore, in a few patients with severe PDR, 
bevacizumab caused tractional retinal detachment [34]. 
2.3 Retinopathy of Prematurity 
Around 10 % of all births worldwide occur preterm [35]. Of these preterm births, 73 % of 
infants with a gestational age of 27 weeks or less are prone to develop ROP [36], a 
condition which blinds around 50,000 children worldwide every year [37]. The most 
important risk factor for the development of ROP is the supplemental oxygen found in 
neonatal incubators. On one hand, supplemental oxygen significantly improves the 
survival of preterm infants, but on the other hand, it contributes heavily to the 
pathogenesis of ROP [5]. In the first phase, hyperoxia leads to suppression of angiogenic 
growth factors like erythropoietin and VEGF [5]. This halts physiological vessel growth. 
After the neonatal oxygen therapy is finished, the matured retina, which has an increased 
metabolic activity, experiences hypoxic conditions. The local hypoxia upregulates pro-
angiogenic growth factors stimulating neovascularization. However, the newly formed 
blood vessels are leaky and insufficiently perfuse the retina [5]. This results in fibrous 
scarring, which can cause retinal detachment and subsequently lead to blindness [38]. To 
date, the standard therapy for ROP has been laser or cryoablation of the peripheral 
avascular retina with the goal of controlling pathologic neovascularizations [5]. However, 
due to the limited efficiency and high morbidity, anti-VEGF treatments have recently 
been investigated as an alternative [2]. Although successful for many children, treatment 
with bevacizumab did not show significant results for neovascularizations in all retinal 
areas. Moreover, because a rigorous VEGF knockdown is highly detrimental for the 
developing retina, the right dose of antibody must be carefully titrated to inhibit 
pathologic neovascularizations but allow normal vascular development [39]. For this 
reason, alternative VEGF-independent strategies would be incredibly beneficial in the 
treatment of ROP.  
3 Systemic nanoparticle therapy – Opportunities and Challenges 
3.1 Is there a need for a systemic therapy? 
Discovery of the anti-VEGF antibodies ranibizumab (Lucentis®) and bevacizumab 
(Avastin®) as well as the anti-VEGF aptamer pegaptanib (Macugen®) were a major 
breakthrough in the therapy of eye diseases that are characterized by neovascularization 
and exudation. Lucentis®, Macugen® and Eylea® have the FDA approval for the treatment 
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of AMD, whereas Avastin® is approved for treatment of several forms of cancer and is 
used on an off-label basis for AMD therapy, mainly due to its significantly lower cost per 
dose [40]. Especially for AMD, antibody-based therapeutics were the first to not only 
prevent vision loss but also significantly improve visual acuity. Compared with 
intravenous administration, intravitreal dosing reduces systemic exposure and requires a 
500-fold reduced dose of antibody [19]. As such, the therapeutics are usually administered 
intravitreally once every four weeks. Although highly beneficial, ocular injections are 
associated with patient discomfort and carry attendant risks. These include infection, 
bleeding, inflammation and more severe side-effects like elevated intraocular pressure, 
endophthalmitis and detachment of the retina [41,42]. Besides injection-related risks, the 
patient and the patient’s caretaker must visit the ophthalmologist’s office on a monthly 
basis. Furthermore, the economic burden that is connected to the frequent intravitreal 
injections should not be underestimated [43]. 
With less invasive therapeutic options, the current treatment burden for anti-VEGF 
therapy could be enormously reduced. Here, a safe systemic therapy using nanoparticles 
to deliver potent drugs and genes to the ocular tissue could be highly beneficial.  
3.2 Importance of choroidal blood flow in systemic delivery 
The retina has by far the highest oxygen consumption of any tissue in the human body, as 
a direct consequence of the photoreceptor’s tremendous metabolic activity [22]. This 
activity leads to the generation of an enormous amount of heat, which can severely 
damage the photoreceptors if it is not dissipated [44]. The choroid, which acts as the 
predominant of the two retinal blood supplies supports the immense oxygen and 
nutrients needs of the retina, removes waste products like lactic acid and actively controls 
retinal temperature via cooling or heating [45]. This is accomplished by an incredibly 
high blood flow through the choroid, which far exceeds the perfusion of all other vascular 
beds within the human body (Fig. 2). Compared to the brain, the blood flow which 
transits the choroid is 10 times higher per unit tissue weight [46], reaching values up to 
2000 mL/min/100 g tissue [47].  
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Figure 2: Rate of blood flow normalized to weight in several tissues as measured in cynomolgus monkeys . 
(Adapted from [46,47])  
For a nanoparticle formulation to successfully accumulate within a specific tissue after 
systemic administration the colloids need to have long circulation time and the site must 
be well-perfused and readily accessible. Here, the enormous blood flow through the 
choroid is very useful for delivering nanoparticles to ocular tissue. Although AMD and 
PDR can lead to a decrease in choroidal blood flow [48,49], the perfusion is still immense 
and thus very favorable for the deposition of nanomaterials in ocular tissue. 
3.3 Passive accumulation via an EPR-like effect 
The enhanced permeability and retention (EPR) effect of tumors was originally observed 
by Maeda and Matsumura nearly 30 years ago [50]. When tumors reach a certain size, 
tumor cells far away from existing vessels become hypoxic due to limited diffusion of 
oxygen into the neoplastic tissue [8]. As a result of hypoxia, the expression of pro-
angiogenic molecules such as VEGF and angiostatin are highly upregulated [51]. This 
leads to rapidly growing, pathological neovascularizations that show a multitude of 
structural aberrations. The trademarks of this ill-formed vasculature are wide intercellular 
clefts between endothelial cells and a disrupted or absent basement membrane [52]. 
Additionally, high intratumoral VEGF concentration causes the endothelial lining to be 
packed with wide fenestrations [53]. These abnormalities lead to extravasation and thus 
passive accumulation of macromolecules and nanoparticles into the tumor tissue. 
Furthermore, the absence of lymphatic vessels in the tumor architecture results in 
retention of accumulated macromolecules and NPs. Discovery of the EPR effect was the 
starting point for the development of a plethora of polymeric drugs and nanoparticles for 
cancer therapy.  
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Figure 3: Schematic depiction of passive nanoparticle accumulation in the subretinal space as a result of 
choroidal neovascularizations that breach the RPE. 
A similar but not identical situation can be found in neovascular pathological lesions in 
the eye. As originally observed for high molecular weight polymers and polymer-drug 
conjugates at the beginning of the century [54–56], intravenously administered 
macromolecules showed increased accumulation in the CNV areas and were retained for 
a prolonged time in the eye. The cause of this passive accumulation may be found in the 
morphology of the CNV lesions themselves: Similar to the conditions in tumor 
vasculature, ocular neovascular membranes have fenestrations [57,58] that allow NPs to 
extravasate. Moreover, before maturing, the vessels of the leaky lesions exhibit open 
interendothelial clefts [59], through which leakage can occur. Upon maturation, the 
interendothelial junctions close, but the fenestrations remain [59]. Because the eye lacks a 
functional lymphatic system – it is characterized instead by the presence of prelym-
phatics [60] - accumulated nanoparticles are retained around the neovascularized areas 
where they may then release drugs and exert their effects. In the context of tumor therapy, 
the EPR effect is often overestimated [61,62]. Although artificial tumor xenografts in mice 
exhibit a strong EPR effect, several “naturally grown” human tumors do not [63]. This is 
one of the main reasons many nanoparticle systems fail in human trials, even though they 
demonstrated potency in animal studies [62]. Two important reasons for this discrepancy 
are high tumor cell density and high interstitial fluid pressure (IFP), hypothesized to be 
the main barriers for macromolecules and NPs to deeply penetrate tumor tissue [64]. The 
high IFP is a consequence of the EPR effect itself, namely the increased permeation of 
fluid into the tissue and the lack of lymphatic drainage, but it is also a result of the dense 
collagen network in the tumor extracellular matrix [65]. This situation is slightly different 
in ocular tissue. In the eye, when the outer BRB breaks down due to subretinal 
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neovascularizations, intense exudation creates a fluid pressure gradient for proteins [66], 
other macromolecules and NPs. In addition, blood vessel defects, especially in advanced 
disease, can be more pronounced, resulting in not only fluid leakage but also bleeding into 
the surrounding tissue. This hemorrhage into the retina can be one of the first signs of wet 
AMD [27] and one of the main reasons for the loss of visual acuity [67]. Overall, 
compared to the tumor EPR effects, the EPR effect exerted by neovascularities in ocular 
tissue is potentially even greater. Thus, especially in advanced and end-stage 
neovascularizations, the capability of macromolecules and nanoparticles to passively 
accumulate in ocular lesions strongly suggests a path toward effective systemic 
administration. 
3.4 Initial use of the ocular EPR effect with the photosensitizer Visudyne®  
Visudyne® is a liposomal formulation of the photosensitizer verteporfin that was 
approved by the FDA in 2000 for the therapy of occult subfoveal choroidal 
neovascularizations in AMD [12,68]. Its application is a two-step process which involves 
intravenous application of Visudyne® followed by activation by shining infrared light 
directly into the eye. After injection, the liposomes encapsulating verteporfin 
preferentially accumulate in the abnormal and leaky blood vessels in the eye. Thus, 
Visudyne® was the first commercially available and systemically administered 
pharmaceutical product that exploited the unique neovascular environment in the eye. 
Because of the large amount of unsaturated phosphatidylglycerols and the absence of 
cholesterol in the formulation, Visudyne® liposomes are characterized by a high level of 
membrane disorder and are easily destabilized [69]. Therefore, in the presence of serum, 
the hydrophobic photosensitizer is rapidly transferred from the liposomal formulation to 
lipoproteins such as low density lipoprotein (LDL) [70]. By virtue of the EPR effect, these 
also accumulate at neovascular sites and are taken up by endothelial cells, which usually 
have increased expression of LDL receptors [71]. Upon activation with infrared light, the 
photosensitizer generates reactive oxygen species (ROS) like singlet oxygen and free 
radicals. The cytotoxic radicals damage the pathologic neovascularizations and “close” the 
abnormal blood vessels.  
However, the clinical efficacy of Visudyne® was not overwhelming [72], which prompted 
researchers to evaluate new photosensitizers as well as new nanoparticle formulations for 
the photodynamic therapy of CNV. Ideta and coworkers designed a dendrimer-based 
photosensitizer, where a porphyrin molecule is surrounded by poly(benzyl ether) 
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dendrons [73]. This architecture inhibits photosensitizer aggregation, thus preventing 
self-quenching effects [74]. In a model of CNV initiated by laser-induced 
photocoagulation, a micellar formulation of the dendrimer-based photosensitizers 
accumulated in the neovascular lesions and resulted in a 280-fold increase in 
phototoxicity, which led to significantly reduced fluid leakage from the 
neovascularizations [73]. Since a distinct upregulation of VEGF after PDT can lead to 
CNV regrowth [75], another approach combined PDT with an anti-VEGF therapy in 
targeted liposomes [76]. Sorafenib, an active multi-kinase inhibitor that targets VEGF 
receptor tyrosine kinase signaling, and photocyanine as photosensitizer were encapsulated 
in liposomes which were toxic to human umbilical vein endothelial cells (HUVECs) but 
showed no toxicity to RPE cells in vitro. In a mouse model of laser-induced CNV the 
targeted liposomes loaded with both substances exhibited the lowest CNV area and 
leakage [76]. When verteporfin was incorporated into cationic liposomes, photodynamic 
therapy of the neovascular lesions was as effective as Visudyne® but induced less damage 
in the surrounding tissue, showing a more specific accumulation [77]. Cationic 
nanoparticles preferentially bind to angiogenic endothelial cells due to an increased 
exposure of anionic molecules on the proliferating blood vessel surface [78], a 
phenomenon that has also been thoroughly investigated for targeting of tumor 
vasculature [79]. Likewise, compared to cationic liposomes, neutral liposomes showed no 
specific accumulation at the angiogenic sites in the eye [80]. 
3.5 Active targeting of nanoparticles to the posterior eye 
In the early stages of neovascular diseases, where an effective treatment would be highly 
desirable, the capillaries are less leaky and dislocated, preventing extensive passive 
accumulation of nanoscale carriers. In this case, to successfully target the endothelial 
lining in the choriocapillaris and the intraretinal capillaries, where cells proliferate under 
increased VEGF concentrations, high affinity targeting strategies have to be applied. By 
far the most widely used approach to actively target NPs to neovascular lesions is 
attachment of the arginine-glycine-aspartate (RGD) peptide sequence to the nanoparticle 
corona. The RGD sequence is capable of binding several integrins, including αvβ3 and 
αvβ5: two common integrins that are pivotal for the formation of new blood vessels and 
are upregulated in the angiogenic state [81]. The reason for this sharp upregulation is the 
function of the αvβ3 integrin: during angiogenesis, it provides endothelial cells with the 
capability of migrating and attaching to extracellular matrix in the process of 
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remodeling [82]. Conversely, in the healthy, non-proliferative choroid, the expression of 
both integrins is only minimal [83]. Interestingly, in the normal healthy eye, nanoparticles 
coupled to linear RGD sequences were unable to bind to intact vasculature and did not 
significantly accumulate [84,85]. However, when a cyclic RGD peptide was coupled to the 
colloidal surface, NPs were able to target and bind healthy capillaries (Fig. 4) [86]. Due to 
the conformational restriction imposed by cyclization, cyclic RGD peptides exhibit 
approximately 100-fold higher integrin affinity than their linear counterparts [87], which 
is reflected in the increased NP binding in the choroid, despite only low-level integrin 
expression. During the pathogenesis of neovascularities, integrin expression 
tremendously increases [88]. We hypothesize that this enables binding of nanoparticles 
coupled to low-affinity ligands like linear RGDs to the endothelium due to increased 
avidity of multivalent binding to the vasculature (Fig. 4). Because NPs display multiple 
identical ligands on their surface, they have the capability to bind several receptors 
simultaneously [89]. Although the affinity of one ligand to the receptor does not change, 
the higher expression of integrin receptors leads to multiple nanoparticle-receptor 
interactions, higher avidity of interaction and subsequently stronger association. 
 
Figure 4: Association of RGD-modified nanoparticles with the ocular vasculature. Cyclo(RGD)-NPs bind 
the retinal vasculature in early and late stages of disease, whereas linear RGD-NPs only bind the 
pathological vessels (a). The cyclo(RGDfC)-modified NPs accumulate in the choriocapillaris (b, top) 
and intraretinal capillaries (b, bottom) of healthy retinae after systemic administration [86]. 
However, besides the targeting function for which the RGD peptides are primarily used, 
they also have intrinsic anti-angiogenic activity. Because of their ability to antagonize 
integrins after binding [90], the cyclic peptides showed a potent inhibitory effect on 
choroidal [54] and retinal neovascularizations [91]. Furthermore, RGD peptides also seem 
to have a positive effect on fibrovascular remodeling during the progression of 
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neovascular diseases in the eye [92]. This inherent anti-fibrotic activity [93] is also a 
consequence of the antagonistic effects of small RGD peptides on αv integrins.  
One of the first examples to show the feasibility of RGD peptide-mediated targeting to 
neovascular lesions was conducted by Singh et al. [84]. They encapsulated a plasmid 
encoding a VEGF intraceptor within poly(lactide­co­glycolide) (PLGA) nano-
particles [84]. The intraceptor is a recombinant construct of the VEGF receptor 1 and is 
coupled to an endoplasmic reticulum (ER) retention signaling sequence, which prevents 
secretion of endogenous ER proteins. With the help of this VEGF intraceptor, VEGF is 
intracellularly bound and degraded without exerting its effects [94]. Interestingly, NPs 
that were not surface-functionalized showed only minute accumulation in the laser-
treated eyes. It is possible that their large size of ~400 nm [94] prevented them from 
extravasating and accumulating passively. However, by introducing linear RGD peptide 
and transferrin targeting moieties onto the surface of the PLGA nanoparticles, NP 
accumulation within the laser-treated eye could be significantly increased. Concomitantly, 
delivery of the intraceptor plasmid and thus CNV lesion therapy could be markedly 
enhanced [84]. In a follow-up study this effect could be translated to primates. Here, the 
systemic administration of RGD-functionalized PLGA nanoparticles encapsulating the 
VEGF intraceptor plasmid was more efficient than the standard therapy of intravitreal 
anti-VEGF antibodies [92].  
3.6 Size does matter: the eye as systemic nanoparticle target 
Despite the excellent specific perfusion rates of the posterior eye segment, the eye is one of 
the smaller organs in the body. The accumulation of nanomaterials follows a perfusion-
driven distribution into the organs, where bigger organs have a natural advantage. In one 
of our own studies we analyzed the deposition of cyclo(RGD)-modified NPs in the 
choroid; we were able to deposit 3.3 ± 0.7 % of the injected dose per g organ weight 
(% ID/g) into the choroid [86]. Compared to the kidney (1.6 % ID/g) and the heart (1.5 % 
ID/g) the nanoparticle content in the choroid was significantly higher, whereas it was 
comparable to the nanoparticle content in the lung (4.4 % ID/g). Although this might 
seem like a high deposited dose into the healthy, non-leaky vascular tissue, it is easy to 
overestimate the amount of accumulated nanoparticles. When not adjusted to the weight 
of the choroid only 0.14 ‰ ± 0.016 ‰ of the total injected dose was deposited after 1 hour 
of nanoparticle circulation [86]. In our experiments, the eye and the choroid had masses 
of 0.19 % and 0.013 % body weight, respectively, which are minuscule compared to the 
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weights of tumor xenografts that easily reach up to 10 % body weight, especially in fast-
growing implanted tumors. Although the percent dose per gram of tissue may be lower 
here, the actual deposited dose is of course much higher. Nevertheless, during the 
progression of neovascular diseases in the eye and with the leakiness of abnormal vessels, 
nanoparticle accumulation greatly increases (see EPR-like effect). Taken together, this 
means that in the early stages of retinal disease in which capillaries are not yet leaky and 
dislocated, highly effective targeting strategies are needed to deliver a sufficient dose for a 
successful therapy. That being said, unless the circulation time of NPs greatly increase 
from what is presently possible, the majority of colloids will not end up in ocular tissue. 
3.7 Bruch’s membrane as the main barrier after systemic administration 
Although potent targeting strategies are able to bind NPs to the vasculature in early stages 
of retinal disease [86], the actual cause for CNV may occur elsewhere. The retinal pigment 
epithelium (RPE), the key component of the outer blood-retinal-barrier (oBRB), has a 
central role in the pathogenesis of AMD. Impairment of RPE cell functions can be an 
initial and deciding event leading to the clinical signs of AMD [95]. Furthermore, VEGF 
secretion by the RPE, which is pivotal for maintenance of the choriocapillaris, is also 
speculated to itself induce CNV [1]. Therefore, a nanoparticle therapy targeted to the RPE 
to tackle the early stages of AMD could be incredibly beneficial. Although several reports 
show the feasibility of RPE targeting with NPs in vitro [96–99] and in vivo after 
intravitreal [21,100] and subretinal injection [101–103], in vivo data describing systemic 
administration of NPs targeted to RPE cells before neovascularizations take place is 
scarce. 
Like the photoreceptors, the RPE is supplied by the choroid and especially the 
choriocapillaris. Between the choriocapillaris and the RPE lies Bruch’s membrane (BM), a 
2-4 µm acellular, five-layered extracellular matrix (Fig. 5). Interestingly, the endothelial 
lining of the choriocapillaris that faces Bruch’s membrane is highly fenestrated, 
potentially allowing NP extravasation towards Bruch’s membrane in the extravascular 
space (Fig. 5). However, the capillaries’ fenestrations are limited to a diameter of 
approximately 80 nm and feature a fenestral diaphragm [104]. Additionally, an 
endothelial glycocalyx surrounds the fenestrations and further reduces the pore size. 
These ultrastructural properties already heavily limit the passage of macromolecules and 
nanoparticles through the fenestrae [105]. However, the most effective barrier to 
nanoparticle passage to the RPE is the five-layered Bruch’s membrane. 
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Figure 5: Schematic overview of nanoparticle transport to the RPE. After leaving the fenestrated chorio-
capillaris the NP has to cross the five-layered Bruch’s membrane, consisting of a central elastic layer, 
two collagenous layers and the RPE and choriocapillaris basal laminae (adapted from [27]). 
Although earlier studies suggested a molecular exclusion limit of 100- 200 kDa for 
crossing Bruch’s membrane, depending on patient age [106], more recent studies show 
that LDL with a size of 19 – 23 nm and a mass up to 3900 kDa are able to pass through. 
Even though LDL, which has a size comparable to small NPs and micelles, cannot pass 
completely freely, its transport is only modestly inhibited [107]. Similarly, 20 nm gold 
NPs were also found to pass the BRB and distributed throughout the retina [108]. 
However, it is unclear if the gold NPs also passed through Bruchs’ membrane or if they 
exclusively reached the retina by transiting the inner blood-retinal barrier. Similar to all 
basement membranes throughout the body, Bruch’s membrane consists of proteoglycans 
and several other proteins [106]. Its glycosaminoglycan moieties are highly negatively 
charged and decrease the mobility of negative charged NPs by electrostatic 
repulsion [109]. Therefore, for NPs to effectively cross through the Bruchs’ membrane, 
they have to be relatively small (probably <25 nm) and most likely possess a neutral or 
positive surface charge [110,111]. Negatively charged PLGA NPs with a size of ~400 nm 
were only able to transfect the RPE after CNV was induced and the BRB was 
damaged [84]. Interestingly, the amount of glycosaminoglycans in Bruch’s membrane and 
their degree of sulfation decreases with age [112], which possibly weakens the charge-
selective barrier for NPs in elderly patients. With respect to the passage of NPs, the 
structure of the choriocapillaris, Bruch’s membrane and the RPE are similar to that of the 
renal filter. As such, NPs that are able to deliver a payload to the RPE have to be very 
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precisely tailored regarding their size, charge and plasticity, making them similar to 
nanomaterials designed to be filterable by the kidneys [113]. 
However, the permeability of Bruch’s membrane is drastically decreased in an aged eye 
and further still in AMD [114]. Thickening of Bruch’s membrane, drusen formation 
[115], the accumulation of cholesterol [116] and basal linear and laminar deposits [117], 
further complicate the passing of NPs through Bruch’s membrane. Nevertheless, once a 
NP encounters the RPE, sophisticated active targeting strategies are not necessarily 
required, since the RPE is among the most phagocytically active tissues in the body [118]. 
Potentially, that could lead to natural endocytosis of the NPs once within reach of the 
cells, and further to therapeutic activity at the RPE. 
4 Intravitreal nanoparticle therapy 
4.1 Nanoparticle systems for ocular gene therapy  
Gene therapy, which can be defined as the transfer of nucleic acids into a cell, tissue or 
organ [119], ultimately aims to treat the cause rather than the symptoms of a disease. This 
can either happen by the introduction of corrective genes into cells or by blocking 
malfunctioning genes using RNA interference mechanisms. However, the lack of efficient 
and safe viral and non-viral delivery systems has posed substantial problems for gene 
therapy applications in the past. Here, non-viral nanoparticles can tremendously help not 
only to compact the DNA but also to protect it and effectively deliver it to the target 
tissue. The eye is an ideal candidate for gene therapy especially in the context of 
intravitreal injections because of several outstanding features. First, its highly 
compartmentalized anatomy allows precise delivery of nanoparticle vectors into specific 
tissues in the eye, which concomitantly minimizes systemic dissemination [120]. Second, 
since the ocular tissue consists of a stable population of cells, highly efficient transduction 
with adequate longevity can be expected [120]. And last, due to the eye’s immune 
privilege, an immunogenic response can be mostly avoided [121]. For ocular applications, 
several different modalities of gene therapy and gene delivery have been investigated for 
the nanoparticle-based treatment of choroidal and retinal neovascularizations (Table 1). 
In recent approaches, gene therapy has been mainly used to modulate the expression of 
VEGF, the key regulator of angiogenesis and vascular permeability. The two most 
prominent strategies used were (1) increasing the expression of VEGF-capturing 
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molecules or anti-angiogenic factors or (2) directly decreasing the VEGF expression or 
manipulating VEGF-signaling cascades.  
Table 1 
Gene delivery approaches for treatment of experimental CNV using NPs 
Incorporated 
gene 
Type of NP 
NP 
size 
Targeting 
ligand 
Injection 
route 
CNV model Outcome Refs. 
Anti-VEGF sense 
oligonucleotide 
Lipid-lysine 
dendrimer 
n/a none IVT Laser 
photocoagulation 
FA leakage↓ [122] 
[123] 
Plasminogen 
kringle 5 pDNA 
PLGA-chitosan 
NPs 
260 
nm1 
none IVT OIR, streptozotocin-
induced DR 
VEGF 
expression↓ 
FA leakage↓ 
[126] 
Hypoxia-
inducible factor 
1α shRNA pDNA 
PLGA NPs 303 
nm 
none IVT Laser 
photocoagulation 
FA leakage↓ [127] 
VEGF receptor 1 
siRNA 
PEGylated 
liposome-
protamine-
hyaluronic acid 
NPs 
132 
nm1 
none IVT Laser 
photocoagulation 
CNV Area↓ [98] 
Soluble VEGF 
receptor 1 pDNA 
PEG-b-
PASp(DET) 
micelles  
n/a none IV Laser 
photocoagulation 
CNV Area↓ [167] 
ATPµ-Raf pDNA cationic 
polymerized 
lipid-based NPs 
45 
nm1 
linear RGD IV Laser 
photocoagulation 
CNV Area↓ 
 
[85] 
Anti-VEGF 
intraceptor pDNA 
PLGA NPs 375-
420 
nm1 
linear RGD, 
transferrin 
IV Laser 
photocoagulation 
VEGF 
Expression↓ 
CNV Area↓ 
[84] 
Anti-VEGF 
intraceptor pDNA 
PLGA NPs 570 
nm1 
linear RGD IV Laser 
photocoagulation, 
soluble VEGF 
receptor knockdown 
CNV Area↓ 
Fibrosis↓ 
Vision 
function↑ 
[92] 
CNV, choroidal neovascularization; DR, diabetic retinopathy; FA, fluorescein angiography; IV, intravenous; 
IVT, intravitreal; OIR, oxygen-induced retinopathy; nanoparticle; PEG-b-PASp(DET), poly(ethylene 
glycol)-b-poly{N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide}, pDNA, plasmid DNA; PLGA, 
poly(lactide-co-glycolide); shRNA, small hairpin RNA; siRNA, small interfering RNA; VEGF, vascular 
endothelial growth factor 
1 as measured by dynamic light scattering  
One of the first examples of nanomaterial-based intraocular gene therapy to decrease the 
VEGF expression was demonstrated by Marano and coworkers nearly 10 years ago. By 
synthesizing a lipid-lysine dendrimer they were able to deliver a sense oligonucleotide 
with anti-VEGF activity into the choroidal lesions. Interestingly, eyes that were subject to 
photocoagulation two months after intravitreal injection of the dendrimer-
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oligonucleotide complex still showed smaller CNV areas, illustrating the longevity of the 
anti-CNV activity [122]. The complexes not only inhibited CNV development for several 
months, but were also found throughout the whole retina up to the RPE and showed no 
apparent toxicity [123]. Similarly, PEGylated cationic liposomes loaded with small 
interfering RNA (siRNA) targeted to VEGF receptor 1 mRNA lowered the CNV area after 
intravitreal injection [98]. For delivery of plasmids encoding anti-angiogenic proteins, 
nanoparticles made of FDA-approved PLGA have been most extensively investigated for 
ocular applications. As polyesters, PLGA nanoparticles are biodegradable. After injection, 
they undergo hydrolysis and release their payload in a sustained fashion [124]. 
Furthermore, by incorporating the plasmid into the PLGA matrix it can be effectively 
protected against degradation by nucleases [125]. Using a plasmid encoding the 
plasminogen kringle 5, a potent anti-angiogenic polypeptide consisting of 80 amino acids, 
expression of VEGF and intracellular adhesion molecule-1 (ICAM-1) could be 
lowered [126]. In a diabetes model, intravitreal injection of plasminogen kringle 5 
plasmid-loaded PLGA nanomaterials ameliorated retinal damage [126]. PLGA 
nanoparticles encapsulating a plasmid encoding hypoxia-inducible factor 1α (HIF-1α) 
small hairpin RNA (shRNA) resulted in significantly reduced leakage from neovascular 
lesions after intravitreal administration [127]. HIF-1α regulates the transcription of pro-
angiogenic factors like VEGF (Fig. 1); this is why therapeutic interference with shRNA 
leads to decreased VEGF expression [127].  
4.2 Nanoparticle systems for improved drug delivery 
Incorporating a drug into a nanomaterial can offer several advantages over the 
administration of the free drug. Nanoparticle-mediated drug delivery allows for 
prolonged release from the nanocarriers resulting in improved drug bioavailability [128]. 
In addition, when loaded into a nanoparticle system the effective aqueous solubility of the 
drug can be greatly increased and its degradation prevented [128]. A summary of 
intravitreal and intravenous drug delivery approaches can be found in Table 2. The 
controlled release of active substances from nanoparticles holds great potential for ocular 
applications by increasing the dosing interval between intravitreal injections. However, 
release of the drug from the nanoparticles has to be precisely tuned and controlled. For 
example, intravitreal injections of bevacizumab encapsulated in PLGA NPs were unable 
to prolong decreases in the area of CNV lesions compared with bevacizumab injections 
alone [129]. Excluding antibodies and other macromolecules, which already have an 
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acceptable vitreal half-life of 6 to 10 days [130], sustained release from NPs significantly 
favors small drugs with very low vitreal half-lives like triamcinolone acetonide or 
dexamethasone acetate.  
Table 2 
Drug delivery approaches for treatment of experimental CNV using NPs 
Incorporated 
drug 
Type of NP 
NP 
size 
Targeting 
ligand 
Injection 
route 
CNV model Outcome Refs. 
Combrestatin A4 PEGylated 
liposomes 
116 
nm1 
linear RGD IV Laser 
photocoagulation 
FA leakage↓ 
CNV Area↓ 
[168] 
C16Y PLA/PLA-PEG 
NPs 
302 
nm1 
none Sub-retinal Laser 
photocoagulation 
CNV Area↓ [138] 
Bevacizumab PLGA NPs 819 
nm 
none IVT Laser 
photocoagulation 
CNV Area↓ [129] 
Antagonistic 
peptide for VEGF 
receptor 1 
Selfassembled 
hyaluronate-
peptide 
micelles  
234 
nm2 
none IVT Laser 
photocoagulation, 
Streptozotocin-
induced DR 
FA leakage↓ [135] 
Genistein Selfassembled 
hyaluronate-
peptide 
micelles  
172 
nm1 
none IVT Streptozotocin-
induced DR 
Vascular 
hyperper-
meability↓ 
[137] 
Doxorubicin PEG-PSA NPs 650 
nm1 
none IVT Laser 
photocoagulation, 
OIR, VEGF-
overexpressing mice 
CNV Area↓ [140] 
Paclitaxel, 
Paclitaxel 
succinate 
Cationic 
liposomes 
n/a none IV Laser 
photocoagulation 
CNV Area↓ [77] 
Triamcinolone 
acetonide 
PLA NPs 551 
nm2 
none Subcon-
junctival 
Laser 
photocoagulation 
Higher release 
due to CNV 
[132] 
Dexamethasone 
acetate 
PLGA NPs 253 
nm1 
none IVT Laser 
photocoagulation 
CNV Area↓ 
Fibrosis↓ 
[131] 
TNP-470 
(Fumagilin 
analog) 
mPEG-PLA 
micelles[169] 
8 nm 
[169] 
none IVT, PO Laser 
photocoagulation 
CNV Area↓ 
Fibrosis↓ 
Pro-
inflammatory 
cytokines↓ 
[170] 
CNV, choroidal neovascularization; DR, diabetic retinopathy; FA, fluorescein angiography; IV, intravenous; 
IVT, intravitreal; NP, nanoparticle; OIR, oxygen-induced retinopathy; PEG, poly(ethylene glycol); 
PLA, poly(lactic acid); PLGA, poly(lactide-co-glycolide); PO, peroral; PSA, poly(sebacic acid); VEGF, 
vascular endothelial growth factor 
1 as measured by dynamic light scattering 
2 as measured by electron microscopy 
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An intravitreal injection of dexamethasone-loaded PLGA NPs prevented leaking from 
CNV lesions [131]. Conversely, triamcinolone-encapsulated poly(lactic acid) (PLA) NPs 
could not successfully deliver the drug over a prolonged period of time into the ocular 
tissue after a periocular injection [132]. Because of the high surface area to volume ratio of 
NPs, a large amount of glucocorticoid was rapidly released from the colloidal system and 
a sustained release could not be maintained [132]. A similar effect was observed for 
budesonide-loaded PLA NPs after subconjunctival application [133]. While the great 
therapeutic success of intravitreal antibody-based VEGF therapeutics has pushed the 
intravitreal use of corticosteroids into the background [134], a sustained release 
formulation of corticosteroid-loaded NPs that is co-injected together with the antibody 
and shows a similar half-life could have synergistic effects on disease progression without 
further burden for the patient. Oh and coworkers synthesized a micellar system consisting 
of hyaluronate and a water-insoluble VEGF receptor 1-antagonist peptide [135]. In a 
model of streptozotocin-induced diabetic retinopathy, the micelle-like NPs inhibited 
CNV more than the anti-VEGF receptor 1 peptide alone [135]. By loading the micelles 
with genistein, an isoflavonoid that interferes with expression of VEGF and suppresses 
cell proliferation [136], vascular leakage could be further suppressed – similar to 
treatment with the gold standard bevacizumab [137]. Likewise, C16Y, an integrin-
antagonist peptide encapsulated in poly(lactic acid)/poly(lactic acid-b-ethylene oxide) 
(PLA/PLA-PEO) NPs reduced the area of CNV more than the peptide solution itself due 
to controlled release from the nanocarriers [138]. 
Another advantageous aspect of controlled release systems is that by releasing active 
agents in a sustained fashion from NPs, toxicity issues stemming from high drug 
concentrations can be avoided. Doxorubicin (DXR), an anthracycline that acts as an 
inhibitor of HIF-1α, has strong anti-angiogenic potential but is also known and used for 
its antineoplastic properties [139]. Though DXR effectively suppresses neovascularization 
in the eye it also has a deleterious effect on retinal function [140]. However, when 
prepared in poly(ethylene glycol)-poly(sebacic acid) (PEG-PSA) NPs its strong anti-
angiogenic effect remained, whereas the accompanying retinal toxicity was 
diminished [140].  
Unfortunately, one shortcoming that can be seen in several investigations is the lack of 
comparison against the anti-VEGF therapy gold standard. Although the use of 
bevacizumab and ranibizumab is widely established and used on a daily basis in 
ophthalmology, a direct comparison is often avoided. Thus, assessment of neovascular 
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inhibition is difficult, especially when drug-free NPs themselves appear to have a positive 
effect on the neovascular outcomes [77]. In laser-induced CNV, which is the most 
common model for wet AMD, a head-to-head comparison should be a necessity. 
4.3 Anti-oxidative nanoceria for treating ocular neovascularization 
For several years it has been known that oxidative damage plays a fundamental role in the 
pathogenesis of age-regulated macular degeneration (AMD) [141]. Cigarette smoking, 
being over 65 years old, and obesity – all of which are environmental and demographic 
characteristics linked to oxidative stress – are known to be major risk factors for 
developing AMD [142,143]. Another indication that oxidative stress has a prominent role 
in the development of AMD is that supplementation with anti-oxidants like vitamin C/E, 
zinc or beta carotene has a delaying effect on the pathogenesis of AMD and reduces the 
risk of vision loss [144]. Furthermore, many of the proteins found in drusen of patients 
with dry AMD were found to be modified with degradation products of docosahexaenoic 
acid (DHA), which are generated by oxidative damage [145]. Increased levels of reactive 
oxygen species (ROS) in the retina are a consequence of high oxygen levels in the tissue, 
delivered by the well-perfused choriocapillaris, in combination with the intensively 
focused light that reaches the retina every day throughout the lifespan of each 
individual [145,146]. 
Nanoceria, a nanoscale formulation of cerium oxide ranging from 3-5 nm, represent a 
promising nanoparticle platform to treat ocular diseases related to oxidative stress. The 
nanoceria’s capacity to scavenge ROS involves their ability to switch between dual 
oxidation states, making them comparable to biologic antioxidants [147,148]. In an AMD 
model they inhibited the rise of ROS and decreased the formation of intraretinal and 
subretinal neovascularizations after a single intravitreal injection [149]. This is possible 
due to the high redox capacity of cerium oxide and its ability to regenerate its activity 
when formulated as a nanoparticle system [150]. Notably, by catalytically scavenging 
ROS, nanoceria also prevented increase in VEGF and inhibited pro-inflammatory 
cytokines and other pro-angiogenic growth factors besides VEGF [149,151]. In toxicology 
studies, nanoceria were rapidly taken up by the retina but showed neither acute nor long-
term negative effects on retinal function or architecture [152]. Furthermore, the nanoceria 
had a remarkable half-life of 414 days in the retina [152]. Nanoceria sustained their 
antioxidant function for up to 6 weeks and not only reduced vascular leakage from 
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neovascular lesions, but also led to the regression of existing abnormal blood vessels by 
about 50 % (Fig. 6b) [153].  
4.4 Inherent anti-angiogenic properties of nanoparticles  
Ocular diseases like wet AMD, proliferative DR and ROP share pathological 
neovascularization of retina or choroid as a common hallmark. Pioneering work to 
investigate the anti-angiogenic effects of gold nanoparticles (AuNPs) was conducted by 
Bhattacharya and coworkers based on the known positive effects of gold salts in the 
therapy of rheumatoid arthritis [154]. Via in vitro studies they concluded that AuNPs 
derive their intrinsic anti-angiogenic properties by specifically inhibiting heparin-binding 
glycoproteins like VEGF165 and basic fibroblast growth factor (bFGF) [155,156]. 
Interestingly, the proliferation induced by VEGF121 and epidermal growth factor (EGF), 
two non-heparin-binding growth factors, were not inhibited. Interaction between AuNPs 
and VEGF165 was proposed to occur through bindings between thiol and amine groups 
in the heparin binding domain and the gold surface [155]. When VEGF165 was 
preincubated with AuNPs, its proliferative effect was significantly reduced compared to 
the untreated VEGF [156]. Conversely, in the absence of VEGF165, AuNPs showed no 
inhibition of cellular proliferation. Further in vitro investigations on bovine retinal 
pigment epithelium cells revealed that AuNPs additionally inhibited VEGF-induced 
proliferation via blockade of the Src pathway [157], a family of kinases that is pivotal for 
VEGF-induced proliferation in vivo [158]. Besides AuNPs, inhibition of angiogenesis was 
also observed for silver [159], silicate [160] and cuprous oxide nanoparticles [161]. In an 
in vivo study using a mouse model of ROP, the intravitreal injection of 1 µM 20 nm 
AuNPs in 1 µL phosphate-buffered saline greatly inhibited retinal neovascularizations and 
nearly eliminated neovascular lumens (Fig. 6a) [162]. AuNPs showed intraocular 
biocompatibility and did not alter the electrical activity of the retina for at least 6 
weeks [163,164]. Recently, titanium dioxide (TiO2) nanoparticles were evaluated for their 
anti-angiogenic potential [165]; a non-toxic intravitreal injection of 20 nm TiO2 
nanoparticles reduced the number of vascular tufts. Interestingly, gold, silver and silicate 
nanoparticles exerted their anti-proliferative effects through the phosphatidyl inositol 3-
kinase/Akt and ERK1/2 pathways, which are downstream signaling pathway of VEGF-
VEGFR2. In contrast, TiO2 nanoparticles inhibited the VEGFR-2/MAPK pathway and did 
not affect the PI3K/Akt pathway [165].  
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However, because they are non-biodegradable and not easily eliminated after intravitreal 
injection, repeated injections of inorganic nanoparticles could lead to toxicity problems. 
Although one injection may be tolerable, accumulation and decomposition over time may 
pose problems to the sensitive neural retina. For instance, in an ex vivo tissue culture 
model of the retina, gold and silver NPs of 20 and 80 nm exhibited significant neurotoxic 
effects on the photoreceptors, despite being administered in a single dose at a low 
concentration [166]. Therefore, to fully evaluate the potential harm that metallic 
nanoparticles could have on the neural retina, extensive long-term toxicology studies are 
desperately needed. 
 
Figure 6: Anti-angiogenic properties of AuNPs (a) and nanoceria (b). Fluorescein angiography shows 
leakage in retinae after oxygen-induced retinopathy (a, left). Intravitreal injection of 20 nm AuNPs 
greatly inhibited retinal neovascularizations and showed fewer neovascular lumens (a, right). 
Reprinted from Biomaterials 2011; 32(7); 1865-71 [162] with permission from Elsevier. Capital A and 
B refer to the images in the original publication. 
In vldlr knockout mice, a mouse model that features pathological retinal neovascularizations, 
injections of anti-oxidative nanoceria greatly reduced the number of neovascular lesions compared to 
the control injections (b). Reprinted from Biomaterials 2014; 35(1); 249-58 [153] with permission from 
Elsevier. 
5 Concluding remarks and future perspectives  
Nanoscale materials have great potential to resolve the shortcomings of established anti-
neovascular therapies and open new therapeutic avenues. With nanoparticulate systems, 
an effective therapy is within reach that can increase intravitreal drug dosing intervals, 
introduce corrective genes into the ocular tissue or completely circumvent the need to 
inject directly into the eye. Together with powerful NP targeting strategies, an effective, 
safe and intravenously administered treatment can be achieved. In the coming years, we 
will presumably know whether or not the promising preclinical data can be translated to 
yield the first successful clinical studies which demonstrate safety and efficacy in humans. 
Furthermore, the novel anti-oxidative and anti-angiogenic features of selected 
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nanomaterials may potentially allow for interesting compound materials that exert 
synergistic effects in the treatment of neovascular eye diseases. Taken together, NPs hold 
great potential to shape the future of ocular anti-angiogenic therapy. 
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Over the last two decades, nanoparticles have emerged as powerful tools for drug delivery 
and biomedical imaging. Due to their incredible versatility in respect to size, composition 
and surface characteristics they can be chemically engineered to suit a wide range of 
applications. As such, the conjugation of receptor ligands to a colloid’s polymer corona is 
a commonly seen strategy to precisely tailor nanoparticle-cell interactions. This way, it is 
thought that nanoparticles can be efficiently addressed towards specific tissues which 
express the targeted receptors. 
However, the story is much more complex. Cell surface receptors are usually not only 
expressed in diseased tissue but also show significant physiological expression in off-
target tissue. This demands for new strategies that allow distinct discrimination between 
pathological and healthy tissue. One possible way of achieving this is to take advantage of 
the inherent capability of nanoparticles to bind several receptors simultaneously and thus 
differentially target tissues with differences in receptor expression. The angiotensin II 
receptor type 1 (AT1R) is a prominent example of a receptor that is physiologically 
expressed in several organs but shows a distinct up-regulation and overexpression in 
many pathologic conditions. Furthermore, because of its immense pharmacological 
significance it is highly suitable for nanoparticle targeting. 
Although conjugation of ligands to shielding polymer such as poly(ethylene glycol) (PEG) 
is a common technique to increase nanoparticle-cell interactions it is often overlooked 
that the attachment of ligand molecules to the polymer corona can drastically alter their 
receptor binding affinity. Using EXP3174, a small molecule antagonist for the AT1R, the 
price of PEGylation on the ligand affinity was investigated. Furthermore, it was elucidated 
to what extent nanoparticle multivalency can compensate for the ligand affinity loss 
(Chapter 3). 
AT1 receptors play a significant role in proliferative diseases of the vasculature in the 
posterior eye such as proliferative age-related macular degeneration and proliferative 
diabetic retinopathy. In an in vivo study with healthy mice, the accumulation of 
EXP3174-targeted Qdots in the retinal and choroidal blood vessels was investigated. The 
unique Qdot fluorescence was identified by multispectral imaging and pinpointed by 
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immunohistochemistry. Complete biodistribution studies were performed with the help 
of inductively-coupled plasma mass spectrometry (Chapter 4). 
Since Qdots were mainly used as reporter particles and are not well suited for therapeutic 
interventions, the multivalent targeting principle was transferred to polymer structures. 
For that reason ligands were attached to branched PEG molecules and poly(amido amine) 
dendrimers. Besides affinity and cytotoxicity, emphasis was also placed on polymer-drug 
interactions (Chapter 5). 
In contrast to antagonist-modified nanoparticles that rest at the cell membrane, agonist-
coupled colloids are rapidly endocytosed by inducing a distinct receptor response. 
Consequentially, the contact time of the colloids on the cell surface is greatly limited, 
which could impede formation of a multivalent nanoparticle-cell binding. A thiolated 
angiotensin II molecule was used to coat nanoparticles to yield agonistic particles. Flow 
cytometry, confocal microscopy and intracellular calcium measurements were employed 
to characterize cellular association, ligand affinity and thus the extent of multivalency 
(Chapter 6). 
Integrins, a class of cell surface receptors responsible for cell-matrix interactions and 
growth factor signaling, have a high significance in the pathogenesis of glaucoma in the 
trabecular meshwork, a sponge-like tissue responsible for aqueous humor drainage. The 
anti-fibrotic effects of the integrin-specific antagonist cyclo(Arg-Gly-Asp-D-Phe-Cys) 
(RGDfC) were investigated by western blotting and real-time polymerase chain reaction. 
Finally, to explore if cyclo(RGDfC) peptides can be used as nanoparticle targeting 
moieties for the trabecular meshwork, the interaction of cyclo(RGDfC)-coated 
nanoparticles with primary and immortalized trabecular meshwork cells was investigated 
(Chapter 7). 
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Abstract 
The conjugation of receptor ligands to shielded nanoparticles is a widely used strategy to 
precisely control nanoparticle-cell interactions. However, it is often overlooked that a 
ligand’s affinity can be severely impaired by its attachment to the polyethylene glycol 
(PEG) chains that are frequently used to protect colloids from serum protein adsorption. 
Using the model ligand EXP3174, a small-molecule antagonist for the angiotensin II 
receptor type 1 (AT1R), we investigated the ligand’s affinity before and after its 
PEGylation and when attached to PEGylated nanoparticles. The PEGylated ligand 
displayed a 580-fold decreased receptor affinity compared to the native ligand. Due to 
their multivalency, the nanoparticles regained a low nanomolar receptor affinity, which is 
in the range of native ligand’s affinity. Moreover, a four orders of magnitude higher 
concentration of free ligand was required to displace PEGylated nanoparticles carrying 
EXP3174 from the receptor. On average, one nanoparticle was decorated with 11.2 ligand 
molecules, which led to a multivalent enhancement factor of 22.5 compared to the 
monovalent PEGylated ligand. The targeted nanoparticles specifically bound the AT1R 
and showed no interaction to receptor negative cells. Our study shows that the 
attachment of a small-molecule ligand to a PEG chain can severely affect its receptor 
affinity. Concomitantly, when the ligand is tethered to nanoparticles, the immense avidity 
greatly increases the ligand-receptor interaction. Based on our results, we highly 
recommend the affinity testing of receptor ligands before and after PEGylation to identify 
potent molecules for active nanoparticle targeting. 
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1 Introduction 
Camouflaging the surface by PEGylation or other measures is essential to avoid the 
uptake of nanoparticles by the mononuclear phagocyte system (MPS) [1]. Concomitantly, 
it prevents aggregation by sterically stabilizing the colloidal particles [2]. However, with 
the introduction of polyethylene glycol (PEG) strands on its surface, the interaction 
between a nanoparticle and its target cell can be severely hampered. To overcome this 
severe drawback, which is often referred to as the “PEGylation dilemma” [3], the 
nanoparticle surface can be decorated with ligands. These ligands then bind to their 
respective receptors on the cell surface and contribute to greatly controlled nanoparticle-
cell interactions [4]. This includes processes such as nanoparticle endocytosis via 
receptor-mediated pathways [5] or an increased accumulation into a defined target 
tissue [6]. When choosing such targeting moieties for conjugation to a nanoparticle, 
small-molecule ligands (MW < 1000 Da) are preferred over antibodies because they are 
non-immunogenic, do not alter the physicochemical properties of the nanoparticles, and 
do not hinder their extravasation [7–9].  
Unfortunately, the attachment of small molecules to PEG strands can severely affect their 
receptor binding capabilities. This phenomenon, which is well-known for 
macromolecules including proteins, polysaccharides and nucleic acids [10–13], is caused 
by the steric interference of the PEG tether with the active site of the respective binding 
partners [14,15]. Due to the size of small-molecule ligands and their frequently small 
binding pockets, the PEGylation of these molecules can massively damage their receptor 
affinity. Although there are numerous nanoparticle systems that make use of small-
molecule ligands like folic acid [16], RGD peptides [17] or glutathione [18] as targeting 
moieties, few reports address the effect of PEGylation on ligand receptor affinity. Another 
important aspect of such systems is that nanoparticles are able to reach out to several 
receptors simultaneously [19]. This is possible due to the multiple presentation of ligand 
molecules on the nanoparticle surface and can drastically improve the affinity of receptor-
targeted ligands compared to the monovalent units [4,20]. 
Despite the continually growing amount of publications in the field of active nanoparticle 
targeting, the affinity of nanoparticle-bound ligands is rarely evaluated. Although 
multivalent nanoparticle-receptor interactions are well documented in the literature, the 
change in affinity that is a result of the ligand’s attachment to the nanoparticle is often 
neglected. Therefore, we investigated in detail how PEGylation influences a small ligand’s 
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affinity with a simultaneous look at how nanoparticles are able to compensate for this loss 
of affinity. 
For this purpose we made use of the well-investigated G protein-coupled receptor 
angiotensin II receptor type 1 (AT1R), a receptor that recently came into focus for targeted 
drug delivery [21] and offers a multitude of high affinity non-peptide ligands [22]. Here, 
we used the active metabolite of the prominent AT1R antagonist losartan, known as 
EXP3174, and attached it to PEG and PEGylated nanoparticles. Quantum dots (Qdots) 
were chosen as a suitable nanoparticle platform because of their high intrinsic 
fluorescence and their remarkably uniform size [23,24]. We compared the receptor 
affinity of both the native ligand and the PEGylated ligand to the ligand’s affinity when 
conjugated to multivalent nanoparticles. By determining the amount of deposited ligand 
per nanoparticle, we investigated the extent of multivalent interactions. In addition, flow 
cytometry and confocal microscopy studies were conducted to gain further insight into 
the multi-ligand binding nature of the nanoparticles. 
2 Material and methods 
2.1 Material 
Qdots® 655 ITK™ amino PEG (Life Technologies, Carlsbad, CA, USA) were used as 
nanoparticle starting material. EXP3174, also known as losartan carboxylic acid, was 
purchased from Santa Cruz (Heidelberg, Germany). All chemicals were obtained from 
Sigma Aldrich (Taufkirchen, Germany) in analytical grade unless stated otherwise. 
Buffers used for PEGylation, nanoparticle labeling and purification were 10 mM 2-(N-
morpholino)ethanesulfonic acid (MES) buffer pH 4.8, 50 mM borate buffer pH 8.5 and 
Dulbecco’s phosphate buffered saline (DPBS) pH 7.4 consisting of 1.5 mM KH2PO4, 
8 mM Na2HPO4, 2.7 mM KCl and 138 mM NaCl. 
2.2 Cell culture 
Human adrenal gland carcinoma cells NCI-H295R and rat mesangial cells were cultured 
in RPMI1640 medium containing 10 % fetal bovine serum (Sigma Aldrich, Taufkirchen, 
Germany) and supplemented with insulin-transferrin-selenine (PAA, Pasching, Austria), 
penicillin-streptomycin (Life Technologies, Carlsbad, CA, USA) and 100 nM 
hydrocortisone. Rat mesangial cells were a gift from Armin Kurtz (Department of 
Physiology, University of Regensburg, Germany). HeLa cells (ATCC No. CCL-2) were 
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maintained in Eagle's Minimum Essential Medium (EMEM) containing 10 % fetal bovine 
serum and 1 mM sodium pyruvate. All cells were cultured in T-75 cell culture flasks 
(Corning, Corning, NY, USA). 
2.3 EXP3174 PEGylation 
mPEG5k-amine was synthesized from its mPEG5k-OH precursor using the Mitsonubu 
reaction as previously described [25]. EXP3174 (2 µmol) was activated using N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, 25 mM) and N-
hydroxysulfosuccinimide (sulfo-NHS, 10 mM) for 1 h in MES buffer pH 4.8. After 
activation of the carboxylic group of EXP3174, the pH was increased by the addition of 
borate buffer pH 8.5. Amino-mPEG5k (3.3 µmol) was added and the solution was 
vortexed for 16 h at room temperature. Subsequently, the reaction mixture was purified 
by size exclusion chromatography using a Sephadex G-25 resin in a PD-10 column (GE 
Healthcare, Munich, Germany) with DPBS as the eluent. Fractions containing mPEG-
EXP3174 were pooled and further purified by ultrafiltration using a 3 KDa molecular 
weight cut-off Amicon Ultra-15 filter unit (Millipore, Billerica, MA, USA). Final mPEG-
EXP3174 concentration was measured using a LS-55 fluorescence plate reader (Perkin 
Elmer, Waltham, MA, USA) against an EXP3174 calibration using an excitation 
wavelength of 250 nm and an emission wavelength of 370 nm., since the fluorescence 
properties of EXP3174 did not change upon PEGylation (Supplementary information, 
Fig. S2). 
2.4 Nanoparticle labeling 
Similarly to the PEGylation procedure, EXP3174 (16 nmol) was activated using EDC and 
sulfo-NHS in MES-buffered solution. After activation of EXP3174 for 1 h the pH was 
raised by addition of 50 mM borate buffer pH 8.5. Qdots® 655 ITK™ amino PEG 
(160 pmol) were added to the reaction mixture for the actual labeling reaction. After 
16 hours of gentle shaking, EXP3174-modified Qdots were purified by size exclusion 
chromatography using a Sephadex G-25 resin in a PD-10 column with DPBS as the 
eluent. Further purification and concentration of the modified Qdots was achieved by 
ultrafiltration using a 100 KDa molecular weight cut-off Amicon Ultra-4 filter unit 
(Millipore, Billerica, MA, USA). Finally, Qdot concentration was determined by 
fluorescence measurement using a FluoStar Omega fluorescence microplate reader (BMG 
Labtech, Ortenberg, Germany) with an excitation and emission wavelength of 450 nm 
and 650 nm, respectively. 
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2.5 Size-exclusion chromatography 
The purity of ligand-modified Qdots was analyzed by size exclusion chromatography 
(SEC) consisting of a Shimadzu LC-10ATVP pump (Shimadzu, Duisburg, Germany), a 
Shimadzu SIL-10ADVP autosampler connected to a Shimadzu RF-10AXL fluorescence 
detector. As a separation column, a TSKgel G3000 SWXL column, 7.8 mm x 30 mm, 5 µm 
particle size (Tosoh Bioscience, Stuttgart, Germany) was used. The isocratic mobile phase 
consisted of citrate buffer (pH 3; 50 mM)-acetonitrile (80:20 v/v) and the column was 
operated at room temperature. Eluted EXP3174 was detected by fluorescence analysis 
with an excitation wavelength of 250 nm and an emission wavelength of 370 nm. For 
analysis of the Qdot fluorescence a mobile phase consisting of DPBS (pH 7.2)-acetonitrile 
(80:20 v/v) was used. The Qdot fluorescence was detected with an excitation and emission 
wavelength of 350 nm and 655 nm, respectively. 
2.6 Intracellular calcium mobilization assay 
The antagonistic affinity of the conjugated ligands was investigated using the fluorescent 
fura-2 Ca2+ chelator method established by Grynkiewicz et al. [26]. Suspensions of rat 
mesangial cells were incubated with 5 µM fura-2AM (Life Technologies, Carlsbad, CA, 
USA) and 0.05 % Pluronics F-127 in Leibovitz’s L-15 medium (Life Technologies, 
Carlsbad, CA, USA) for 1 h at room temperature in the dark. After loading, cells were 
repeatedly washed by centrifugation (3 x, 5 min, 200 g, RT) and resuspension in 
Leibovitz’s medium. A range of concentrations of EXP3174, mPEG-EXP3174 and 
EXP3174-Qdots were pipetted into 96-well plates (Greiner Bio One, Frickenhausen, 
Germany) at 20 µL per sample and 90 µL of loaded cells (2*106 cells/mL) were then 
injected into the wells. After 10 minutes of antagonist incubation, 90 µL of the EC80 (the 
concentration that leads to 80 % of the maximum signal) of the agonist angiotensin II 
(Bachem, Bubendorf, Switzerland) was injected into each well. The fluorescence signal 
was immediately recorded with a FluoStar Omega fluorescence microplate reader (BMG 
Labtech, Ortenberg, Germany) for 30 s. The EC80 was graphically determined from the 
agonist calcium curve produced with angiotensin II and rat mesangial cells. Excitation 
filters for the ratiometric measurement were 340/20 nm and 380/20 nm and the emission 
was recorded in a 510/20 nm bandpass filter. Analogously, the fluorescence signal was 
calibrated by incubating loaded cells with 0.1 % Triton-X 100 for measuring the maximal 
ratio (Rmax) and 0.1 % Triton-X 100 with 45 mM ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) to determine the minimal ratio 
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(Rmin). The intracellular calcium concentrations were calculated from the maximal 
fluorescence ratios based on the equation of Grynkiewicz et al. assuming a Kd value of 
225 nM for the fura-2-calcium complex [26]. The IC50 values (the half maximal inhibitory 
concentration) were calculated using SigmaPlot 12.2 (Systat Software, San Jose, CA, USA) 
with the help of the sigmoidal dose-response (variable slope) equation. The multivalent 
enhancement (MVE) was calculated as initially proposed by Montet et al. MVE = 
IC50(ligand) / IC50(ligand when displayed by nanoparticle) but with minor changes as 
shown in equation 1 [19]. 
2.7 Flow cytometry 
AT1R expressing NCI-H295R cells were seeded into 24-well plates (Corning, Corning, 
NY, USA) at a density of 150,000 cells/well. Receptor-negative HeLa cells were seeded at a 
density of 100,000 cells/well. For nanoparticle binding studies, Qdot solutions of non-
modified and EXP3174-modified Qdots with a concentration of 10 nM were prepared in 
Leibovitz’s medium supplemented with 0.1 % bovine serum albumin. After the cells 
adhered overnight, they were washed with DPBS and the pre-warmed nanoparticle test 
solutions were pipetted onto the cell monolayer. After 1 h incubation at 37 °C, the cells 
were vigorously washed with DPBS and trypsinized. After suspension, the cells were 
centrifuged (5 min, 200 g), resuspended in DPBS, centrifuged again and finally 
resuspended in 200 µL DPBS and analyzed for their cellular fluorescence with a 
FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Qdot 
fluorescence was excited at 488 nm and the fluorescence was analyzed using a 661/16 nm 
bandpass filter. For Qdot displacement studies, NCI-H295R cells were incubated with 
5 nM EXP3174-modified Qdots and a concentration series of free EXP3174. After 1 h 
incubation at 37 °C the cells were processed analog to the nanoparticle binding studies.  
Flow cytometry data was analyzed using WinMDI 2.9 (The Scripps Research Institute, 
San Diego, CA, USA). Only the population of viable cells was gated and used for the 
analysis of the cellular fluorescence. The geometrical mean was determined from the 
fluorescence histogram. The curve fitting for the displacement study was carried out with 
SigmaPlot 12.2 using the one site competition model, whereas maximal Qdot binding was 
set as cellular fluorescence when incubated with 5 nM EXP3174-modified Qdots and 
minimal binding was set as the cellular autofluorescence, which was determined in the 
absence of Qdots. 
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2.8 Confocal laser scanning microscopy 
To analyze the nanoparticle binding pattern on the cells confocal microscopy was 
conducted. NCI-H295R cells were seeded into 8-well µ-slides (Ibidi, Martinsried, 
Germany) at a density of 15,000 cells/well. After adherence of the cells overnight, they 
were washed with DPBS. The pre-warmed nanoparticle test solution in Leibovitz’s 
medium supplemented with 0.1 % bovine serum albumin were pipetted onto the cells and 
incubated for 1 hour at 37 °C. Then, cells were washed with DPBS, fixed with 
paraformaldehyde 2 % in DPBS for 10 min at room temperature, washed extensively with 
DPBS and analyzed with a Zeiss Axiovert 200 microscope combined with a LSM 510 
laser-scanning device using a 63x Plan-Apochromat (NA 1.4) objective (Zeiss, Jena, 
Germany). Qdot fluorescence was excited with an argon laser at 488 nm. Qdot emission 
was recorded in a 650 nm longpass filter. The focal plane was adjusted to 1.8 µm. For 
image acquisition and processing AIM 4.2 (Zeiss, Jena, Germany) was used. Qdot 
fluorescence was displayed in false color green for better visibility. 
2.9 Indirect ligand quantification 
The amount of covalently bound EXP3174 on the nanoparticle surface was analyzed 
indirectly. One reaction identical to the nanoparticle labeling but without Qdots was 
conducted parallel to the standard nanoparticle labeling procedure (Fig. 5a). In place of 
the nanoparticles, the same volume of borate buffer pH 8.5 was added to the activated 
EXP3174. After 16 h of gentle shaking 50 µL of each mixture were diluted 20-fold with 
50 mM borate buffer pH 9.0 and stirred for 6 h at 60 °C to hydrolyze the unreacted sulfo-
NHS-activated ester of EXP3174. Non-nanoparticle bound EXP3174 concentration was 
analyzed by reversed phase high performance liquid chromatography (RP18-HPLC) 
consisting of a Shimadzu LC-10ATVP pump (Shimadzu, Duisburg, Germany), a 
Shimadzu SIL-10ADVP autosampler connected to a Shimadzu CTO-10ASVP column 
oven and a Shimadzu RF-10AXL fluorescence detector. As the separation column, a 
Luna® 5 µm C18(2) 100 Å 250 x 4.60 mm LC column (Phenomenex, Aschaffenburg, 
Germany) was used. The isocratic mobile phase consisted of citrate buffer (pH 3.0; 
50 mM)-acetonitrile (50:50 v/v) and the column temperature was maintained at 30 °C. 
Eluted EXP3174 was detected by fluorescence analysis with an excitation wavelength of 
250 nm and an emission wavelength of 370 nm. The difference in the amount of soluble 
EXP3174 from the reaction with and without Qdots was related to the Qdot 
concentration of 160 pmol from the initial labeling reaction to calculate the amount of 
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EXP3174 per nanoparticle. The affinity of one EXP3174 molecule when displayed by the 
PEGylated nanoparticle was calculated by multiplying the affinity of the EXP3174-Qdots 
by the number of EXP3174 molecules per nanoparticles using Gauss’ law of error 
propagation. 
2.10 Statistics 
To assess statistical significance two-way analysis of variances (ANOVA) was carried out 
with a multiple comparisons test (Tukey’s test) by using SigmaPlot 12.2. Levels of 
statistical significance were set as indicated. 
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3 Results and discussion  
3.1 Ligand PEGylation and affinity comparison  
First, by utilizing intracellular calcium measurements we characterized the angiotensin 
receptor expression on rat mesangial cells, adrenal gland carcinoma cells (NCI-H295R) 
and HeLa cells. Since the AT1R is a Gq-coupled membrane receptor [27], cytosolic 
calcium measurements can be used to investigate receptor response rates and, therefore, 
to estimate receptor expression levels. Although the calcium signal is not linearly related 
to the ligand binding activity, we chose the calcium mobilization assay to determine 
binding strengths since our main focus is the pharmacological receptor blockade that 
results from a successful ligand-receptor interaction. Rat mesangial cells and the adrenal 
gland carcinoma cell line NCI-H295R both showed a positive calcium signal upon 
binding of the physiological agonist angiotensin II with an EC50 of 70.1 ± 1.8 nM and 
21.6 ± 5.6 nM, respectively. HeLa cells, in contrast, showed no calcium signal after 
angiotensin II stimulation (Fig. 1a). For this reason, rat mesangial cells and NCI-H295R 
cells were used as receptor-positive cells and HeLa cells as receptor-negative control cells 
for ligand and nanoparticle binding experiments. The small non-peptide antagonist 
EXP3174, which is the active metabolite of losartan, blocked the angiotensin II signaling 
on rat mesangial cells with low nanomolar affinity and an IC50 of 1.1 ± 0.2 nM, which is in 
agreement with literature data [28] (Fig. 1b). To determine the affinity of EXP3174 after 
the attachment to a PEG tether, its carboxylic group was conjugated to methoxy-
PEG5000-NH2 with EDC and sulfo-NHS. We chose a PEG with a molecular weight of 
5000 g/mol and a most narrow size distribution (polydispersity index of 1.04). This chain 
length is often considered the minimum PEG chain length to effectively reduce serum 
protein adsorption [29]. Furthermore, the narrow size distribution of the used PEG 
species allows the measuring of discrete PEG-ligand affinities without the added variance 
of the polydisperse polymer tether.  
After purification by size exclusion chromatography and ultrafiltration the purity of the 
synthesized PEGylated ligand and the absence of free EXP3174 were ensured by size-
exclusion chromatography (Supplementary information, Fig. S1). Compared to the native 
EXP3174, the affinity of the PEGylated ligand heavily dropped by a factor of 580 to 630 ± 
130 nM (Fig. 1b). The substantial decrease in receptor affinity can be attributed to the 
location of the receptor binding pocket for non-peptide ligands, which is formed by 
amino acids in the membrane-spanning regions of the AT1R and is buried deep in the 
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seven transmembrane regions [27]. Though the receptor affinity of the mPEG-EXP3174 
ligand was greatly decreased, it was not eliminated. Amides and esters of EXP3174’s 
carboxylic functional group retain a high receptor binding affinity [30], therefore, the 
affinity loss in this system is a consequence of the PEG’s distortion within the binding 
pocket rather than functional group changes. Recently, Vlashi and coworkers reported the 
extent to which the receptor affinity of folic acid, a very prominent small ligand used for 
nanoparticle targeting, is reduced by the attachment of differently sized PEG 
molecules [31]. In their study, the conjugation of linear PEG chains to folic acid and 
rhodamine decreased its binding affinity by a factor of approx. 70 to 187, depending on 
the PEG chain length. Although folic acid is known to retain a high affinity when grafted 
to PEG via its favorable γ-carboxyl group [32], the apparent affinity loss after attachment 
to a PEG chain is still substantial and should not be underestimated. Few cases are known 
where conjugated PEG enhanced the receptor binding of low-affinity ligands, which could 
be attributed to the entropy gain after the PEG-bound water is released upon receptor 
binding [33]. 
 
Figure 1: Affinity comparison of EXP3174 and its PEGylated counterpart. (A) Rat mesangial cells and 
adrenal gland carcinoma cells NCI-H295R express a functional AT1 receptor, as shown through 
intracellular calcium measurements. HeLa cells without a functional AT1R were used as receptor-
negative control cells. (B) The native ligand EXP3174 blocks the AT1R with nanomolar affinity of 1.1 ± 
0.2 nM. Upon PEGylation, the affinity of the small non-peptide ligand is substantially decreased to 
630 ± 130 nM. 
3.2 Nanoparticle binding and localization 
To analyze the affinity of EXP3174 when conjugated to nanoparticles, PEGylated and 
amine-terminated Qdots were covalently labeled with EXP3174 with the help of EDC and 
sulfo-NHS linker chemistry (Fig. 2a). Transmission electron microscopy (TEM) images 
revealed that the ligand conjugation process did not alter the particle uniformity as the 
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Qdots were evenly distributed and showed no sign of aggregation (Supplementary 
information, Fig. S3). 
 
Figure 2. Conjugation reaction of EXP3174 to PEGylated Qdots and purification analysis by size-exclusion 
chromatography (SEC). (A) Illustrated for one PEG chain, EXP1374 was covalently coupled to 
PEGylated Qdots 655 by EDC and sulfo-NHS chemistry. The resulting EXP3174-decorated 
nanoparticles were extensively purified in a three-step procedure to remove unbound ligand. (B) The 
purified EXP3174-Qdots were analyzed by size-exclusion chromatography and showed no alteration 
of the fluorescence signal or the retention time. (C) Unreacted EXP3174 was successfully removed by 
the purification procedure. Since the high absorbance of the quantum dot core quenches the EXP3174 
fluorescence at 370 nm, an indirect EXP3174 quantification method was conducted (see fig. 5a). 
Zeta-potential measurements indicated that the conjugation procedure was successful 
(Supplementary information, Fig. S4). After the coupling of the ligand to the 
nanoparticles, the colloids were purified from unreacted ligand by ultrafiltration and 
preparative size-exclusion chromatography (SEC). With the help of an analytical SEC we 
ensured that the conjugation procedure did not alter the fluorescence properties of the 
Qdots (Fig. 2b) and that the unreacted EXP3174 had successfully been removed (Fig. 2c). 
Confocal laser scanning microscopy (CLSM) and flow cytometry experiments were 
conducted to analyze the association of nanoparticles to receptor-expressing NCI-H295R 
and receptor-negative HeLa cells. Confocal microscopy revealed a strong binding of 
EXP3174-modified Qdots to the cell membrane of the receptor-expressing NCI-H295R 
cells, while the unspecific binding of the non-modified Qdots was substantially weaker 
(Fig. 3a). Since EXP3174 as an AT1R antagonist does not induce receptor 
internalization [34] it is not expected that the nanoparticles are immediately taken up by 
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the cells, but instead rest at the cell membrane where they bind multiple receptors at 
once [4].  
 
Figure 3. Nanoparticle binding to cells as observed by confocal microscopy and flow cytometry. (A) By 
confocal laser scanning microscopy, a strong binding of ligand-conjugated nanoparticles to the cell 
membrane of receptor expressing NCI-H295R cells could be observed (arrowheads). Non-modified 
Qdots only showed sparse unspecific binding to the cells. The autofluorescence of the cells was 
negligible. Qdot fluorescence is depicted in false color green. Scale bar: 20 µm (B) When quantified by 
flow cytometry, the ligand-modified Qdots showed a strong binding to receptor-positive cells and 
virtually no binding to receptor-negative HeLa cells. Although non-modified Qdots showed some 
increased unspecific binding to the NCI-H295R cells, the binding of EXP1374-Qdots was significantly 
higher. (C) In a displacement experiment, a tremendous amount of free ligand was needed to displace 
5 nM of EXP3174-Qdots from the receptor. Levels of statistical significance are indicated as: (**) 
p < 0.01.  
Flow cytometry experiments with receptor-negative and receptor-positive cells further 
demonstrated the strong binding of the EXP3174-modified Qdots to the receptor-
expressing cells (Fig. 3b). Cells were incubated with nanoparticles with different surface 
functionalities, thoroughly washed and analyzed for their Qdot fluorescence. Although 
the non-modified nanoparticles showed weak, unspecific binding, the association of the 
ligand-conjugated Qdots to the receptor-positive cells was significantly higher.  
In contrast, the AT1R-targeted EXP3174-Qdots showed no association to receptor-
negative cells, which confirmed the successful receptor binding to the target cells. To 
displace a concentration of 5 nM EXP3174-Qdots from the cells, extraordinarily high 
amounts of free ligand were needed (Fig. 3c). The inhibitory constant (IC50, the 
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concentration of EXP3174 that displaces 50 % of the nanoparticles) was 112.3 ± 6.0 µM, 
which is about four orders of magnitude higher than the applied concentration of 
nanoparticles. This phenomenon, in which exceptionally high concentrations of free 
ligand are needed to displace the nanoparticles from the receptor, is often observed and is 
typical for multivalent ligand-receptor interactions [4,19,35]. 
3.3 Affinity of ligand-conjugated nanoparticles 
Once we verified that EXP3174-modified Qdots bind the angiotensin II receptor type 1 
and show no association to receptor-negative cells, we analyzed the affinity of both 
ligand-modified and non-modified Qdots by intracellular calcium quantifications with 
AT1R-expressing rat mesangial cells. The high and broad absorbance of Qdots can 
interfere with many fluorescent calcium chelators, which is the reason we chose fura-2AM 
as the calcium indicator due to its ratiometric measurement.  
 
Figure 4: Ligand-conjugated nanoparticles regain high affinity by exhibiting multivalent interactions. (A) 
By binding several receptors at once, EXP3174-modified Qdots have an enhanced affinity of 2.5 ± 
0.02 nM compared to the monovalent PEGylated unit. (B) Non-modified Qdots showed no receptor 
blocking and therefore no influence on the receptor binding of angiotensin II and the subsequent 
calcium influx into the cytosol. 
In this intracellular calcium measurement, the antagonist-modified Qdots regained a 
nanomolar IC50 of 2.5 ± 0.02 nM, which is an affinity increase of a factor of 252 compared 
to the monovalent PEGylated ligand (Fig. 4a). The enhanced affinity of the EXP3174-
Qdots compared to the mPEG-EXP3174 can be explained by multivalent ligand-receptor 
interactions, where one nanoparticle binds several receptors simultaneously. This 
multivalent enhancement is described for several nanoparticle platforms including 
Qdots [36–38], dendrimers [39,40], polymeric [41] or gold nanoparticles [42,43]. Another 
mechanism that could lead to measuring an increased affinity is the steric blockade of 
receptors by nanoparticles that bind neighboring receptors. However, we think this effect 
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is not predominant in our calcium assay since the signal-inducing angiotensin II, a small 
octapeptide, is able to diffuse rather freely and the nanoparticle is not able to shield the 
receptor from this small molecule. In addition, the high affinity loss upon PEGylation 
seen for mPEG-EXP3174 could be a consequence of the soluble PEG chain wrapping 
around the ligand molecule. When the PEG chain is covalently linked to the nanoparticle 
core, in contrast, its spatial flexibility could be decreased and the ligand molecule could be 
more accessible.  
Compared to ligand-targeted nanoparticles, non-modified Qdots showed no influence on 
the cytosolic calcium concentrations, proving that the receptor blockage was indeed 
triggered by the surface-immobilized ligand and not the nanoparticle species itself 
(Fig. 4b). Since it is not the absolute fura-2 emission, but rather its ratio that is important, 
the broadband absorbance of Qdots only resulted in problems with higher nanoparticle 
concentrations than tested here. 
3.4 Ligand quantification  
To know if a nanoparticle exhibits a multivalent enhancement compared to the 
monovalent ligand or if the increased affinity is just the sum of ligand-receptor bindings, 
the exact amount of surface-bound EXP3174 had to be evaluated. However, because of the 
broad absorbance of Qdots [44], direct ligand quantification based on spectroscopic 
methods is not feasible. For this reason, the amount of surface-conjugated ligand is often 
only estimated based on the coupling efficiency but rarely quantified [45–47]. 
Additionally, fluorescence or isotopic labeling of the small-molecule ligand can drastically 
alter the receptor binding and the coupling efficacy to the nanoparticle. 
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Figure 5: The analysis of ligand deposition on the nanoparticle surface allows for calculation of the 
nanoparticle-bound ligand affinity. (A) Scheme for the indirect quantification of ligand conjugated to 
the Qdots. As illustrated, two separate labeling reactions were conducted, in which one was free of 
Qdots. This allowed for the amount of deposited ligand to be determined as 11.2 ± 3.1 molecules 
EXP3174 per nanoparticle by. (B) When the monovalent PEGylated EXP3174 is compared to the 
nanoparticle-bound PEGylated EXP3174, the multi-ligand binding influence on the ligand affinity is 
obvious. 
To circumvent these problems we made use of an indirect ligand quantification strategy 
to measure the nanoparticle-conjugated ligand. We evaluated the amount of non-reacted 
soluble ligand with reversed-phase high performance liquid chromatography (RP-18 
HPLC) and compared it to an identical reaction that was free of Qdots (Fig. 5a).This way, 
ligand adsorption phenomena to glass and plastic could be quantified and the exact 
amount of nanoparticle-associated ligand was readily available. Using this method, we 
determined that 11.2 ± 3.1 molecules EXP3174 were bound to each Qdot. This is 
consistent with literature data, where 1 to 15 small ligands were covalently coupled to 
20 nm Qdots with similar EDC/sulfo-NHS chemistry [48]. The calculated affinity of a 
single nanoparticle-bound PEG-EXP3174 is 28 ± 7.8 nM (Fig. 5b). Compared to the 
monovalent mPEG-EXP3174, the multivalent enhancement factor (MVE) was 22.5, 
which is in range of other multivalent systems described in the literature [19,49]. It must 
be noted that the MVE is highly dependent on the analyzed receptor and the applied 
assay. MVE estimations with living cells usually yield lower values [19] than calculations 
based on experimental conditions where nanoparticles interact with artificially 
immobilized binding partners such as receptors on a surface plasmon resonance (SPR) 
sensor chip [49–51]. The multivalent formation is mainly influenced by the nanoparticle 
size [52] and shape [53], the ligand density [54] and the receptor response after ligand 
binding. However, for a complete insight into multivalent interactions between ligands 
and receptors, the nanoparticle-bound ligand should not be compared to the native 
ligand, but rather to the PEGylated counterpart (Eq. 1). This way, the affinity decrease 
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that arises from the PEG tether would be included and the real nanoparticle multivalent 
enhancement would be accessible.  
MVE	= 
IC50 (PEGylated ligand)
IC50 (ligand when displayed by PEGylated nanoparticle)
 
Equation 1. Adaption to the calculation of the multivalent enhancement factor (MVE) that was originally 
proposed by Montet et al. [19] for the assessment of the real multivalency. 
The present example shows the necessity of this approach: When the free EXP3174 is 
compared to the EXP3174-decorated nanoparticle it appears there are no multivalent 
effects since the affinity is marginally decreased. However, when compared to the 
PEGylated counterpart, the multivalent enhancement of the nanoparticles can be clearly 
seen and measured.  
 
Figure 6: Summary of monovalent and multivalent ligand receptor interaction between EXP3174 and AT1R 
4 Conclusion 
We demonstrated that the affinity of a small non-peptide ligand can severely suffer from 
its attachment to a PEG chain. By binding to their target receptors in a multivalent 
fashion, nanoparticles have the ability to compensate for this profound affinity loss. These 
avidity-driven interactions lead to strong particle-receptor bindings that surpass that of 
monovalent ligands. The present work is the first study that addresses both effects in a 
common context, which is pivotal for understanding the targeting efficacy of 
nanoparticles (Fig. 6). 
Based on our findings, we strongly recommend affinity testing of small-molecule ligands 
after PEGylation and before attaching them to the PEG corona of nanoparticles. This way, 
many results in which the active-targeted nanoparticles are not more effective than their 
passive-targeted counterpart could eventually be attributed to a strong ligand affinity 
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decline after the conjugation to nanoparticles. If PEGylation nullifies the binding capacity 
of the ligand, a different ligand or even another targeting strategy should be applied.  
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1 Size exclusion chromatography 
The purity of mPEG-EXP3174 was analyzed by size exclusion chromatography (SEC) 
consisting of a Shimadzu LC-10ATVP pump (Shimadzu, Duisburg, Germany), a 
Shimadzu SIL-10ADVP autosampler connected to a Shimadzu RF-10AXL fluorescence 
detector. As a separation column, a TSKgel G3000 SWXL column, 7.8 mm x 30 mm, 5 µm 
particle size (Tosoh Bioscience, Stuttgart, Germany) was used. The isocratic mobile phase 
consisted of citrate buffer (pH 3; 50 mM)-acetonitrile (80:20 v/v) and the column was 
operated at room temperature. Eluted EXP3174 and mPEG-EXP3174 were detected by 
fluorescence analysis with an excitation wavelength of 250 nm and an emission 
wavelength of 370 nm. 
 
Figure S1. Size exclusion chromatogram of EXP3174 and mPEG-EXP3174. The absence of unreacted 
EXP3174 can be clearly seen for the mPEG5K-EXP3174 derivative. 
2 Fluorescence Spectra of EXP3174 and mPEG5k-EXP3174 
The fluorescence spectra of EXP3174 and EXP3174 upon PEGylation were investigated 
with a LS-55 fluorescence plate reader (Perkin Elmer, Waltham, MA, USA) at a 
concentration of 100 µM in citrate buffer pH 2.5 (100 mM).  
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Figure S2. Excitation and emission spectra of EXP3174 and PEGylated EXP3174 show no significant 
change in fluorescence properties upon PEGylation  
3 Transmission electron microscopy 
4 µL of a 60 nM aqueous solution Qdots was pipetted on a carbon-coated copper grid 
(Plano, Wetzlar, Germany) and air dried. The sample was analyzed using a Zeiss Libra 
120 electron microscope (Zeiss, Oberkochen, Germany). Electron micrographs were 
acquired and analyzed with Image SP (Zeiss, Oberkochen, Germany). 
 
Figure S3. Transmission electron micrograph displaying non-modified (a) and EXP3174-modified Qdots 
655 (b). Both nanoparticles have a rod-like shape. EXP3174-modified Qdots are monodisperse and 
show no sign of aggregation after the conjugation and purification procedure. The inorganic core of 
the non-modified Qdots has a length of 16.0 ± 1.6 nm with a width of 7.9 ± 0.9 nm. Similarly, the 
inorganic core of EXP3174-modified Qdots has a length of 17.8 ± 2.1 nm and a width of 7.7 ± 1.1 nm 
(each value was analyzed for 50 nanoparticles). 
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4 Zeta-potential 
The electrophoretic mobility was measured at 25 °C using a Malvern ZetaSizer Nano ZS 
(Malvern Instruments GmbH, Herrenberg, Germany). Purified Qdot samples were 
diluted to a concentration of 10 nM with DPBS 0.1X and analyzed using a standard 
capillary electrophoresis cell (Malvern Instruments). For comparison purposes glycolic 
acid was similarly conjugated to the terminal amine-groups of the Qdots as EXP3174 
using EDC and sulfo-NHS chemistry as stated in the Materials and Methods.  
 
Figure S4. Zeta-potential measurements of non-modified, EXP3174- and glycolic-acid conjugated Qdots. 
By coupling of EXP3174 to the Qdot amine groups, the zeta potential is substantially lowered. The 
reason is the tetrazole group of EXP3174 (circled), which is deprotonated at physiologic pH values. To 
exclude that the more negative zeta-potential is not due to the depletion of the terminal amine groups 
a comparable coupling with glycolic acid was conducted. Here, the zeta-potential is comparable to the 
non-modified Qdots, proving the more negative zeta-potential of EXP3174-Qdots is a consequence of 
the EXP3174 coupling.  
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Abstract 
The angiotensin II receptor type 1 (AT1R), which is expressed in blood vessels of the 
posterior eye, is of paramount significance in the pathogenesis of severe ocular diseases 
such as diabetic retinopathy and age-related macular degeneration. However, small 
molecule angiotensin receptor blockers (ARBs) have not proven to be a significant 
therapeutic success. We report here on a nanoparticle system consisting of ARB 
molecules presented in a multivalent fashion on the surface of quantum dots (Qdots). As 
a result of the multivalent receptor binding, nanoparticles targeted cells with high AT1R 
expression and inhibited their angiotensin receptor signaling with an IC50 of 3.8 nM while 
showing only minor association to cells with low AT1R expression. After intravenous 
injection into the tail vein of mice, multivalent nanoparticles accumulated in retinal and 
choroidal blood vessels of the posterior eye. At the same time, multivalent ligand display 
doubled the Qdot concentration in the blood vessels compared to non-targeted Qdots. 
Remarkably, ARB-targeted Qdots showed no pronounced accumulation in AT1R-
expressing off-target tissues such as the kidney. Following systemic application, this 
multivalent targeting approach has the potential to amplify AT1R blockade in the eye and 
concomitantly deliver a therapeutic payload into ocular lesions. 
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1 Introduction 
The angiotensin II receptor type 1 (AT1R) is a G protein-coupled receptor (GPCR) that is 
known for its role in regulating physiologic fluid and salt homeostasis and blood 
pressure [1]. However, it also serves as a key mediator of inflammation [2] and potent 
growth factor [3]. As such, AT1R and its ligand angiotensin II are critically important in 
pathological angiogenesis [4]. Two prominent examples of pathologies in which the 
receptor plays a pivotal role are exudative age-related macular degeneration (wet AMD) 
and proliferative diabetic retinopathy, diseases of the posterior eye that lead to blindness 
and severe visual impairment in a large number of patients each year [5,6]. In both of 
these neovascular diseases, inflammation mediated by AT1R appears to be crucial for 
pathogenesis and disease progression [7,8]. This is not surprising, since angiotensin II 
stimulates formation of retinal blood vessels and concomitantly increases their 
leakiness [9]. Despite this clear link between AT1R and ocular disease, the effect of 
angiotensin receptor blockers (ARBs) on therapeutic outcomes has only been 
modest [10–12]. Since ARBs display enormous plasma protein binding of more than 
95 % [13,14] and may be taken up by several other tissues such as kidneys, adrenal glands, 
vascular smooth muscle cells and heart, all of which abundantly express the receptor [15], 
it is possible that therapeutic ARB levels cannot be maintained in the eye. 
To improve AT1R antagonism in the ocular vasculature we developed a nanoparticle 
system that displays multiple receptor antagonists at the surface of a colloid, thus allowing 
the formation of multivalent ligand-receptor interactions towards AT1 receptors [16]. The 
nanoparticles retain overall binding affinity while each individual ligand receptor-
interaction is reduced. This gives these colloids the capability to differentially target 
tissues with higher AT1R expression. We envision a scenario in which the enhanced 
receptor binding – resulting in prolonged contact times on the cell surface – and the 
nanoparticles’ diminished off-target tissue accumulation could enhance the ocular 
bioavailability of ARBs and thus amplify their therapeutic benefit. 
Although in vitro data have convincingly proven that multivalent nanoparticles bind 
AT1R-expressing cells [16], the capability of these nanomaterials to interact with the 
choroidal and retinal blood vessels has not been assessed so far. Since the choroidal blood 
vessels, the major underlying blood vessels of the retina, have the highest perfusion of all 
vascular beds within the human body [17], only a limited timeframe is available for the 
colloids to establish strong nanoparticle-cell interaction and thus bind endothelial cells. 
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Therefore, this study aims to explore the in vivo potential of nanomaterials that use ARBs 
as multivalent targeting ligands and not as the nanoparticles themselves [18] or as a 
nanoparticle payload [19,20]. EXP3174, the active metabolite of the prominent ARB 
losartan, was covalently immobilized on the surface of highly fluorescent PEGylated 
quantum dots (Qdots), which were used as model colloids due to their intense 
fluorescence and highly monodisperse size [21]. In vitro binding and receptor affinity of 
nanoparticles to cell lines with different levels of AT1R expression was investigated with 
confocal microscopy and intracellular calcium measurements. Multi-spectral imaging, 
immunohistochemistry and inductively coupled plasma mass spectrometry (ICP-MS) 
were utilized to follow the nanoparticles’ fate in vivo and gain insight into their 
biodistribution and tissue accumulation. 
2 Materials and methods 
2.1 Materials 
EXP3174, also known as losartan carboxylic acid, was purchased from Santa Cruz 
(Heidelberg, Germany). Qdots® 655 ITK™ amino PEG (Life Technologies, Carlsbad, CA, 
USA) were used as nanoparticle starting material. All chemicals were obtained from 
Sigma Aldrich (Taufkirchen, Germany) in analytical grade unless stated otherwise. All 
buffers and solutions were prepared using ultrapure water, which was obtained from a 
Milli-Q water purification system (Millipore, Billerica, MA, USA). Buffers used for 
nanoparticle labeling and purification were 10 mM 2-(N-morpholino)ethanesulfonic acid 
(MES) buffer pH 4.8, 50 mM borate buffer pH 8.5 and Dulbecco’s phosphate buffered 
saline (DPBS) pH 7.4 consisting of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl and 
138 mM NaCl. 
Mowiol mounting medium was prepared by mixing 6.9 g glycerol 87 % (AppliChem 
GmbH, Darmstadt, Germany) with 2.4 g Mowiol 4-88, 5.1 mL H2O and 12.0 mL Tris 
buffered solution (0.2 M, pH 8.50). Mowiol mounting medium was prepared without the 
antifading agent 1,4-diazabicyclo[2.2.2]octane (DABCO) since it potentially quenches the 
Qdot fluorescence [22]. 
2.2 Cell culture 
Human adrenal gland carcinoma cells NCI-H295R (ATCC No. CRL-2128) were cultured 
in RPMI1640 medium containing 10 % fetal bovine serum (Sigma Aldrich, Taufkirchen, 
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Germany) and supplemented with insulin-transferrin-selenium (Life Technologies, 
Carlsbad, CA, USA), penicillin-streptomycin (Life Technologies, Carlsbad, CA, USA) and 
100 nM hydrocortisone. HeLa cells (ATCC No. CCL-2) were maintained in Eagle's 
Minimum Essential Medium (EMEM) containing 10 % fetal bovine serum and 1 mM 
sodium pyruvate. All cells were cultured in T-75 cell culture flasks (Corning, Corning, 
NY, USA). 
2.3 Real-time PCR 
To quantify the AT1 receptor expression on NCI-H295R and HeLa cells, real-time 
reverse-transcriptase polymerase chain reaction (qRT-PCR) was conducted. For that 
reason, cells were cultured in T-25 cell culture flasks (Corning, Corning, NY, USA). After 
the cells had reached subconfluency, RNA was isolated using the peqGOLD total RNA kit 
(Peqlab, Erlangen, Germany) including an on-column DNAse digestion step (peqGOLD 
DNase I Digest Kit, Peqlab, Erlangen, Germany). The purity and concentration of RNA 
was determined with the help of a Nanodrop ND-1000 spectrophotometer (Peqlab, 
Erlangen, Germany). To generate single-stranded cDNA, 3 µg of the isolated RNA were 
reversely transcribed using the cDNA-Synthesis Kit H Minus (Peqlab, Erlangen, 
Germany) according to the manufacturer’s instructions. For quantification of human 
AT1R expression (sense: 5′-GGC CAG TGT TTT TCT TTT GAA TTT AGC AC-3′, 
antisense: 5′-TGA ACA ATA GCC AGG TAT CGA TCA ATG C-3′), real-time RT-PCR 
was performed using a LightCycler® Instrument (Roche Diagnostics, Rotkreuz, 
Switzerland) and a LightCycler® 480 SYBR Green I Master (Roche Diagnostics, Rotkreuz, 
Switzerland). Due to the different tissue origins of both carcinoma cell lines we related the 
AT1R expression to the expression of three different housekeeping genes: glyceraldehyde 
3-phosphate dehydrogenase GAPDH (sense: 5′-GAA GGT GAA GGT CGG AGT C-3′, 
antisense: 5′-GAA GAT GGT GAT GGG ATT TC-3′), β-actin (sense: 5’-AGC CTC GCC 
TTT GCC GA-3’, antisense: 5’-CTG GTG CCT GGG GCG-3’) and RNA polymerase II 
(sense: 5’-GCA CCA CGT CCA ATG ACA T-3’, antisense: 5’-GTG CGG CTG CTT CCA 
TAA-3’). Especially RPII has been shown to have a constant expression in different 
tissues [23], which makes it an ideal reference gene when comparing expression levels 
between different tissues. Primers were purchased from Eurofins Genomics (Ebersberg, 
Germany). Real-time PCR was run for 50 cycles with 15 s denaturation at 95 °C, 20 s 
annealing at 60 °C, and 20 s elongation at 72 °C. The accuracy of the amplicon was 
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verified by performing a melting-curve analysis after amplification. Data is expressed as 
mean ± standard deviation (n=3).  
2.4 Nanoparticle labeling 
EXP3174 (16 nmol) was activated using N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC, 10 mM) and N-hydroxysulfosuccinimide (sulfo-
NHS, 5 mM) in MES-buffered solution. After activation of the carboxylic group of 
EXP3174 for 1 h, the pH was raised by addition of 50 mM borate buffer at pH 8.5. Qdots® 
655 ITK™ amino PEG (160 pmol) were immediately added to the reaction mixture for the 
labeling reaction. After 16 hours of gentle shaking, EXP3174-modified Qdots were 
purified by size exclusion chromatography using Sephadex G-25 resin in a PD-10 column 
(GE Healthcare, Munich, Germany) with DPBS as eluent. Fractions containing EXP3174-
coupled Qdots were pooled and further purified by ultrafiltration using a 100 kDa 
molecular weight cut-off Amicon Ultra-4 filter unit (Millipore, Billerica, MA, USA). 
Finally, Qdot concentration was determined by fluorescence measurement in a range of 0 
to 10 nM using a FluoStar Omega fluorescence microplate reader (BMG Labtech, 
Ortenberg, Germany) with an excitation and emission wavelength of 450 nm and 650 nm, 
respectively. 
2.5 Confocal laser scanning microscopy 
Adrenal gland carcinoma NCI-H295R and HeLa cells were seeded into 8-well µ-slides 
(Ibidi, Martinsried, Germany) at a density of 10,000 cells per well. After 96 hours (NCI-
H295R) or 24 hours (HeLa) of adhering and growing, nanoparticle binding to the cells 
was analyzed. In a first step, cells were washed with warm DPBS. Pre-warmed 
nanoparticle test solution in Leibovitz’s medium supplemented with 0.5 % bovine serum 
albumin (BSA) was pipetted onto the cells and incubated for 1 hour at 37 °C. BSA was 
added to the nanoparticle solutions to block nonspecific nanoparticle binding to the cells. 
After the incubation period, cells were washed with DPBS, fixed with 2 % 
paraformaldehyde in DPBS for 10 min at room temperature and washed extensively with 
DPBS. Analysis of nanoparticle binding to the cells was conducted using a Zeiss Axiovert 
200 microscope combined with a LSM 510 laser-scanning device using a 63x Plan-
Apochromat (NA 1.4) objective (Zeiss, Jena, Germany). Qdot fluorescence was excited 
with an argon laser at 488 nm. Qdot emission was recorded after a 650 nm longpass filter. 
The focal plane was adjusted to 1.1 µm. For image acquisition and processing AIM 4.2 
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(Zeiss, Jena, Germany) was used. Qdot fluorescence was displayed in false color (green) 
for better visibility. 
2.6 Intracellular calcium mobilization assay  
The affinity of the EXP3174-modified Qdots for AT1R was investigated by the fluorescent 
fura-2 Ca2+ chelator method as originally established by Grynkiewicz et al. [24] and as 
recently described [16]. Confluent HeLa and NCI-H295R cells grown in cell culture flasks 
were harvested with trypsin, centrifuged (5 min, 200 g, RT) and loaded in suspension with 
5 µM fura-2AM (Life Technologies, Carlsbad, CA, USA) and 0.05 % Pluronic F-127 in 
Leibovitz’s L-15 medium (Life Technologies, Carlsbad, CA, USA) for 1 h at room 
temperature in the dark. After loading of the cells, they were repeatedly washed by 
centrifugation (3 times, 5 min, 200 g, RT) and resuspended in Leibovitz’s medium. 
For determination of the agonist stimulation curve, a concentration series of 
angiotensin II (Bachem, Bubendorf, Switzerland) with each concentration having a 
volume of 20 µL were pipetted into 96-well plates (Greiner Bio One, Frickenhausen, 
Germany). Subsequently, 180 µL of the loaded cell suspension (1*106 cells/mL) were 
injected into the wells and the fluorescence signal was recorded for 60 s. For the 
antagonistic efficacy of EXP3174-Qdots, 20 µL were pipetted into 96-well plates and 90 µL 
of loaded cells with a concentration of 2*106 cells/mL were injected into the wells. After 
10 min of antagonist incubation, 90 µL of the EC80 of angiotensin II was subsequently 
injected into each well and the fluorescence signal was immediately recorded with a 
FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg, Germany) for 
a time of 30 s. Excitation filters for the ratiometric measurement were 340/20 nm and 
380/20 nm and the emission was recorded in a 510/20 nm bandpass filter. The 
fluorescence signal was calibrated by incubating loaded cells with 0.1 % Triton-X 100 to 
measure the maximal ratio (Rmax) and 0.1 % Triton-X 100 supplemented with 45 mM 
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) to determine 
the minimal ratio (Rmin). The intracellular calcium concentrations were calculated from 
the maximal fluorescence ratios based on the equation of Grynkiewicz et al. assuming a Kd 
value of 225 nM for the fura-2-calcium complex [24]. The IC50 values (the half maximal 
inhibitory concentration) and EC50 values (the half maximal effective concentration) were 
calculated using SigmaPlot 12.2 (Systat Software, San Jose, CA, USA) with the help of the 
sigmoidal dose-response (variable slope) equation.  
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2.7 Animal experiments 
All animal experiments were carried out in accordance with the national and institutional 
guidelines and were approved by the local authority (Regierung der Oberpfalz, reference 
number: 54-2532,1-23/11) and the Animal Care and Use Committee (Tierschutz-
ausschuss) of the University of Regensburg.  
NMRI (nu/nu) mice with an age of at least 12 weeks and weighing around 30 grams were 
used as model animals. Mice were bred in-house at the University of Regensburg under 
specified pathogen free (SPF) conditions with food and water ad libitum. 
2.8 Biodistribution of targeted and non-targeted Qdots 
For assessing the overall biodistribution of non-modified and EXP3174-coupled Qdots, 
100 µL of a 2 µM Qdot solution (total dose: 200 pmol) of either targeted or non-targeted 
Qdots were intravenously injected into the jugular vein of mice that were anesthetized by 
isoflurane inhalation. After one hour of nanoparticle circulation, blood samples of 100 µL 
were obtained from the vena facialis using heparinized microcapillaries. After the blood 
was centrifuged the plasma was collected. Subsequently, mice were sacrificed and organs 
harvested. Eyes were immediately enucleated and fixed in 4 % paraformaldehyde for 1 h. 
All other organs were fixed overnight. After several washing steps in DPBS, organs were 
weighed and a representative portion of every organ with a weight of approximately 
100 mg was dissolved by microwave-assisted nitric acid digestion using a MARSXpress 
system (CEM, Matthews, NC, USA). For eyes, only the posterior eye segment with retina, 
choroid and sclera was used for Qdot quantification. The anterior eye with cornea, lens 
and vitreous was discarded. Due to their CdSe core, the measured cadmium 
concentration is linearly related to the nanoparticle amount. With the help of a 
quadrupole-based inductively coupled plasma mass spectrometer ICP-MS 7700cx system 
(Agilent Technologies, Boeblingen, Germany) the cadmium-111 concentration in the 
dissolved tissues was quantified. If the measured cadmium concentration was below the 
limit of quantification, which was 5 ng g-1 tissue (5 ppb), it was set to 0. The total plasma 
volume was estimated to be 59.4 mL/kg body weight [25]. To assess statistical significance 
Student’s t-test was carried out using SigmaPlot 12.2.  
2.9 Localization of Qdots in the retinal vasculature 
Prior to nanoparticle administration, mice were anesthetized by intraperitoneal injection 
of a mixture of ketamine (150 mg/kg) and xylazine (10 mg/kg). After pre-warming the tail 
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in warm water (approximately 50°C), 200 pmol of either ligand-modified or unmodified 
nanoparticles were injected into the lateral tail vein. After one hour of nanoparticle 
circulation in the animals, mice were killed by cervical dislocation and the eyes were 
enucleated. Eyes were immediately transferred to 4 % paraformaldehyde solution in DPBS 
and fixed for 4 hours. After a brief washing in DPBS, eyes were cryoprotected using a 
sucrose gradient in 0.1 M phosphate buffer pH 7.4 at 4 °C, embedded in Tissue Tek® 
O.C.T.™ Compound (Sakura Finetek, Torrance, CA, USA) and frozen in the gas phase of 
liquid nitrogen. Specimens were cut into 12 µm thick sections using an HM 500 OM 
microtome (Microm International, Walldorf, Germany) and transferred onto Superfrost™ 
plus glass slides (Thermo Scientific, Waltham, MA, USA). Finally, sagittal sections were 
washed with DPBS and mounted with Mowiol mounting medium. The slides were 
analyzed using a Zeiss Axiovert 200 microscope combined with an LSM 510 laser-
scanning device using a 40x Plan-Neofluar (NA 1.3) objective (Zeiss, Jena, Germany). For 
localization of Qdot fluorescence in tissue sections, an excitation wavelength of 488 nm 
was chosen and the emitted light was detected using a Zeiss meta detector (Zeiss, 
Oberkochen, Germany). The meta detector was set to record the emitted light from 500 to 
700 nm in 30 nm intervals (515, 547, 580, 612, 644 and 676 nm). The acquired wavelength 
stacks were displayed as color-coded pictures. The software used for image acquisition 
and processing was AIM 4.2 (Zeiss, Oberkochen, Germany).  
For retinal flat mounts, eyes were enucleated and fixed in 4 % paraformaldehyde for 1 h. 
After a thorough washing in DPBS, the cornea and anterior eye segment were removed, 
retinas were dissected from the eye cups and four radial cuts were made to allow flat-
mounting. Specimens were immediately mounted with Mowiol mounting medium. For 
microscopical analysis, slides were illuminated with a mercury-vapor lamp (Zeiss, 
Oberkochen, Germany) and Qdot fluorescence was detected using a Qdot 655 filter set 
(Chroma Technology, Olching, Germany) consisting of an excitation filter with an 
excitation wavelength maximum of 460 nm and a bandwidth of 50 nm (full width at half 
maximum, FWHM), a beam splitter at 475 nm and a bandpass emission filter with a 
center wavelength at 655 nm and a bandwidth of 40 nm (FWHM). The software used for 
image acquisition and processing of the flat-mounted retinas was AxioVision 4.6 with the 
MosaiX module (Zeiss, Oberkochen, Germany). For improved visibility, the lookup table 
“Red Hot” was applied to the microscopic pictures using ImageJ (NIH, Bethesda, MD, 
USA, http://imagej.nih.gov/ij). The Z-stack was recorded using a confocal Zeiss Axiovert 
200 microscope combined with an LSM 510 laser-scanning device using a 40x Plan-
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Neofluar (NA 1.3) objective (Zeiss, Jena, Germany). Flat-mounted retinas were excited 
with an argon laser at 488 nm and scanned using a 650 nm longpass filter with z-stack 
step size of 6.0 µm. 
2.10 Immunohistochemistry 
For immunohistochemical staining of CD31, freshly cut cryosections were circled with 
an ImmEdge Pen (Vector, Burlingame, CA, USA) and blocked for 30 min at room 
temperature with 10 % horse serum and 1 % BSA in DPBS. After blocking, sections were 
incubated with polyclonal goat anti-CD31/PECAM-1 IgG 1:40 (#AF3628, R&D systems, 
Wiesbaden, Germany) formulated in 10 % horse serum and 1 % BSA in DPBS in a moist 
chamber at 4 °C overnight. As a secondary antibody, donkey anti-goat IgG (1:500) 
conjugated to Alexa Fluor® 546 (#A11056, Life Technologies, Carlsbad, CA, USA) was 
used in 1 % BSA in DPBS.  
For F-actin staining, eye sections were incubated with phalloidin conjugated to Alexa 
Fluor® 546 (#A22283, Life Technologies, Carlsbad, CA, USA) in 1 % BSA in DPBS for 60 
min. Labeled sections were mounted with Mowiol mounting medium and analyzed using 
the aforementioned Zeiss meta detector, which was set to record the emitted light from 
560 to 700 nm in 30 nm increments (558, 590, 622, 654 and 687 nm). The tissue sections 
were excited using a 488 nm argon laser. For visual representation the 590 nm channel 
representing Alexa Fluor® 546 and the 654 nm channel depicting the Qdots were used. 
3 Results and discussion 
EXP3174-modified nanoparticles were obtained by covalently conjugating the carboxylic 
acid functional group of EXP3174 to amino-PEG terminated Qdots with the help of 
EDC/NHS chemistry. Use of a 100-fold molar excess of EXP3174 with respect to the 
Qdots resulted in approximately 11 ligands per nanoparticle. Following a thorough 
purification process, no unreacted ligand was present [16]. The inorganic core of the 
semiconductor nanoparticles had a length of 17.8 ± 2.1 nm and a width of 7.7 ± 
1.1 nm [16]. Especially in the context of evaluating multivalent nanoparticle-cell 
interactions, the use of nanomaterials with narrow dispersity is crucial [26]. 
3.1 Nanoparticle binding in vitro 
Two cell lines, used to demonstrate in vitro nanoparticle binding behavior, were assayed 
for AT1R expression and functionality using quantitative reverse-transcriptase PCR (qRT-
Results and discussion 
99 
PCR) and intracellular calcium measurements, respectively. At the mRNA level, AT1R 
expression was more than 100-fold higher in NCI-H295R cells than in HeLa cells for all 
tested reference genes (Fig. 1A). 
 
Figure 1: Receptor characterization and nanoparticle binding for NCI-H295R and HeLa cell lines. (A) 
When AT1R expression was determined by qRT-PCR, NCI-H295R cells showed an over 100-fold 
greater expression compared to HeLa cells. (B) Similarly, using intracellular calcium measurements 
with fura-2AM, NCI-H295R cells exhibited a vastly increased intracellular calcium mobilization upon 
angiotensin II agonist binding (C) When NCI-H295R cells were incubated with non-targeted and 
EXP3174-Qdots, only EXP3174-coupled Qdots significantly interacted with AT1R-high NCI-H295R 
cells. When EXP3174-Qdots were incubated with HeLa cells, the nanoparticles showed only minor 
cellular binding. For NCI-295R cells, the fluorescence of EXP3174-Qdots was clearly associated with 
the cell membrane. 
Although small varieties in gene expression oftentimes do not equally transfer to the 
protein level, this distinct difference in gene expression clearly provided strong evidence 
for markedly different AT1R expression levels in the two cell lines. The lack of specific 
antibodies against AT1R [27,28], rendered the verification of the AT1R expression at the 
protein level impossible. Fortunately, due to their Gq-coupling, AT1 receptors respond 
with an increase in cytosolic calcium following agonist binding. Echoing our AT1R mRNA 
expression results the cytosolic calcium concentration of NCI-H295R cells upon AT1R 
activation with angiotensin II reached calcium concentrations of over 500 nM. 
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For HeLa cells, on the other hand, the intracellular calcium levels upon agonist 
stimulation did not exceed calcium concentrations of approximately 100 nM (Fig. 1B). 
Thus, for nanoparticle binding experiments, NCI-H295R and HeLa cells were used as cell 
lines with high and low receptor expression, respectively. Although nanoparticle binding 
to both cell lines was previously investigated, HeLa cells were originally not identified as a 
cell line with low receptor expression due to the absence of qRT-PCR data and were 
initially designated receptor negative cells [16]. 
Binding of non-targeted and EXP3174-targeted Qdots was demonstrated with confocal 
microscopy and intracellular calcium measurements. We found EXP3174-Qdots to 
exhibit a high degree of association with AT1R-high NCI-H295R cells (Fig. 1C). The 
colloids were primarily located at the cell membrane and showed no significant uptake 
after one hour, which is typical for nanoparticles bound to a receptor antagonist, as 
originally observed for the neuropeptide Y receptor Y1 [29] and the melanocortin type-1 
receptor [30]. Since angiotensin receptor blockers bind the receptor but do not initiate 
receptor internalization [31], antagonist-coupled nanoparticles are not immediately taken 
up into the cells but instead rest at the surface of the cell membrane. In contrast, 
PEGylated but non-targeted Qdots showed only weak and non-specific interaction with 
NCI-H295R cells. When AT1R-low HeLa cells were incubated with EXP3174-coupled 
nanoparticles, only minor Qdot fluorescence was observable, lending further support to 
the multivalent receptor-mediated nature of the nanoparticle binding. For the colloids to 
establish an affine binding to the cell a certain AT1 receptor density is undoubtedly 
needed. That AT1 receptors on NCI-H295R cells can be targeted in a multivalent fashion 
was recently demonstrated with agonist-modified nanoparticles [32]. 
Next, the influence of EXP3174-modified nanoparticles on GPCR activation was 
investigated using calcium-sensitive ratiometric imaging techniques [24]. In this binding 
assay, EXP3174-Qdots blocked the angiotensin II-induced calcium influx into the cytosol 
with an IC50 of 3.8 ± 0.9 nM (Fig. 2). Non-targeted Qdots exhibited no influence on the 
calcium signal, proving that the fluorescence ratio decrease of the calcium chelator fura-2 
was indeed due to successful receptor blockade by EXP3174 immobilized on the 
nanoparticle surface and not due to a quenching of the fluorescent signal by the highly 
absorbing Qdot core. The affinity of the EXP3174-conjugated nanoparticles for the cells 
was slightly lower than that of free EXP3174, which had an IC50 of 2.0 ± 0.5 nM 
(Supporting information Fig. S1). This minor decrease in receptor affinity is a result of the 
ligand’s attachment to the hydrophilic PEG corona that protects the colloid from serum 
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protein adsorption. When attached to the PEG chains, the ligands lose a significant degree 
of receptor affinity. Due to the low affinity of this monovalent interaction, which is above 
500 nM [16], the colloids have to necessarily build up multivalent nanoparticle-cell 
interactions in order to establish a strong interaction with the target cell. This is in turn is 
only possible if the receptor density on the target cell surface is sufficiently high. The 
capacity of multivalent nanomaterials to increase receptor binding affinity has already 
been demonstrated for other GPCRs such as the adenosine [33] and neuropeptide 
receptors [29]. Besides increasing cellular affinity, nanoparticle multivalency has also been 
successfully utilized for cell-specific targeting [34], control of colloidal cytotoxicity [35] 
and alteration of cell responses by crosslinking membrane receptors [36]. 
 
Figure 2: Influence of EXP3174-Qdots on the angiotensin II-induced calcium mobilization on NCI-H295R 
cells. EXP3174-modified Qdots blocked receptor signaling with an IC50 of 3.8 ± 0.9 nM. In contrast, 
non-targeted Qdots showed no influence on the angiotensin II receptor binding or the fura-2 
fluorescence. 
3.2 Biodistribution and accumulation in off-target tissue 
Since EXP3174-Qdots strongly associated with cells of high receptor expression and 
exhibited only minor binding to cells of low AT1R expression in vitro, we asked whether 
the nanoparticles would be able to sufficiently circulate in the blood and if the Qdots 
would accumulate in AT1R expressing off-target tissue. For that reason, mature adult mice 
were intravenously injected with a dose of 200 pmol of either targeted or non-targeted 
Qdots. The extremely low affinity of the monovalent PEGylated EXP3174 ligand (IC50 of 
630 nM) [16] is insufficient to appreciably bind AT1 receptors at the applied equivalent 
nanoparticle concentration in the blood (~66 nM), which is why PEGylated, non-targeted 
Qdots were used as a control nanomaterial. After injection the nanoparticles were allowed 
to circulate for 1 h. This duration was chosen as it allows the nanoparticles in sufficient 
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time to bind the endothelium and accumulate in the tissue [37–39]. In addition, due to 
the relatively short blood circulation time of these Qdots [40], a major fraction of 
unbound and weakly bound nanoparticles will be rapidly cleared from the blood and 
sequestered within organs with a prominent mononuclear phagocyte system, such as liver 
and spleen [41]. After the mice were sacrificed, representative portions of major organs 
were dissolved by microwave-assisted nitric acid digestion and then analyzed for 
cadmium-111 content by inductively coupled plasma mass spectrometry (ICP-MS). 
Because the Qdots consist of a CdSe/ZnS core/shell structure, the cadmium concentration 
is linearly related to the amount of deposited nanoparticles in the tissue. Measuring Cd-
111 by ICP-MS is the standard technique for quantitative assessment of the 
biodistribution pattern of Cd-containing Qdots [42,43], and is more accurate and 
sensitive than fluorescence imaging techniques [44]. 
In our experiments, kidneys, lung and heart exhibited comparable nanoparticle uptake for 
non-targeted and EXP3174-Qdots (Fig. 3A), whereas liver and spleen, the two most 
prominent organs of the mononuclear phagocyte system, accumulated significantly less 
EXP3174-Qdots than non-targeted Qdots. This is remarkable, as attachment of targeting 
ligands usually leads to decreased blood circulation time and an elevated hepatosplenic 
uptake by liver and spleen-associated macrophages [45,46]. Epifluorescence pictures of 
spleen and liver confirmed the ICP-MS findings (Supporting information Fig. S2). 
Although EXP3174 possesses a charged tetrazole ring that could theoretically attract 
blood plasma proteins, the integrity of the nanoparticle’s PEG corona is obviously not 
compromised. Moreover, organs with high AT1R expression such as kidney and heart [15] 
showed no significant accumulation of EXP3174-modified Qdots, which is mostly due to 
the inaccessibility of the receptors to circulating nanoparticles. Especially in the heart, 
AT1R is mainly associated with the conduction system [47] and is not within reach of 
circulating nanoparticles. 
Although elevated for EXP3174-Qdots, the plasma cadmium concentration was not 
significantly different than that of non-targeted Qdots after 1 hour of circulation. Since 
the kidneys are an important off-target organ due to their large amount of AT1 receptors 
that are easily accessible from the blood stream we investigated the detailed distribution 
pattern of EXP3174-targeted Qdots. CD31 immunohistochemistry, which stains 
endothelial cells, was performed on cryosections of kidneys that passively accumulated 
EXP3174-targeted Qdots during their circulation. The stained peritubular capillaries and 
glomerular endothelium showed only minute nanoparticle association (Fig. 3B). 
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However, a significant amount of Qdots accumulated in the glomerular mesangium. This 
is not surprising, since the kidney mesangium has been shown to be a passive 
accumulation site for several nanoparticle species [48–50], as well as non-targeted CdSe 
Qdots of the same size [51]. Similar to observations by Praetner et al. on non-targeted 
Qdots [52], the nanoparticles were mainly eliminated via hepatobiliary excretion whereas 
renal elimination was only minute. 
 
Figure 3: Nanoparticle distribution in off-target tissue. (A) Biodistribution of non-targeted and EXP3174-
modified nanoparticles after systemic administration and one hour of circulation. Qdot concentration 
in tissues was analyzed by determining the cadmium concentration with ICP-MS. Data is expressed as 
mean ± SEM (n=3). Levels of statistical significance are indicated as: (*) p < 0.05; (n.s.) p > 0.05. (B) 
Distribution pattern of EXP3174-coupled Qdots in the kidney. Qdots are mainly associated with the 
glomerular mesangium but not with the glomerular or peritubular capillaries. 
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3.3 EXP3174-Qdots accumulate in the choriocapillaris 
After we had experimentally confirmed that EXP3174-Qdot had a sufficient blood 
circulation time we investigated whether the nanoparticles could actively accumulate in 
the AT1R-expressing microvasculature of the posterior eye segment. To this end, mature 
adult mice were again intravenously injected with a dose of 200 pmol of either targeted or 
non-targeted Qdots, which were allowed to circulate for 1 h. After the mice had been 
sacrificed, the eyes were enucleated, sagittal cryosections were obtained and Qdot 
fluorescence was investigated. To clearly distinguish between nanoparticle fluorescence 
and bright tissue autofluorescence and to identify the nanoparticles in the highly complex 
tissue of the posterior eye segment, we used multi-spectral imaging with the help of a 
Zeiss META detector. Due to the Qdots’ large Stokes shift und their narrow emission 
spectrum this technique allowed to precisely locate the nanoparticles in the complex 
ocular tissue. 
In the posterior eye of mice who received non-targeted Qdots, no specific Qdot 655 
fluorescence could be observed. This is in accordance with earlier studies which 
investigated the distribution of non-functionalized Qdots in the posterior eye [37]. 
Conversely, in eye sections of mice that received a bolus of EXP3174-Qdots, a substantial 
accumulation of magenta Qdot 655 fluorescence was clearly visible (Fig. 4A). The 
EXP3174-conjugated nanoparticles were detected principally in the choroid and its 
immediate vicinity (Fig. 4A) as well as in the intraretinal blood vessels (Supporting 
information Fig. S3). Although the bright yellow-green tissue autofluorescence gave good 
structural hints as to the location of the nanoparticles, F-actin and CD31 counterstaining 
using fluorescently-labeled phalloidin and a labeled anti-CD31 antibody, respectively, was 
conducted to pinpoint the nanoparticles’ location within the posterior eye (Fig. 4B). 
EXP3174-Qdots were exclusively associated with the endothelium and were not observed 
within the RPE or sclera. The choriocapillaris is highly fenestrated towards the RPE [53] 
with pores of approximately 80 nm [54]. These fenestrae could potentially allow 
nanoparticle extravasation, similar to the hyperpermeable vasculature of solid 
tumors [55]. Furthermore, the RPE itself expresses several components of the renin-
angiotensin-system [56] including AT1R [57], to which EXP3174-targeted nanoparticles 
could bind. However, EXP3174-Qdots showed no observable extravasation. This can be 
attributed to a fenestral diaphragm that spans the fenestrations and reduces the 
endothelial cell fenestration size to approximately 20-30 nm [58]. Given that the Qdots’ 
hydrodynamic diameter is approximately 36 nm [52], they were likely unable to transit  
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Figure 4: Sagittal eye sections of mice that received 200 pmol either ligand- or non-targeted Qdots. (A) 
Upon systemic administration, EXP3174-modified Qdots accumulated in the choriocapillaris and 
intraretinal capillaries in the posterior eye. Fluorescence of non-targeted Qdots could not be found in 
sagittal eye sections. CC-choriocapillaris, RPE-retinal pigment epithelium, OS-outer segment, IS-inner 
segments, ONL-outer nuclear layer, OPL-outer plexiform layer, INL-inner nuclear layer. (B) With the 
help of F-actin and CD31 counterstaining using fluorescently labeled phalloidin and a labeled anti-
CD31 antibody, the precise localization of EXP3174-Qdots in the eye sections could be determined. 
Qdot fluorescence was limited to the capillaries and showed no distribution within the sclera or RPE. 
Arrowheads indicate the colocalization of CD31 and nanoparticles. BM-Bruch’s membrane. 
the endothelial fenestrations. Immunohistochemical staining of CD31 further confirmed 
association of the nanoparticles with endothelial cells, showing distinct colocalization of 
EXP3174-Qdot fluorescence with the CD31 endothelial cell marker (Fig. 4B arrowheads). 
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Similar to AT1R, CD31 is expressed on the surface of endothelial cells [59]. Since 
EXP3174-Qdots are not immediately internalized upon receptor binding but rest at the 
endothelial cell surface, the nanoparticles were not found inside the cell 1 h after 
intravenous injection as observed by the F-actin staining. 
3.4 EXP3174-coupled nanoparticles bind retinal vessels 
For a more complete picture of nanoparticle accumulation in the retinal blood vessels, 
retinas of mice that received either non-targeted or EXP3174-Qdots were flat-mounted 
and analyzed as a whole. Epifluorescence images of flat-mounted retinas from mice that 
received an intravenous infusion of non-targeted Qdots showed only a small degree of 
nanoparticle fluorescence throughout the retinal blood vessels, indicating that most of the 
Qdots had already exited from circulation. In contrast, retinas of mice that received 
EXP3174-Qdot displayed a high degree of nanoparticle accumulation in small and larger 
blood vessels (Fig. 5A). Upon magnification, EXP3174-nanoparticle binding to the retinal 
microvasculature was clearly evident, whereas non-targeted Qdots only sparsely adhered 
to the vessel walls. Confocal z-stack imaging analysis of EXP3174-Qdot-filled retinas 
showed nanoparticle fluorescence in all three layers of the retinal network: the superficial 
vascular plexus, the intermediate vascular plexus and the deep vascular plexus (Fig. 5B). 
Considering that in proliferative diabetic retinopathy these intraretinal capillaries begin to 
proliferate rapidly and sprout into the vitreous [60], this finding is quite promising. For a 
quantitative comparison of nanoparticle accumulation in the posterior eye, the cadmium 
concentration in retina and in the RPE/choroid/sclera complex was analyzed using ICP-
MS. In mice that received no Qdots at all, the Cd concentration was below the limit of 
quantitation of 5 ng g-1 tissue. Mice that intravenously received non-targeted Qdots had 
0.22 µg Cd g−1 whereas mice injected with EXP3174-Qdots accumulated a significantly 
higher dose of 0.40 µg Cd g−1 (Fig. 5C). 
Although the targeting and receptor binding we present could itself act as a therapeutic, 
encapsulation of a “second” drug to further potentiate the colloid’s therapeutic efficacy is 
possible. However, for this to occur, the base material for the nanoparticle would have to 
be altered to allow encapsulation and controlled release; therapeutic nanomaterials such 
as liposomes, polymeric micelles or poly(lactide-co-glycolide) (PLGA) nanoparticles are 
all possibilities. These colloids allow for attachment of a targeting moiety and 
simultaneous incorporation of an active therapeutic, which could be another small 
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molecule drug, an siRNA (e.g. targeting VEGF, hypoxia-inducible factor 1α [61] or 
erythropoietin [62]) or a plasmid (e.g. encoding for an anti-VEGF intraceptor [63]).  
 
Figure 5: Microscopic analysis of flat-mounted retinas. (A) Epifluorescence images of whole retina show a 
marked increase in nanoparticle accumulation for EXP3174-modified Qdots. At higher magnification, 
the capillary-associated nanoparticle fluorescence is clearly visible. scale bar: 1000 µm (top), 200 µm 
(bottom) (B) In a confocal z-stack picture, EXP3174-Qdot fluorescence can be clearly seen through all 
three retinal vascular layers. (C) When the nanoparticles are quantified by ICP-MS, a significantly 
higher concentration of cadmium can be found in mice that received EXP3174- Qdots. Data is 
expressed as mean ± SEM (n=6). Levels of statistical significance are indicated as: (*) p < 0.05 
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However, due to the different sizes of these colloids compared to the Qdots and the 
resulting impact on circulation and cellular interactions, a careful evaluation must be 
made.  
Due to multivalent binding of the EXP3174-modified nanoparticles, the colloids 
exclusively bind cells and tissues with a sufficiently high level of receptor expression at the 
cell surface. Differential AT1R expression between the retina (higher) and other organs 
(lower) is one possible reason targeted nanoparticles bind to the retinal vasculature but 
not to the endothelium of other organs such as the kidney. Notably, the ICP-MS values 
represent nanoparticle accumulation in the healthy posterior eye. During the course of 
choroidal neovascularization, the hallmark of exudative age-related macular 
degeneration, AT1R expression is dramatically increased [7], which would further 
augment the multivalent nanoparticle binding. Likewise, in streptozotocin-induced 
diabetic retinopathy AT1R expression is also markedly increased [8]. Although 
preferential binding of the targeted Qdots to the retinal or choroidal vasculature was not 
observed, AT1R up-regulation in the proliferating vessels of one or the other will naturally 
lead to increased binding of such multivalent nanoparticles to the diseased sites.  
In addition, when neovascularizations form in the posterior eye, blood vessels become 
leaky. This leads to enhanced permeation and retention (EPR) of macromolecular and 
colloidal structures [17], which is typically known from the angiogenesis of solid tumors. 
Around these leaky areas the microvascular blood velocity is decreased, which could 
further enhance the retention of the colloids and thus increase the capability to form a 
strong multivalent binding. Since AT1R blockade has beneficial effects on retinal 
cells [64,65], extravasation of ARB-targeted nanoparticles could further extend their 
therapeutic potential. 
4 Conclusion 
We have demonstrated that ARB-conjugated nanoparticles bind cells with high AT1R 
expression in vitro and retinal and choroidal blood vessels in vivo. Using confocal 
microscopy and intracellular calcium measurements we confirmed the multivalent 
binding of EXP3174-Qdots to their cognate receptor. Due to their multivalency EXP3174-
Qdots specifically accumulated in the intraretinal and choroidal blood vessels of the 
posterior eye in mice as shown with multi-spectral imaging and ICP-MS measurements. 
Moreover, the colloids only sparsely accumulate in off-target tissues such as the kidney, as 
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a prominent and well-perfused organ known to express AT1R. The multivalent targeting 
approach presented here opens the door for highly attractive nanoparticle targeting 
strategies in which nanoparticles are able to multivalently bind a tissue, exhibit a 
pharmacological effect and deliver a therapeutic payload.  
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1 Intracellular calcium measurements 
 
Figure S1: Using calcium mobilization with fura-2AM, EXP3174 blocked the angiotensin II-induced 
calcium influx into the cytosol of NCI-H295R cells with an IC50 of 2.0 ± 0.5 nM. 
2 Nanoparticle deposition in liver and spleen 
 
Figure S2: Accumulation of non-targeted and EXP3174-targeted Qdots in cryosections of liver and spleen 
after 1 h circulation as investigated by epifluorescence microscopy. Blue fluorescence depicts DAPI-
stained cell nuclei whereas red fluorescence represents the Qdots. Scale bar: 100 µm. 
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3 Nanoparticle accumulation in the posterior eye segment 
 
Figure S3: Multispectral-imaging of sagittal eye sections shows EXP3714-Qdot fluorescence in intraretinal 
blood vessels but no fluorescence of non-modified Qdots 
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Abstract 
The use of angiotensin receptor blockers (ARBs) for treatment of ocular diseases 
associated with neovascularizations, such as proliferative diabetic retinopathy, shows 
tremendous promise but is presently limited due to short intravitreal half-life. 
Conjugation of ARB molecules to branched polymers could vastly augment their 
therapeutic efficacy. EXP3174, a potent non-peptide ARB, was conjugated to branched 
poly(ethylene glycol) (PEG) and poly(amido amine) (PAMAM) dendrimers: 7.8 ligand 
molecules were tethered to each 40 kDa PEG molecule whereas 16.7 ligand molecules 
were linked to each PAMAM generation 5 dendrimer. The multivalent PEG and PAMAM 
conjugates blocked AT1R signaling with an IC50 of 224 and 36.3 nM, respectively. The 6-
fold higher affinity of the multivalent ligand-conjugated PAMAM dendrimers was due to 
their unique microarchitecture and ability to suppress polymer-drug interactions. 
Remarkably, both polymer-drug conjugates exhibited no cytotoxicity, in stark contrast to 
plain PAMAM dendrimers. With sufficiently long vitreous half-lives, both synthesized 
polymer-ARB conjugates have the potential to pave a new path for the therapy of ocular 
diseases accompanied by retinal neovascularizations. 
 
Introduction 
125 
1 Introduction 
Blockade of the angiotensin II receptor type 1 (AT1R) has proven highly beneficial for the 
treatment of retinal neovascularizations [1–3]. Unfortunately, systemic therapy with 
angiotensin receptor blockers (ARBs) only modestly inhibited disease progression [4]. 
Due to their high plasma protein binding [5] and the plethora of off-target sites that 
express the AT1 receptor [6], systemically administered ARBs lack intravitreal efficacy [7]. 
One way to overcome this limitation would be to increase intraocular drug bioavailability 
by directly injecting drugs into the vitreous chamber. In this way, intravitreally 
administered antibody formulations are able to sustain therapeutic drug concentrations 
for several weeks [8]. However, since ARBs have a drastically shorter intravitreal half-life, 
typically only a few hours [9], new techniques which sustain effective angiotensin receptor 
antagonism in the eye are urgently needed. One method proven to successfully increase 
the half-lives of intravitreal drugs is polymer conjugation; attachment of a 40 kDa 
poly(ethylene glycol) (PEG) molecule to pegaptanib (Macugen®), a vascular endothelial 
growth factor (VEGF)-binding RNA aptamer, significantly decreased its clearance from 
the eye [10], since the aptamer’s mobility in the vitreous humor was markedly 
slowed [11]. 
With the present approach, we explored the AT1R blocking potential of an angiotensin 
receptor antagonist conjugated to branched, eight-armed poly(ethylene glycol) with a 
molecular weight of 40 kDa or to poly(amido amine) (PAMAM) generation 5 
dendrimers. Specifically, we evaluated the multivalent receptor affinity and cytotoxicity of 
said constructs; in addition to intravitreal half-life, both AT1R affinity and cytotoxicity are 
key performance metrics for intravitreal inhibition of pathologic neovascularizations. 
PEG was chosen as a candidate polymer backbone due to its excellent 
biocompatibility [12] and because PEGylation is the most common strategy for half-life 
extension [13]. In addition, PAMAM dendrimers were used as an alternative polymer 
material because of their fundamentally different microarchitecture. Furthermore, 
PAMAM dendrimers selectively accumulate in neuroinflamed retinal cells after 
intravitreal injection and persist there for several weeks [14,15]. However, although 
chemical conjugation could potentially increase intravitreal drug half-life, attachment of 
small molecule ligands to PEG or other hydrophilic polymers can drastically alter their 
receptor binding capability. PEGylation of EXP3174, a non-peptide ARB which is the 
active metabolite of losartan, decreased its receptor affinity 580-fold [16]. Therefore, to 
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obtain highly affine conjugates, multivalent interactions between the cell surface receptors 
and the polymer-drug conjugate are highly desirable. Due to the small size of ARB 
molecules (mostly <500 Da), several ligands can be conjugated to one polymer molecule, 
possibly allowing for formation of multivalent ligand-receptor interactions.  
The present work aims to investigate the in vitro receptor binding affinity of EXP3174 
molecules after conjugation to polymeric scaffolds. Furthermore, since toxicity concerns 
are relevant for dendrimer-based therapeutics [17], cytotoxicity testing of plain and 
conjugated polymers was performed. Overall, this is the first study that addresses 
conjugation, affinity testing and cytotoxicity of multivalent polymer-drug conjugates that 
block angiotensin receptors. 
2 Experimental Section 
2.1 Materials 
The angiotensin receptor blocker EXP3174 was purchased from Santa Cruz (Heidelberg, 
Germany). Eight-armed poly(ethylene glycol), molecular weight 40 kDa (hexaglycerol 
core, 8armPEG40k-NH2 and eight-armed poly(ethylene glycol), molecular weight 20 kDa 
(hexaglycerol core, 8armPEG20k-OH) were purchased from JenKem Technology (Allen, 
TX, USA). Poly(amido amine) generation 5 dendrimers with an ethylene diamine core 
and 128 amine surface groups were purchased from Sigma Aldrich (Taufkirchen, 
Germany). 
All chemicals were obtained from Sigma Aldrich (Taufkirchen, Germany) in analytical 
grade unless stated otherwise. Ultrapure water was obtained from a Milli-Q water 
purification system (Millipore, Billerica, MA, USA). Dulbecco’s phosphate buffered saline 
(DPBS) pH 7.4 consisting of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl and 138 mM 
NaCl was purchased from Life Technologies (Carlsbad, CA, USA). 
2.2 Cell culture 
Rat mesangial cells were chosen as a model cell line for assaying receptor affinity due to 
their stable expression of AT1R, and were cultured in RPMI 1640 medium containing 
10 % fetal calf serum (FCS) (Sigma Aldrich, Taufkirchen, Germany) supplemented with 
insulin-transferrin-selenium (Life Technologies, Carlsbad, CA, USA), penicillin-
streptomycin (Life Technologies, Carlsbad, CA, USA) and 100 nM hydrocortisone. 
Mouse fibroblast L-929 cells (ATCC No. CCL-1) were cultured in Eagle's Minimum 
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Essential Medium (EMEM) containing 10 % FCS and were used for cytotoxicity 
measurements. All cells were cultured in T-75 cell culture flasks (Corning, Corning, NY, 
USA). 
2.3 Conjugation of EXP3174 to branched 8armPEG40k 
2.9 µmol EXP3174 were dissolved in 250 µL dimethyl sulfoxide (DMSO). After complete 
dissolution, 450 µL of 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer at 
pH 4.8, 200 µL of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
solution (EDC, 250 mM in MES buffer) and 100 µL of N-hydroxysulfosuccinimide (sulfo-
NHS, 100 mM in MES buffer) were added. The solution was stirred for 1 h for complete 
activation of EXP3174’s carboxylic group. Subsequently 0.18 µmol 8armPEG40k-NH2 in 
500 µL borate buffer (50 mM, pH 8.5) were added to the solution and stirred for 18 h at 
room temperature. After successful conjugation the mixture was diluted with water to a 
total volume of 4 mL and initially purified by ultrafiltration using a 10 kDa molecular 
weight cut-off Amicon Ultra-15 filter unit (Millipore, Billerica, MA, USA). The 
concentrated solution was further purified by size exclusion chromatography using a 
Sephadex G-25 resin in a PD-10 column (GE Healthcare, Munich, Germany) with DPBS 
as the eluent. The 8armPEG40k-EXP3174 concentration of each fraction was determined 
by fluorescence measurements: 50 µL of each fraction were diluted with 50 µL citrate 
buffer (100 mM, pH 2.5) and analyzed with an LS-55 fluorescence plate reader (Perkin 
Elmer, Waltham, MA, USA) using an excitation wavelength of 250 nm and an emission 
wavelength of 370 nm. Fractions containing 8armPEG-EXP3174 were pooled and further 
purified by 3-fold ultrafiltration as described above. 
2.4 Conjugation of EXP3174 to generation 5 PAMAM dendrimers 
1.5 µmol EXP3174 were dissolved in 500 µL DMSO and activated with 50 mM EDC and 
25 mM sulfo-NHS in 500 µL MES buffer (5 mM, pH 4.8), for a total reaction volume of 
1000 µL. After 1 h of activation in a glass reaction microtube, 0.15 µmol PAMAM G5 
dendrimer in 500 µL borate buffer (50 mM, pH 8.5) were added to the mix and stirred 
overnight. Purification of the dendrimer-EXP3174 conjugate was identical to the 
purification of the branched PEGs. To remove all EXP3174 molecules non-covalently 
‘encapsulated’ in the dendritic box, size exclusion chromatography was performed with 
DPBS as eluent. As an isotonic solution it will lead to rapid release of encapsulated 
EXP3174 due to weakening of electrostatic interactions between the cationic dendrimer 
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and the anionic EXP3174 as shown for other weak acids such as methotrexate [18] and 
ibuprofen [19]. 
2.5 Determination of concentration and degree of conjugation 
The total concentration and degree of labeling was determined by quantification of 
unreacted and reacted surface amine groups. Amine groups that had reacted with 
EXP3174 were quantified by measuring the EXP3174 fluorescence using an excitation 
wavelength of 250 nm and an emission wavelength of 370 nm. Briefly, conjugate solutions 
were diluted with citrate buffer (100 mM, pH 2.5), excited on a fluorescence plate reader 
and analyzed against an EXP3174 standard.  
The amount of unreacted amine groups was determined by a fluorescamine assay. Briefly, 
80 µL borate buffer (50 mM, pH 8.5), 10 µL fluorescamine solution (0.3 mg/mL in 
acetone) and 10 µL of test solution were mixed in 1.5 mL reaction tubes. The fluorescence 
was analyzed with an LS-55 fluorescence plate reader using an excitation wavelength of 
360 nm, a 430 nm beam splitter and an emission wavelength of 480 nm. Concentrations 
of unreacted amine groups were then determined by using a calibration of diluted 
solutions of respective unreacted polymers. The concentration of the conjugate was 
calculated using equation 1. 
cconjugate =
cEXP3174+ cunreacted amines
ntotal available amines
 
Equation 1: Calculation of conjugate concentration based on the measured concentrations of 
EXP3174 and unreacted amines 
Due to the long Stokes shifts of EXP3174 and EXP3174-amide[16] and because there is no 
overlap between the emission and extinction spectrum, non-radiative chromophore-
chromophore interactions such as FRET are impossible. Fluorescence self-quenching and 
thus distortion of ligand quantification measurements as described for fluorescein [20] or 
coumarin-based dyes [21] can, therefore, be ruled out for the EXP3174-conjugates. 
2.6 Reversed-phase high performance liquid chromatography (RP18-HPLC) 
The purity of EXP3174-conjugated branched PEGs and dendrimers was analyzed by a 
reversed phase high performance liquid chromatography (RP18-HPLC) system consisting 
of a Shimadzu LC-10ATVP pump (Shimadzu, Duisburg, Germany), a Shimadzu SIL-
10ADVP autosampler connected to a Shimadzu CTO-10ASVP column oven.  
Experimental Section 
129 
For elution of branched PEGs a Luna® 5 µm C18(2) 100 Å 250 x 4.60 mm LC column 
(Phenomenex, Aschaffenburg, Germany) was used. The mobile phase consisted of citrate 
buffer (pH 2.5, 50 mM)-acetonitrile (50:50 v/v) at a flow rate of 1 mL/min. The column 
temperature was maintained at 30 °C. A Shimadzu RF-10AXL fluorescence detector set to 
an excitation of 250 nm and an emission wavelength of 370 nm detected the conjugated 
polymers. 
PAMAM G5 dendrimers labeled with EXP3174 were analyzed using a Vydac 218 TP C18 
5 µm 300 Å 250 x 4.60 mm LC column (Sigma Aldrich) and eluted by a linear 
acetonitrile–trifluoroacetic acid (TFA)–water gradient with a flow rate of 1 mL/min. 
Elution was obtained by using the following gradient of solvents A (0.1 % (v/v) TFA in 
water) and B (0.1 % (v/v) TFA in acetonitrile): 90:10 (A:B) to 20:80 in 14 min and 
reequilibration to 90:10 in the following 8 min. The column was operated at 35 °C and the 
dendrimers were detected using the exact same technique used to detect PEG conjugates, 
described above.  
2.7 Intracellular calcium measurements 
The intracellular calcium concentration was measured with a plate reader-based system 
using the ratiometric fluorescent calcium chelator fura-2AM, as recently described [16]. 
Briefly, suspensions of rat mesangial cells were incubated with 5 µM fura-2AM (Life 
Technologies, Carlsbad, CA, USA) and 0.05 % Pluronic F-127 in Leibovitz’s L-15 medium 
(Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature in the dark. After 
removal of excess fura-2AM, the cells were incubated with a concentration series of 
EXP3174-conjugated polymers in 96-well plates (Greiner Bio One, Frickenhausen, 
Germany). After an incubation time of 10 min, a quantity equivalent to the EC80 of 
angiotensin II (300 nM, Bachem, Bubendorf, Switzerland) was added to the cells. The 
fluorescence signal was immediately recorded with a FluoStar Omega fluorescence 
microplate reader for 30 s. Excitation filters for the ratiometric measurement were 
340/20 nm and 380/20 nm and the emission was recorded using a 510/20 nm bandpass 
filter. The intracellular calcium concentrations were calculated using the Grynkiewicz 
equation [22]. 
2.8 Pyrene assay 
25 µL of a 40 mg/mL pyrene solution in acetone was pipetted into HPLC vials, yielding 
1 mg pyrene per vial. After evaporation with nitrogen, the vials were dried under vacuum 
Chapter 5 – Branched polymer-drug conjugates 
130 
for 1 h. Subsequently, 200 µL of an 8armPEG40K-EXP3174 or Ceteareth-20 (Kolb, 
Hedingen, Switzerland) dilution were added to a pyrene aliquot and incubated for 24 h 
under gentle shaking. Ceteareth-20 is an amphiphilic linear PEG(20) cetyl/stearyl ether 
and is also known as Sympatens ACS/200 G. In a next step, the solutions were centrifuged 
at 12,000 g for 10 min to sediment undissolved pyrene. 100 µL of the supernatant was 
transferred to a 96-well fluorescence plate (Greiner Bio One, Frickenhausen, Germany). 
Pyrene fluorescence was analyzed with an LS-55 fluorescence plate reader using an 
excitation wavelength of 339 nm, a 350 nm beam splitter and an emission wavelength of 
390 nm. 
Emission spectra of pyrene were obtained by dissolving a 10 µg pyrene aliquot in 2 mL of 
pure water, an aqueous solution of 0.025 % Ceteareth-20 or an aqueous solution of 
0.025 % 8armPEG40k-EXP3174. Pyrene fluorescence was excited at 339 nm and recorded 
from 350 to 450 nm with an LS-55 fluorescence plate reader using a quartz glass cell 
(Hellma, Müllheim, Germany). 
2.9 Labeling and analysis of 8armPEG20k-AngII 
8armPEG20k-succinimidyl carbonate (8armPEG20k-SC), the precursor of the labeling 
reaction, was synthesized as described in the literature [23]. For the preparation of the 
ligand-polymer conjugate, 4 µmol angiotensin II were mixed with 0.25 µmol 
8armPEG20k-SC, yielding a 16-fold excess of ligand over polymer. In a total volume of 
1000 µL borate buffer (50 mM, pH 8.5) the solution was stirred for 16 h at room 
temperature. Purification of the resulting conjugate was achieved with the help of 
ultrafiltration and size exclusion chromatography. First, unreacted angiotensin II was 
removed via ultrafiltration using a 10 kDa molecular weight cut-off Amicon Ultra-15 
filter unit. Second, the concentrated solution was purified by size exclusion 
chromatography using a Sephadex G-25 resin in a PD-10 column with DPBS as the 
eluent. The 8armPEG20k-AngII concentration of each fraction was determined with a 
bicinchoninic acid (BCA) Assay using the Pierce™ BCA Protein Assay Kit (Life 
Technologies). Briefly, 25 µL of each fraction were thoroughly mixed with 200 µL of the 
reagent mix containing 196 µL kit reagent A and 4 µL kit reagent B. After a 30 min 
incubation at 37 °C the fractions were analyzed on a plate reader at 562 nm. Subsequently, 
fractions containing 8armPEG20k-AngII were pooled and further purified by 
ultrafiltration as described above. 
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The concentration of the conjugate was analyzed with the help of RP18-HPLC and a well-
plate PEG determination assay. For the latter, 125 µL 8armPEG20k-SC solutions yielding 
a final concentration of 2.5 µg/mL to 25 µg/mL 8armPEG20k-SC were mixed with 50 µL 
of a 5 % BaCl2 solution in 1 M hydrochloric acid and 25 µL of 0.1 N iodine solution (Carl 
Roth, Karlsruhe, Germany). The 8armPEG20k-AngII solution was prepared similarly. 
After a 15 min incubation at room temperature the absorbance of the PEG-iodine 
complex was measured at 535 nm. Ang II concentration and purity were analyzed with a 
RP18-HPLC system using a Luna® 5 µm C18(2) 100 Å 250 x 4.60 mm LC column. Elution 
of angiotensin II and its polymer conjugate was obtained by using the following gradient 
of solvents A (0.1 % (v/v) TFA in water) and B (0.1 % (v/v) TFA in acetonitrile): 85:15 
(A:B) to 30:70 in 14 min and reequilibration to 85:15 in the following 8 min.  
2.10 Cytotoxicity 
To assess the cellular toxicity of the synthesized conjugates, a metabolic assay using the 
reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) 
(PanReac AppliChem, Darmstadt, Germany) according to ISO 10993-5:2009 (Biological 
evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity) was performed. 
Briefly, mouse fibroblast L-929 cells were seeded in 96-well plates at a density of 10,000 
cells per well. After the cells had adhered overnight, the conjugate test solutions, which 
were prepared in EMEM medium with 10 % FCS, were pipetted onto the cells and 
incubated for 4 h in a humidified incubator with a 5 % CO2 atmosphere. Subsequently, the 
test solutions were substituted by a 1.5 mM MTT solution in serum-containing medium 
and similarly incubated for 4 h. After removal of the MTT solution, 80 µL of a 10 % 
sodium dodecyl sulfate (SDS) solution was added to each well. The plates were incubated 
at room temperature overnight to completely solubilize the synthesized purple formazan 
derivative. Finally, the absorbance at 570 nm and 690 nm was measured for each well 
using a FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg, 
Germany). The difference (A570 - A690) was used to calculate the viability of cells. As a 
viability control, cells were incubated with serum containing medium alone. In contrast, a 
0.1 % SDS solution was used as positive control to ensure complete cell death. Where 
possible, IC50 values were calculated with SigmaPlot 12.2 using sigmoidal dose-response 
curve fitting with a variable slope. Microscope images were recorded with a Nikon DS-U1 
camera (Nikon, Düsseldorf, Germany) connected to a Leica DM IRB microscope (Leica, 
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Wetzlar, Germany) and processed using ImageJ (NIH, Bethesda, MD, USA, 
http://imagej.nih.gov/ij). 
2.11 Flow cytometric assessment of apoptosis 
Mouse fibroblast L929 cells were grown to subconfluency and harvested by trypsinization. 
Subsequently, 100,000 suspended cells were incubated with 10 µM PAMAM G5-NH2 or 
10 µM PAMAM G5-EXP3174 in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % fetal calf serum. Cells were incubated with pure FCS-containing 
medium as live control. After 4 h of incubation at 37 °C, cells were centrifuged (200 rpm, 
5 min) and resuspended in Tyrode’s solution (20 mM HEPES, 134 mM NaCl, 2.9 mM 
KCl, 5 mM glucose, 0.34 mM NaH2PO4, 1 mM MgCl2, 12 mM NaHCO3, 1 mM CaCl2 and 
0.5 % bovine serum albumin) containing 2.5 µg/mL FITC-lactadherin (Haematologic 
Technologies, Essex Junction, VT, USA). After further incubation for 30 min at room 
temperature, propidium iodide (Sigma Aldrich) was added to a final concentration of 
1 µg/mL. Finally, cells were analyzed on a FACSCalibur flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA). FITC-lactadherin and propidium iodide (PI) 
fluorescence were both elicited by excitation at 488 nm and recorded using a 530/30 nm 
FL1 bandpass filter and a 670 nm FL3 longpass filter, respectively. The resulting data was 
evaluated using WinMDI 2.9 (The Scripps Research Institute, San Diego, CA, USA). The 
population of intact cells was gated and used for fluorescence analysis. All experiments 
were performed in triplicate. 
2.12 Statistics 
To assess the statistical significance of cytotoxicity data, Student’s t-tests were carried out 
using SigmaPlot 12.2. Levels of statistical significance were set as indicated. 
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3 Results and Discussion 
3.1 Conjugation procedure and purification 
Our two-step synthesis strategy provided us with two branched polymer-EXP3174 
conjugates: an 8armPEG40k polymer, (Fig. 1B) with an average of 7.8 conjugated 
antagonist molecules per polymer molecule and a PAMAM generation 5 dendrimer, 
(Fig. 1A) to which 16.7 molecules of EXP3174 were bound on average. This left only 0.2 
unreacted amine groups for the branched PEG. In contrast, only 13 % of 128 total amine 
groups on the PAMAM dendrimer surface reacted with EXP3174, leaving the majority of 
terminal amine groups unreacted. 
 
Figure 1: Chemical structure of the polymers used and their conjugation to EXP3174. (A) Depiction of a 
generation 1 PAMAM dendrimer representing the ethylene diamine core and the typical tree-like 
structure of PAMAM dendrimers. (B) Chemical structure of an 8armPEG-NH2 molecule. Depending 
on the molecular weight the individual PEG chains differ in their total length (C) The conjugation 
procedure to covalently couple EXP3174 to the terminal amine groups of the polymers using 
EDC/sulfo-NHS chemistry and a 2-step buffer system. 
To ensure that no unreacted EXP3174 was present after the purification, as this would 
distort affinity measurements, reversed phase high performance liquid chromatography 
(RP18-HPLC) was conducted. Due to its bright fluorescence, EXP3174 concentrations 
down to a minimum of 0.5 ng/mL can be quantified by HPLC analysis [24]. Neither the 
8armPEG40k-EXP3174 nor the PAMAM G5-EXP3174 dendrimer exhibited free 
EXP3174 (Fig. 2). In the chromatogram corresponding to the G5-EXP3174 dendrimer, a 
second peak appeared at a retention time of 13.0 min, clearly distinct from the EXP3174 
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peak at 13.6 min. This peak most likely represented oligomeric branching defects such as 
dimers and trimers present in the purchased dendrimer [25,26]. Since the ultrafiltration 
and size exclusion chromatography purifications only eliminated smaller impurities and 
trailing generations, it is expected that the slower-eluting oligomeric branching defects 
reacted with EXP3174 and were retained post-purification. Conjugation of EXP3174 to 
the polymers led to decreased retention times in the reversed phase HPLC, clearly 
indicating successful conjugation of the hydrophobic ligand to the hydrophilic polymers. 
 
Figure 2: RP18-HPLC chromatograms of the conjugated polymers. (A) HPLC Chromatogram of 8arm-
PEG40K-EXP3174 and EXP3174 for comparison. Due to the highly hydrophilic polymer, the 
conjugate has a markedly faster elution. The chromatogram shows the absence of free EXP3174, 
proving the success of the purification procedure (B) HPLC chromatogram of PAMAM G5-EXP3174 
and free EXP3174 for comparison. Again, the hydrophilic G5 PAMAM dendrimer is eluted earlier 
than EXP3174 and shows no unreacted EXP3174. The additional peak in the chromatogram can 
presumably be attributed to multimeric impurities. 
3.2 Conjugate affinity 
The affinity of the synthesized EXP3174 conjugates for AT1R was measured with an 
intracellular calcium mobilization assay using fura-2AM. Because the AT1R is a Gq-
coupled receptor [27], calcium ions act as a second messenger in the cytosol. Upon 
angiotensin II receptor binding, the intracellular calcium concentration rapidly increases, 
resulting in calcium chelation by supplemented fura-2. The binding of calcium ions to 
fura-2 leads to a distinct change in the dye’s excitation spectrum [28], which permits the 
calculation of calcium ion concentrations, and thus ligand affinities. The 8armPEG40k-
EXP3174 polymer-drug conjugate exhibited a receptor binding affinity of 224 ± 34 nM. 
Although PAMAM G5-EXP3174 showed a 6-fold improved affinity towards AT1R, with 
an IC50 of 36.3 ± 4.6 nM (Fig. 3A), the conjugate affinity was about 30-fold lower than the 
native ligand’s affinity, which is approximately 1 nM [16]. Interestingly, when normalized 
on a per-unit-ligand basis, the affinity of the dendrimer-bound EXP3174 was still 3-fold 
higher (606 nM) than that of the branched 8armPEG-bound EXP3174 (1750 nM). 
Compared to the affinity of a linear mPEG5k-EXP3174 conjugate, which was 
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approximately 630 nM [16], the attachment of EXP3174 to the multi-arm PEG polymers 
decreased its affinity even further. Besides the affinity loss from steric hindrance of the 
PEG chain, another effect apparently prevents EXP3174 from binding its cognate 
receptor. The flexible nature of the PEG chains of the multi-arm PEGs could lead to 
extensive wrapping of the PEG molecule around the ligand, leading to masking of the 
ligand (Fig. 3B). This shroud formation has been observed with PEGylated proteins such 
as PEGylated staphylokinase [29] PEGylated trypsin [30] and PEGylated bovine serum 
albumin [31]. García-Arellano and coworkers proposed that conjugated PEG coils around 
the protein surface and thus acts as a cage due to interactions between the hydrophobic 
cluster on the protein surface and the hydrophobic regions of PEGs [32]. In general, the 
biphenylimidazole class of angiotensin receptor antagonists are also quite hydrophobic, 
resulting in the potential for a similar interaction with PEG. That EXP3174 has strong 
hydrophobic character can be observed from its tremendous plasma protein binding of 
over 99.7 % [33]. In addition, losartan, the precursor of EXP3174, has a poor aqueous 
solubility of only 71.4 µg/mL [34]. Although EXP3174 possesses an additional carboxylic 
group, its solubility is not increased. In addition, this extra acidic character is abolished 
when EXP3174 is present as part of a polymer conjugate, as the carboxylic acid is used to 
link EXP3174 to the polymers’ terminal amines. 
 
Figure 3: Affinity measurements of polymer-drug conjugates (A) Intracellular calcium mobilization dia-
grams for both EXP3174-conjugated polymers. The PAMAM generation 5 dendrimer showed an IC50 
of 36.3 ± 4.6 nM. In contrast, the 8armPEG40K branched star polymer inhibited the angiotensin II-
induced receptor signaling with an IC50 of 224 ± 34 nM. (B) Schematic depiction of ligand-conjugated 
dendrimer and 8armPEG polymer binding to cell surface receptors. The extended structure of the 
dendrimer allows for easier multivalent binding. For simplicity’s sake a generation 4 dendrimer is 
pictured. 
In contrast to the coiling of PEG, poly(amido amine) chains of dendrimers exhibit a 
greatly different microarchitecture. At neutral pH conditions, at which the receptor 
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binding experiments were performed, most of the primary amines are charged [35], 
leading to electrostatic repulsion between neighboring groups [36]. Consequently, 
dendrimers of generation 4 to 6 show a significant ‘stretching-out’ effect [37], which 
results in the presentation of the ligands on the dendrimer surface [38]. Through 
molecular dynamics simulations Maiti and coworkers revealed that 75 of the 128 terminal 
amines of the PAMAM G5 dendrimer are located at the periphery under neutral pH 
conditions resulting in a high sphericity of the dendrimer [39]. Together with fact that the 
G5 dendrimer is a threshold generation between the sterically crowded and thus more 
rigid dendrimers (G ≥ 6) and the more flexible dendrimers (G ≤ 4) [40], its stretched-out 
structure could be the reason that the PAMAM G5-EXP3174 dendrimer exhibited a 
higher multivalency and thus an increased avidity for the receptors compared to the 
8armPEG40k-EXP3174 conjugate (Fig. 3). That dendrimers have the capability to enable 
multivalent binding of cell surface receptors was already demonstrated for 
concavalin A [41], folic acid receptors [42] and the adenosine A3 receptor [43]. Notably, 
Banaszak Holl and coworkers showed that due to strong nonspecific interactions between 
dendrimers and the folate binding protein, a monovalent folic acid-PAMAM dendrimer 
conjugate exhibited enhanced binding when compared to free folic acid [44]. Bao and 
coworkers synthesized a chitosan-poly(ethyleneimine)-candesartan conjugate for 
inhibition of tumor-associated angiogenesis [45]. However, instead of multivalent AT1R 
blockade, their complexes were designed to release candesartan in a controlled fashion 
upon linker cleavage. 
Although conjugation to polymer scaffolds markedly decreased the binding affinity of the 
antagonists (Table 1), a significantly increased intravitreal half-life could readily 
compensate for the loss of affinity. For example, despite a four-fold reduction in the 
affinity of pegaptanib towards VEGF following aptamer PEGylation [46], the greatly 
decreased elimination from the vitreous humor still led to improved therapeutic 
efficacy [47] and ultimately introduction of the PEGylated form onto the market [48]. 
Since ARB molecules are rapidly cleared from the vitreous in only few hours [9], an 
extension of the intravitreal half-life could be even more pronounced for these molecules. 
In addition, Iezzi and coworkers impressively showed that after intravitreal injection, 
PAMAM dendrimers were retained in the neuroinflamed retina for more than one month 
and accumulated in activated microglia [14]. In a similar fashion, hydroxyl-terminated 
PAMAM dendrimers accumulated for several weeks in an ischemia/reperfusion mouse 
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eye [15]. Thus, conjugation to polymers could tremendously increase antagonist efficacy 
although binding affinity is initially decreased. 
3.3 Investigation of hydrophobic interactions 
To investigate whether the decreased affinity of the 8armPEG40k-EXP3174 conjugate was 
due to the formation of micellar structures between several ligand molecules or due to 
polymer-drug interactions, a pyrene assay was conducted. Upon micelle formation, the 
hydrophobic pyrene exhibits an increased effective aqueous solubility, yielding a 
measurable increase in fluorescence. Similar to linear PEG, branched PEG can easily form 
micelles and micelle-like structures when its chain ends are tethered to hydrophobic 
molecules [49–51]. For 8armPEG40k-EXP3174 at concentrations up to approximately 
0.1 % (m/V), which corresponded to the highest tested concentration in the affinity 
measurements (30 µM), no increase in pyrene fluorescence was observed, indicating that 
the ligand-PEG conjugate did not form micelle-like structures (Fig. 4A). In contrast, 
Ceteareth-20, also known as Sympatens ACS/200G, is an amphiphilic linear PEG (20) 
cetyl/stearyl ether and clearly demonstrated increased pyrene fluorescence and thus 
formation of micelles over the same range of concentrations (Fig. 4A). Depending on the 
hydrophobicity of the environment, the emission spectrum of pyrene changes 
significantly; relative intensities of the five vibronic bands found in the fine structure 
change noticeably and can be used to probe hydrophobic cavities [52]. The ratio of I1 
(372 nm) to I3 (383 nm) was 1.7 for pyrene in ultrapure water (Fig. 4B). The vibronic band 
I3 is insensitive to the environment whereas I1 greatly varies upon hydrophobicity changes 
of the solvent [53]. When pyrene was incubated with an aqueous solution of Ceteareth-20 
the I1/I3 fluorescence ratio was reduced to 1.0, which clearly indicated changes in the 
hydrophobicity of the probe environment. However, when pyrene was incubated with an 
aqueous solution of 8armPEG40k-EXP3174 its emission spectrum was almost identical to 
the spectrum in water, with a nearly identical I1/I3 ratio of 1.7 (Fig. 4B). This 
demonstrated that pyrene was solely surrounded by water molecules and that polymer-
tethered EXP3174 molecules did not form hydrophobic cavities to which pyrene 
distributed.  
To further investigate the influence of ligand hydrophobicity on conjugate affinity for 
AT1R, the AT1R agonist angiotensin II (Ang II) was conjugated to the arms of an 
8armPEG20k polymer. As opposed to most ARBs, Ang II is a hydrophilic molecule with 
good aqueous solubility of about 25 mg/mL. Via reaction with 8armPEG20k-succinimidyl 
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carbonate, the N-terminal amine group of Ang II was covalently bound to the branched 
polymer. After conjugation and purification, around 4.6 Ang II molecules were 
conjugated to each polymer. This 8armPEG20k-Ang II activated the receptor with an EC50 
of 225 ± 13 nM, which was only 3.2-fold less affine than free Ang II (Fig. 4C). In contrast, 
8armPEG40k-EXP3174 had a 200-fold decreased affinity when compared to free 
EXP3174, which underscores the impact of ligand hydrophobicity on affinity. However, 
due to different PEG lengths, different receptor binding pockets and different receptor 
responses upon ligand binding, the comparison of 8armPEG40k-EXP3174 and 
8armPEG20k-Ang II must be interpreted with caution.  
 
Figure 4: Investigation of the decreased affinity of ligand-conjugated branched PEGs. (A) With the help of a 
pyrene assay the capability of 8armPEG40k-EXP3174 to form micellar structures was investigated. 
Ceteareth-20, a PEG-containing surfactant, was used as a positive control. (B) Pyrene in water and a 
solution of 8armPEG40k-EXP3174 exhibited similar emission spectra. In a solution of Ceteareth-20 
the vibronic bands of pyrene emission clearly changed. (C) When the hydrophilic AT1R ligand 
angiotensin II was conjugated to an 8armPEG20k polymer its affinity was only decreased by 3.2-fold. 
3.4 Conjugate cytotoxicity 
Finally, the cytotoxicity of the conjugates and their precursors was assessed using an MTT 
assay, performed with mouse fibroblast L-929 cells according to ISO 10993-5:2009. First, 
in 96-well plates, seeded L-929 cells were incubated with PEG polymers or PAMAM 
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dendrimers for 4 hours. Then, after removal of the test solutions, water-soluble MTT was 
added to the cells. Viable and active cells reduce MTT to an insoluble purple formazan, 
whose concentration can be determined after solubilization with sodium dodecyl sulfate.  
 
Figure 5: Cytotoxicity of unconjugated and EXP3174-conjugated polymers as tested with an MTT and 
apoptosis assay. (A) Besides the raw PAMAM generation 5 dendrimers, the polymers showed no 
toxicity in L-929 cells over the range of concentrations within the incubation time of 4 h. The dashed 
line indicates 70 % cell viability. Levels of statistical significance are indicated as: (*) p < 0.01 compared 
to cell viability of PAMAM G5-EXP3174 at the same concentration (B) Microscopic pictures of L-929 
cells after 4 h incubation with the respective polymers. Cells incubated with unfunctionalized PAMAM 
generation 5 dendrimer display severe cellular damage. (C) When apoptosis was quantified using 
phosphatidylserine detection, PAMAM G5-NH2 but not PAMAM G5-EXP3174 induced apoptosis in 
L929 cells. Levels of statistical significance are indicated as: (**) p < 0.01; (n.s.) p > 0.05 compared to 
live control. 
In our tests neither unconjugated 8armPEG40k-NH2 nor 8armPEG40k-EXP3174 
exhibited any cytotoxicity over the tested concentration range, up to 30 µM (Fig. 5A), 
consistent with the well-known biocompatibility of PEG. In contrast, incubation with 
unconjugated PAMAM generation 5 dendrimers had a substantial influence on cell 
viability: after 4 h of incubation the cellular dye-reducing potential decreased to 28 % 
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compared to the control (Fig. 5A), demonstrating pronounced cell death. The LC50 
(concentration that leads to 50 % cell death) was 2.7 µM, which agrees well with PAMAM 
dendrimer cytotoxicity studies by Roberts et al. [54]. Due to the high surface density of 
cationic groups, the dendrimers readily interact with negatively charged cell membranes 
leading to membrane disruption, pore formation and ultimately, cell death [55]. 
Microscopic pictures of cells following incubation with plain PAMAM dendrimers 
further revealed the toxic nature of unconjugated dendrimers (Fig. 5B). A vast amount of 
cellular debris was visible, which suggested the formation of apoptotic bodies due to the 
induction of programmed cell death by plain dendrimers. When quantified by a flow 
cytometry-based apoptosis assay using fluorescently labeled-lactadherin, it was clearly 
observable that treatment with plain amine-terminated PAMAM dendrimers induced 
apoptosis in the majority of L929 cells (Fig. 5C). As a result, lactadherin-positive 
apoptotic bodies were generated upon treatment with plain dendrimers (Supporting 
information, Fig. S1). This is in line with observations that exposing cells to plain 
PAMAM dendrimers leads to generation of reactive oxygen species (ROS) [56,57], 
disruption of the mitochondrial membrane potential [58,59], and ultimately apoptosis. 
For this reason, several strategies to reduce the inherent toxicity of PAMAM dendrimers 
have been employed, which include acetylation [60], PEGylation [61] or attachment of 
small carbohydrates to yield glycodendrimers [62]. Remarkably, PAMAM G5-EXP3174 
dendrimers showed no cytotoxicity over the tested range of concentrations, up to 10 µM. 
None of the concentrations reduced the cell viability below 70 %, which is the threshold of 
biocompatibility according to ISO 10993-5:2009. Apparently, substitution of 
approximately 16 of the total 128 surface amine groups significantly altered the toxicity 
profile for L-929 cells. In contrast to cells that were incubated with unconjugated 
dendrimers, cells exposed to PAMAM G5-EXP3174 showed neither observable cell 
toxicity nor alteration of cell morphology (Fig. 5B). Furthermore, PAMAM G5-EXP3174 
dendrimers did not induce significant apoptosis (Fig. 5C) or formation of apoptotic 
bodies (Supporting information, Fig. S1) in L929 cells, which was in stark contrast to 
amine-terminated PAMAM dendrimers. 
However, in scenarios where further derivatization or bioconjugation is intended, the 
substantial number of surface-facing functional groups per dendrimer molecule can be 
considered a distinct advantage. Aside from the amino groups used for ligand 
conjugation, the remaining amines can be utilized to attach fluorescent or radioactive 
labels, which help track the polymers in cell culture and in vivo environments. 
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Commercially available isothiocyanates or NHS-esters of fluorophores and chelating 
agents readily react with these amine groups. NHS-esters of anionic chelators show 
especially high conjugation efficiency when reacted with dendrimers, due to strong 
electrostatic interactions between the anionic NHS esters and the cationic dendrimer 
surface [63]. If desired, unnecessary surface amine groups can be acetylated to yield multi-
functional drug delivery platforms.  
Table 1 
Overview of native EXP3174 and the synthesized ligand-coupled polymers 
conjugate 
# EXP3174 
ligands 
# unreacted 
amines 
Conjugate 
affinity 
(nM) 
Affinity per 
ligand (nM) 
Toxicity, 
IC50 
(µM) 
EXP3174 1 n/a 
1.1 ± 0.2 
[16] 
1.1 ± 0.2 n/a 
mPEG5k-
EXP3174 
1 0 
630 ± 130 
[16] 
630 ± 130 n/a 
8armPEG40K-
EXP3174 
7.8 0.2 224 ± 34 1750 > 30 
PAMAM G5-
EXP3174 
16.7 111.3 36.3 ± 4.6 606 > 30 
4 Conclusions 
Multivalent polymer-drug conjugates that bind and block AT1R have been successfully 
synthesized. Conjugation of EXP3174 to generation 5 PAMAM dendrimers resulted in a 
higher overall and per-ligand affinity than the branched PEG conjugates, presumably due 
to hydrophobic ligand-polymer interactions that masked the ligand. EXP3174 
conjugation to dendrimers, and the concomitant reduction of surface amine groups, 
resulted in a significant decrease in the toxicity of the conjugate relative to the original 
dendrimer. Optimization of ligand density on PAMAM dendrimers could further 
increase the degree of multivalency, and hence increase the overall affinity. Derivatization 
of the remaining amine groups with fluorescence or radioactive labels could help track the 
in vitro or in vivo fate of these conjugates. This is the first study to report polymer-drug 
conjugates that effectively block angiotensin receptors. 
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Flow cytometric apoptosis detection 
 
Figure S1: Flow cytometry analysis of apoptosis induced by PAMAM G5 dendrimers. A 4 hour incubation 
of L929 cells with 10 µM PAMAM G5-NH2 led to distinct apoptosis in the majority of cells as shown 
by lactadherin binding to externalized phosphatidylserine. In contrast, 10 µM PAMAM G5-EXP3174 
induced no apoptotic events. Upon treatment with PAMAM G5-NH2, lactadherin-positive apoptotic 
bodies are formed. 
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Abstract 
The angiotensin II receptor type 1 (AT1R) is a G protein-coupled receptor of paramount 
significance since it is overexpressed in a number of diseased tissues that are highly 
attractive for nanoparticle targeting. However, it is also expressed at physiological levels in 
healthy tissue. Multivalent interactions mediated by multiple AT1R-binding moieties per 
nanoparticle could promote a high binding avidity to AT1R overexpressing cells and 
concomitantly spare off-target tissue. To investigate the feasibility of this approach, 
angiotensin II was thiolated and conjugated to PEGylated quantum dots. Nanoparticle 
binding, uptake and affinity to several cell lines was investigated in detail. The colloids 
were rapidly taken up by clathrin-mediated endocytosis into AT1R-expressing cells and 
showed no interaction with receptor negative cells. The EC50 of the thiolated 
angiotensin II was determined to be 261 nM, whereas the ligand-conjugated Qdots 
activated the receptor with an EC50 of 8.9 nM. This 30-fold higher affinity of the 
nanoparticles compared to the unconjugated peptide clearly demonstrated the presence of 
multivalent effects when using agonist-targeted nanoparticles. Our study provides 
compelling evidence that, despite being immediately endocytosed, Ang II-coupled 
nanoparticles exert potent multivalent ligand-receptor interactions that can be used to 
establish high affinities to an AT1R overexpressing cell and tissue. 
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1 Introduction 
The angiotensin II receptor type 1 (AT1R) is an attractive target for nanoparticle-based 
drug delivery due to its marked overexpression in severe pathologies such as myocardial 
infarctions [1,2], cancer [3,4] or choroidal neovascularization [5]. With the present work 
we demonstrate that nanoparticles to which the physiological ligand angiotensin II 
(Ang II) is conjugated are able to bind cells expressing the AT1 receptor in a multivalent 
nature. Although particles with similar targeting moieties have already been prepared for 
targeting the infarcted heart [2] and for studying receptor trafficking routes [6,7], the 
ability of AT1R-targeted nanoparticles to bind several receptors simultaneously has never 
been investigated. In situations such as this, where targeting of a receptor present in both 
healthy and diseased tissue is desirable, multivalency allows for preferential binding of 
ligand-targeted nanoparticles to cells that overexpress the targeted receptor [8]. 
Concomitantly, interactions with off-target cells that express the receptor at a lower level 
can be minimized. In the case of the AT1R this is of fundamental importance since AT1 
receptors, which are usually known for their role in blood pressure regulation and fluid 
retention, are not only overexpressed in diseased tissue but also expressed at physiological 
levels within off-target tissues like the endothelium [9] or the kidney glomerulus [10,11]. 
Both are exposed to intravenously administered nanoparticles during their circulation in 
the blood [12] and are prone to off-target nanoparticle binding [13,14]. 
We recently demonstrated that angiotensin receptor blockers (ARBs), when immobilized 
on a nanoparticle surface, bind AT1 receptors by a multi-ligand binding mechanism [15]. 
However, ARBs do not provoke receptor internalization after binding [16]. This gives the 
ARB-conjugated particles sufficient time to reach out to further receptors on the cell 
surface and consequently build up a strong multivalent binding. In contrast to the 
antagonists, the agonist Ang II immediately induces receptor internalization after 
binding [17], which we hypothesized could impair the formation of stable multivalent 
interactions. Furthermore, we were interested if nanoparticles would still be taken up by 
cells, despite crosslinking several receptors, and thus, exhibiting multivalent attachment 
to the cell surface. Multivalent interactions between cells and nanoparticles have already 
been reported for other important receptors such as transferrin receptor [18,19], folate 
receptor [20,21] or the human epidermal growth factor receptor 2 (HER2) [22,23]. 
To gain insight into the multivalent nature of Ang II-coupled nanoparticles, the ligand 
was coupled to highly fluorescent core-shell quantum dots (Qdots). Flow cytometry and 
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confocal microscopy were utilized to investigate nanoparticle endocytosis, subcellular 
localization and mechanism of uptake. Changes in intracellular calcium concentrations 
induced by both the soluble ligands and the ligands conjugated to the nanoparticle surface 
were measured to quantify the degree of nanoparticle multivalency towards AT1 
receptors. 
2 Material and methods 
2.1 Materials 
Qdots® 655 ITK™ amino PEG (#Q21521MP, Life Technologies, Carlsbad, CA, USA) were 
used as nanoparticle starting material. Losartan carboxylic acid, also known as EXP3174, 
was purchased from Santa Cruz (Heidelberg, Germany). All chemicals were obtained 
from Sigma Aldrich (Taufkirchen, Germany) in analytical grade unless stated otherwise 
and used without further purification. Ultrapure water was obtained from a Milli-Q water 
purification system (Millipore, Billerica, MA, USA). Dulbecco’s phosphate buffered saline 
(DPBS) pH 7.40, which was used for nanoparticle purification and cell experiments, 
consisting of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl and 138 mM NaCl, was 
purchased from Life Technologies (Carlsbad, CA, USA). 
2.2 Cell culture 
Rat mesangial cells were a kind gift from Dr. Armin Kurtz (Department of Physiology, 
University of Regensburg, Germany) and were cultured in RPMI1640 medium containing 
10 % fetal bovine serum (Sigma Aldrich, Taufkirchen, Germany) supplemented with 
insulin-transferrin-selenium (Life Technologies, Carlsbad, CA, USA), penicillin-
streptomycin (Life Technologies, Carlsbad, CA, USA) and 100 nM hydrocortisone. 
Human adrenal gland carcinoma cells NCI-H295R (ATCC No. CRL-2128) were 
maintained in the same medium. HeLa cells (ATCC No. CCL-2) were cultured in Eagle's 
Minimum Essential Medium (EMEM) containing 10 % fetal calf serum (FCS) and 1 mM 
sodium pyruvate. All cells were cultured in T-75 cell culture flasks (Corning, Corning, 
NY, USA). 
2.3 Thiolation of angiotensin II 
1.5 µmol angiotensin II (Bachem, Bubendorf, Switzerland) was reacted with 1.875 µmol 2-
iminothiolane HCl in borate buffer pH 8.00 (50 mM) for 24 h at room temperature. The 
resulting N-substituted 2-iminothiolate intermediate was hydrolyzed for 48 hours in 
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acetate buffer pH 5.00 (100 mM), to which ethylenedinitrilotetraacetic acid disodium salt 
(Merck, Darmstadt, Germany) in a concentration of 1 mM was added. 
To quantify the amount of reactive thiol groups, an Ellman’s assay was performed. Briefly, 
a sample of thiolated peptide was incubated with (5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB) in phosphate buffer pH 8.00 (100 mM) for 15 min and analyzed on a UVIKON 
900 double-beam spectrophotometer (Kontron instruments, Milan, Italy) at a wavelength 
of 412 nm. Using a molar extinction coefficient of 14,150 M-1cm-1 the concentration of the 
thiolated peptide was quantified. Purity and conversion were further analyzed by high-
performance liquid chromatography (HPLC) and electrospray ionization mass 
spectrometry (ESI-MS). The HPLC system consisted of a Shimadzu LC-10ATVP pump 
(Shimadzu, Duisburg, Germany), a Shimadzu SIL-10ADVP autosampler connected to a 
Shimadzu SPD-10A UV-Vis detector. A Luna® 5 µm C18(2) 100 Å 250 x 4.60 mm LC 
column (Phenomenex, Aschaffenburg, Germany) was used as stationary phase. The 
peptides were analyzed based on a linear acetonitrile–trifluoroacetic acid (TFA)–water 
gradient with a flow rate of 1 mL/min. Elution was obtained by using the following 
gradient of solvents A (0.1 % (v/v) TFA in water) and B (0.1 % (v/v) TFA in acetonitrile): 
90:10 (A:B) to 30:70 in 15 min and reequilibration to 90:10 in the following 7 min. The 
column was operated at 35 °C and the peptides were detected at 275 nm, at which 
angiotensin II has an absorbance maximum. ESI-MS spectra were recorded on a Q-TOF 
6540 UHD system (Agilent Technologies, Böblingen, Germany). 
2.4 Conjugation of thiolated Ang II to PEGylated Qdots 
160 pmol Qdots® 655 ITK™ amino PEG were activated in borate buffer pH 8.50 (50 mM) 
with 160 nmol sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(sulfo-SMCC) (Thermo Fisher, Waltham, MA, USA) at room temperature. After 1 h of 
gentle shaking the activated Qdots were purified from unreacted sulfo-SMCC by size 
exclusion chromatography using a Sephadex G-25 resin in a PD-10 column (GE 
Healthcare, Munich, Germany) with DPBS as eluent. Fractions containing activated 
Qdots were collected and pooled. Subsequently, 16 nmol of thiolated angiotensin II (100-
fold excess) were added to the pooled, purified and maleimide-activated Qdots and 
reacted for 1 h at room temperature to yield a stable thioether bond. Unreacted maleimide 
groups on the nanoparticle surface were inactivated with a 100-fold excess of 2-
mercaptoethanol for 30 min. The reaction mixture was purified from excess peptide and 
2-mercaptoethanol by ultrafiltration using a 100 kDa molecular weight cut-off Amicon 
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Ultra-4 filter unit (Millipore, Billerica, MA, USA) for 10 min at 1500 g and size exclusion 
chromatography as described above. Finally the Qdot solution was up-concentrated by 
ultrafiltration. Qdot concentration was determined by fluorescence measurements using a 
FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg, Germany) 
with an excitation and emission wavelength of 450 nm and 650 nm, respectively. 
2.5 Flow cytometry 
The binding of nanoparticles to receptor positive and receptor negative cell lines was 
quantified by flow cytometry measurements. NCI-H295R cells, rat mesangial cells and 
HeLa cells were seeded into 24-well plates (Corning, Corning, NY, USA) at a density of 
150,000 cells/well (NCI-H295R) or 100,000 cells/well (HeLa cells, rat mesangial cells). 
After the cells had been seeded and allowed to grow inside the 24 well-plates for 48 h, they 
were washed with DPBS. Pre-warmed nanoparticle solutions were then added to the cell 
monolayer. Qdot solutions of non-targeted and Ang II-targeted Qdots were prepared in 
Leibovitz’s medium (Life Technologies, Carlsbad, CA, USA) at a concentration of 10 nM 
and supplemented with 0.1 % bovine serum albumin. After a 1 h nanoparticle incubation 
at 37 °C, the cells were vigorously washed with DPBS and trypsinized. Leibovitz’s medium 
containing 10 % FCS was added to the cells to quench the trypsin activity. After 
resuspension of the cells, they were centrifuged (5 min, 200 g), resuspended in DPBS, 
centrifuged again (5 min, 200 g) and finally resuspended in 200 µL DPBS. The cells were 
analyzed for fluorescence with a FACSCalibur flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA). Qdot fluorescence was elicited by excitation at 488 nm and the 
fluorescence was analyzed using a 661/16 nm FL4 bandpass filter. The resulting data was 
analyzed using WinMDI 2.9 (The Scripps Research Institute, San Diego, CA, USA). Only 
the population of intact cells was gated and used for the analysis of cellular fluorescence. 
The geometrical mean, which was used for further analysis and statistics, was determined 
from the fluorescence histogram. 
2.6 Confocal laser scanning microscopy 
NCI-H295R cells and rat mesangial cells were seeded into 8-well µ-slides (Ibidi, 
Martinsried, Germany) at a density of 15,000 cells/well (NCI-H295R) and 10,000 
cells/well (rat mesangial cells). After the cells had adhered to the cell culture plastic, 
nanoparticle binding was assessed. First, cells were washed with warm DPBS. Then, pre-
warmed nanoparticle solutions in Leibovitz’s medium supplemented with 0.1 % bovine 
serum albumin (BSA) were pipetted onto the cells and incubated for 1 hour at 37 °C. 
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After the incubation period, cells were vigorously washed with DPBS. Live cells were 
analyzed in Leibovitz’s medium. Confocal analysis of nanoparticle binding to the cells was 
performed with a Zeiss Axiovert 200 microscope combined with a LSM 510 laser-
scanning device using a 63x Plan-Apochromat (NA 1.4) oil immersion objective (Zeiss, 
Jena, Germany). Qdot fluorescence was elicited by excitation at 488 nm with an argon 
laser and recorded after filtering with a 650 nm longpass filter. The confocal pinhole was 
set to 150 µm, which corresponds to a focal plane of 1.1 µm. For image acquisition AIM 
4.2 software (Zeiss, Jena, Germany) was used. Images were processed using ImageJ (NIH, 
Bethesda, MD, USA, http://imagej.nih.gov/ij).  
For colocalization studies NCI-H295R cells and rat mesangial cells were simultaneously 
incubated with 10 nM Ang II-Qdots and 5 µg/mL Alexa Fluor® 488-labeled transferrin 
(Life Technologies, Carlsbad, CA, USA) in Leibovitz’s medium supplemented with 0.1 % 
BSA for 30 min. After washing with DPBS the adhering cells were analyzed. The green 
Alexa Fluor® 488 dye was excited with a 488 nm argon laser and its fluorescence recorded 
using a 505-530 nm bandpass filter.  
2.7 Intracellular calcium measurements 
The intracellular calcium concentration was measured via a microscope and plate reader-
based system using the ratiometric fluorescent calcium chelator Fura-2. For microscopic 
analysis, NCI-H295R cells were grown on cell culture dishes (Corning, Corning, NY, 
USA) and loaded with 5 µM Fura-2AM (Life Technologies, Carlsbad, CA, USA) in the 
presence of 1X PowerLoad™ permeabilizing reagent (Life Technologies, Carlsbad, CA, 
USA) in a Ringer type buffer (5 mM HEPES, 138.9 mM NaCl, 3.6 mM KCl, 1 mM MgCl2, 
1.3 mM CaCl2, 1.6 mM Na2HPO4 and 5.4 mM NaH2PO4 at pH 7.40) for 1 h at room 
temperature. After extensive washing, the cellular fluorescence was measured at 510 nm 
following excitation at 340 and 380 nm using a Zeiss examiner A1 microscope (Zeiss, 
Jena, Germany), equipped with a WN-Achroplan 40X objective (Zeiss, Jena, Germany). 
Images were continuously acquired at 1 image/second using Axiovision 4.8.2.  
For determination of EC50 values a microplate reader was used. Suspensions of rat 
mesangial cells were incubated with 5 µM fura-2AM (Life Technologies, Carlsbad, CA, 
USA) and 0.05 % Pluronic F-127 in Leibovitz’s L-15 medium (Life Technologies, 
Carlsbad, CA, USA) for 1 h at room temperature in the dark. The cells were repeatedly 
washed by centrifugation (3 x, 5 min, 200 g, RT) and resuspension in Leibovitz’s medium. 
A concentration series of each ligand was pipetted into 96-well plates (Greiner Bio One, 
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Frickenhausen, Germany) at 20 µL per sample (10X concentration) and 180 µL of loaded 
cells (1*106 cells/mL) were injected into the wells. The fluorescence signal was 
immediately recorded with a FluoStar Omega fluorescence microplate reader (BMG 
Labtech, Ortenberg, Germany) for 60 s. Excitation filters for the ratiometric measurement 
were 340/20 nm and 380/20 nm. Emission was recorded using a 510/20 nm bandpass 
filter. The intracellular calcium concentrations were calculated using the Grynkiewicz 
equation [24] as recently described [15]. 
2.8 Statistics 
To assess the statistical significance of flow cytometry data, two-way analysis of variances 
(ANOVA) was carried out with a multiple comparisons test (Tukey’s test) by using 
SigmaPlot 12.2. Levels of statistical significance were set as indicated. 
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3 Results  
3.1 Angiotensin II modification and nanoparticle labeling 
To enable conjugation to amine-decorated PEGylated nanoparticles, angiotensin II was 
covalently modified at the primary amine group of its N-terminal aspartic acid by 
reaction with 2-iminothiolane (also known as Traut’s reagent) in a 2-step reaction 
(Fig. 1A). Reversed-phase high performance liquid chromatography (RP-HPLC) and 
Ellman’s assay with DTNB confirmed the complete conversion of the native peptide into 
the thiolated form (Fig. 1B). Electrospray ionization mass spectrometry (ESI-MS) further 
verified the successful reaction (Fig. 1C). Absence of the (M+3H)3+ peak in the mass 
spectrograph indicated that the conjugation chemically altered a basic group, which 
clearly suggests reaction at the N-terminal aspartic acid.  
The modified Ang II peptide was then coupled to the amine groups of the PEGylated 
Qdots using the heterobifunctional linker sulfo-SMCC (Fig. 1D). Qdots were activated by 
reacting their peripheral amine groups with the sulfo-NHS ester of sulfo-SMCC. After 
purification and removal of unreacted sulfo-SMCC the maleimide-activated nanoparticles 
were covalently conjugated with the thiolated Ang II in a thiol-ene Michael addition click 
reaction to form a stable thioether bond. Transmission electron microscopy revealed that 
the conjugation of the ligand to the Qdot PEG corona did not lead to aggregation. After 
coupling the Qdots remained monodisperse and evenly distributed (Supporting 
information Fig. S1). 
3.2 Nanoparticle binding and uptake 
Nanoparticle binding to selected cell lines was investigated by flow cytometry and 
confocal laser scanning microscopy. AT1R-expressing NCI-H295R cells and rat mesangial 
cells as well as AT1R-negative HeLa cells were incubated with non-targeted and Ang II-
targeted Qdots at a concentration of 10 nM. Although non-targeted Qdots showed some 
association to the AT1-expressing cell lines, binding of Ang II-targeted Qdots to NCI-
H295R and rat mesangial cells was significantly higher (Fig. 2). Conversely, ligand-
coupled Qdots showed no association nor binding to receptor negative HeLa cells, 
indicating that ligand immobilization on the nanoparticle surface was indeed successful.  
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Figure 1: Strategy for angiotensin II conjugation to nanoparticles. (A) First, a thiol group was introduced at 
the N-terminal aspartic acid of angiotensin II using 2-iminothiolane (B) Reversed phase HPLC 
analysis verified the successful two-step reaction (C) Electrospray ionization mass spectrometry (ESI-
MS) of the native and the modified peptide (D) To conjugate the thiolated angiotensin II to 
nanoparticles, PEGylated amine-terminated Qdots were activated with sulfo-SMCC and subsequently 
coupled to the ligand. A thorough purification was performed after each step. 
By confocal laser scanning microscopy, subcellular localization of the nanoparticles was 
analyzed in detail. From this data, it is evident that not only did the ligand-targeted Qdots 
bind to the cell surface, but they were also rapidly taken up into the cells. After just a 30-
minute incubation, the cells had begun to exhibit a massive amount of Qdot fluorescence. 
Nanoparticles were visible in vesicular regions throughout the cytoplasm and seemed to 
accumulate preferentially in the perinuclear region (Fig. 3), whereas non-targeted Qdots 
appeared to adhere in a non-specific manner to the cell surface. When the cells were 
coincubated with Ang II-targeted nanoparticles and losartan carboxylic acid, a specific 
and potent AT1R antagonist, most of the intracellular fluorescence was eliminated, 
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verifying that the nanoparticle uptake was predominantly mediated by the AT1 receptor. 
With the help of fluorescently labeled transferrin the predominant uptake route of the 
nanoparticles was studied in more detail. The distinct endocytic vesicles of Ang II-
targeted Qdots clearly colocalized with the Alexa Fluor® 488-transferrin fluorescence 
(Fig. 4); this was the case for both the NCI-H295R cells and the rat mesangial cells.  
 
Figure 2: Nanoparticle binding to receptor positive and receptor negative cell lines by flow cytometry after 
1 h incubation. Ang II-targeted Qdots strongly associated with AT1R-expressing rat mesangial cells 
and NCI-H295R cells, whereas they showed no association with AT1 negative HeLa cells. Levels of 
statistical signi{cance are indicated as: (†) p < 0.01 compared to fluorescence of untreated control cells; 
(**) p < 0.01 compared to cellular fluorescence of non-targeted Qdots. Data is expressed as mean ± 
standard deviation (n=3). 
3.3 Receptor binding affinity and activation 
The cellular binding affinity and thus the multivalency of both the ligand alone and the 
ligand-conjugated nanoparticles was determined by intracellular calcium measurements 
with the help of the fluorescent calcium chelator fura-2. First, a microscope-based single 
cell tracking approach was used to examine the influence of the highly absorbing 
semiconductor Qdot core on fura-2 emission. When NCI-H295R cells were perfused with 
10 nM of non-targeted Qdots the fura-2 emission ratio was unchanged (Fig. 5A, top). 
However, when the cells were perfused with 10 nM angiotensin II, a sharp increase in the 
emission signal was observed, indicating a calcium influx into the cytosol. When the cells 
were perfused with 10 nM Ang II-targeted Qdots, an increase in the fura-2 emission ratio 
was observed, to an even greater extent than the change elicited by the Ang II peptide 
alone (Fig. 5A, bottom). In addition, a plate reader-based calcium mobilization approach 
was used to pinpoint the receptor binding affinities. Again, non-targeted Qdots showed 
no alteration of the basal calcium signal over a wide range of concentrations (Fig. 5B, top). 
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In contrast, the native angiotensin II peptide bound and activated the receptor with an 
EC50 of 70.1 ± 1.8 nM. Modification of the N-terminal aspartic acid of Ang II by 
introducing a thiol moiety decreased the receptor affinity to 261 ± 25 nM. Likewise, 
introduction of a 5 kDa PEG chain to the N-terminal amino acid lowered the peptide’s 
affinity to 320 ± 42 nM (Supporting information Fig. S2). Ang II-targeted nanoparticles 
activated the AT1 receptor with an EC50 of 8.9 ± 0.3 nM indicating the multivalent nature 
of the nanoparticle binding. Qdot concentrations higher than 30 nM could not be tested 
since the broad and potent Qdot absorbance quenched the Fura-2 emission signal.  
 
Figure 3: Nanoparticle uptake as investigated with confocal microscopy. Ang II-targeted Qdots are readily 
endocytosed by rat mesangial and NCI-H295R cells and located in the perinuclear region of cells. 
Arrowheads mark cell nuclei. The AT1R antagonist losartan carboxylic acid (10 µM) markedly 
inhibited the uptake of ligand-modified Qdots. Non-targeted Qdots showed only weak association to 
cells. 
4 Discussion 
An N-terminal thiolated angiotensin II derivative was synthesized and covalently coupled 
to PEGylated quantum dots. The thiol moiety required for coupling to Qdots was 
introduced at the amino-terminus of the peptide since the negatively charged carboxy 
terminus is essential for receptor binding and activation [25,26]. Thus, the alternative 
modifications using an amide or ester formation at the C- terminus would lead to loss of 
the negative charge and a subsequent loss of the peptide’s and conjugate’s ability to bind 
the AT1 receptor.  
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However, the reaction of the primary amino group of Asp1 with 2-iminothiolane (Traut’s 
reagent) was anomalous and did not immediately form the mercapto group. Instead, an 
N-peptidyl-2-iminothiolane intermediate was generated that had to be hydrolyzed at a 
reduced pH of 5.0 (Fig. 1A). After acid-catalyzed hydrolysis an N-peptidyl-4-
mercaptobutyramide was formed with the intended reactive thiol moiety. This quite 
uncommon reaction pathway has also been observed for bombensin antagonists [27] and 
has been systematically investigated using short dipeptides [28]. The success of the 
subsequent angiotensin II conjugation to the nanoparticle surface was verified by flow 
cytometry and confocal microscopy. HeLa cells, which do not express functional AT1 
receptors [15], were not observed to associate with the obtained nanoparticles. In 
contrast, Ang II-targeted Qdots bound extensively to NCI-H295R and rat mesangial cells, 
both of which are AT1R positive [29,30].  
 
Figure 4: Coincubation of cells with fluorescently labeled transferrin reveals the endocytosis route. Receptor 
positive cells were incubated with Ang II-targeted Qdots and Alexa Fluor® 488 labeled transferrin and 
incubated for 30 min. Colocalization of Qdots and Alexa Fluor® 488 indicate that Qdots are taken up 
by clathrin-mediated endocytosis. 
Qdots were mainly taken up into the cells by clathrin-mediated endocytosis, since most of 
the Qdots were colocalized with fluorescently labeled transferrin, a typical pathway 
marker for both clathrin-mediated uptake [31,32] and early and recycling 
endosomes [33]. Similar to many other GPCRs, the AT1 receptor is mainly internalized by 
clathrin-mediated endocytosis upon agonist binding, which explains why a potent 
inhibitor of clathrin-mediated endocytosis greatly hindered angiotensin II inter-
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nalization [34]. For targeted drug or gene delivery with nanoparticles, uptake of colloids 
into the cell is highly valuable. This is especially true for nucleic acid therapeutics like 
plasmids or siRNA, which have to reach intracellular targets. These molecules usually 
cannot cross the cell membrane by themselves and need potent carriers to promote their 
uptake. Since the AT1 receptor is a Gq-coupled receptor [26], binding of agonist to the 
receptor leads to a calcium influx into the cytosol. Kobilka and coworkers discovered that, 
although intracellular signal transduction via inositol 1,4,5-trisphosphate and Ca2+ 
pathways had been completely desensitized, AT1 receptors were still being rapidly 
internalized after Ang II binding due to the receptor’s immediate recycling [35]. This 
interesting feature of the AT1R underscores the receptor’s feasibility as a nanoparticle 
target, since it allows for extensive nanoparticle uptake into the target cells.  
Non-targeted Qdots, which were not endocytosed after 1 h of incubation, had no effect on 
the basal calcium concentration. In contrast, Ang II-targeted nanoparticles induced a 
calcium influx into the cytosol that was higher compared to the calcium influx that was 
induced by the same concentration of Ang II. When quantified, the EC50 of the native 
peptide and the thiolated peptide were determined to be 70.1 nM and 261 nM, 
respectively. A salt bridge between the terminal amino group Asp1 and the terminal 
carboxy group of Phe8 gives Ang II its classical hairpin-like conformation [36], which also 
stabilizes the binding of the peptide to the receptor [26]. When the terminal Asp1 amino 
group is converted to a thiol moiety, this ion pair formation is no longer possible, 
ultimately leading to nearly 4-fold loss of receptor binding affinity for the N-thiolated 
peptide (Fig. 5B, bottom). Likewise, introduction of a 5 kDa mPEG chain to the amino 
group of Asp1 lowered the receptor affinity by a factor of 4.5 (Supporting information 
Fig. S2). This is in great contrast to the ARB EXP3174, where PEGylation led to a 580-fold 
affinity loss [15]. Since the amino acids of the receptor that contribute to the angiotensin 
II binding are mainly located in the extracellular receptor regions [26], PEGylation only 
had a minor influence on its affinity. On the other hand, because the receptor residues 
that are implicated in antagonist binding are located deep in the transmembrane 
region [37] PEGylation of EXP3174 severely harmed its receptor affinity and led to a 
profound loss of affinity by a factor of 580 [15]. Qdots on which the thiolated Ang II was 
immobilized regained affinity with an EC50 of 8.9 nM, which was approximately 30-fold 
more affine than the thiolated ligand alone.  
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Figure 5: Influence of Ang II-targeted Qdots on cytosolic calcium concentrations. (A) Perfusion of NCI-
H295R cells with non-targeted Qdots does not alter their intracellular calcium concentration, whereas 
incubation with 10 nM Ang II-targeted Qdots led to an influx of calcium ions into the cytosol, 
demonstrating receptor activation. (B) When quantified in a plate reader-based approach, non-
targeted Qdots again show no influence on the cytosolic calcium (top). angiotensin II and N-modified 
angiotensin II bind and activate the receptor with an EC50 of 70.1 ± 1.8 nM and 261 ± 25 nM, 
respectively, whereas Ang II-targeted Qdots activate the AT1 receptor with an EC50 of 8.9 ± 0.3 nM, 
demonstrating a distinct multivalent effect. 
Based on the number of available amine groups on the nanoparticle surface and the 
observed coupling efficiency, we estimate that 5 to 7 ligand molecules were conjugated to 
each Qdot. The same conjugation procedure using endothelial growth factor (EGF) 
instead of angiotensin II resulted in 4 EGF molecules per Qdot [38]. Since Ang II is a 
smaller peptide we believe that a higher ligand number could be conjugated to the 
nanoparticle surface. As defined by Montet [39], 6 Ang II ligands per Qdot would result 
in a multivalent enhancement (MVE, β) of 5 compared to the unbound ligand. Compared 
to the multivalent enhancement of AT1R antagonist-modified nanoparticles, which was 
22.5 [15], the MVE of the Ang II-targeted Qdots was substantially lower. This can be 
explained by the decreased contact time of the colloids with the cell surface. Due to their 
rapid internalization into the cell the time available for each nanoparticle to bind to 
several receptors is limited. However, although this prompt endocytosis weakens the 
multivalent interactions between particles and cells, the increased uptake could be 
immensely useful as a method for increasing intracellular concentrations of molecules 
with otherwise poor membrane permeability. Since cells with a higher receptor expression 
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can be expected to endocytose a significantly higher amount of bound nanocarriers, such 
multivalent interactions could lead to selective drug delivery into specific cells and tissues. 
5 Conclusions 
Ang II-targeted nanoparticles strongly interact with the AT1 receptor in a highly 
multivalent fashion and show no association to cells that do not express the receptor. 
After binding, the colloids are rapidly taken up via clathrin-mediated endocytosis. This 
constitutes the first experimental evidence that the binding of Ang II-targeted 
nanoparticles to their cognate type 1 receptors is multivalent in nature, which potentially 
allows for their use in the targeting of tissue that overexpresses this receptor.  
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1 Transmission electron microscopy 
3 µL of a 60 nM aqueous solution Qdots was pipetted on a carbon-coated copper grid 
(Plano, Wetzlar, Germany) and air dried. The sample was analyzed using a Zeiss Libra 
120 electron microscope (Zeiss, Oberkochen, Germany). Electron microscopy pictures 
were acquired with Image SP (Zeiss, Oberkochen, Germany) and analyzed with ImageJ. 
 
Figure S1: Transmission electron microscopy pictures of Qdots before and after conjugation. The 
conjugation process did not alter the dispersity and did not lead to Qdot aggregation.  
2 PEGylation of angiotensin II 
2 µmol angiotensin II was reacted with 4 µmol mPEG5k-succinimidyl carbonate for 16 
hours at room temperature in borate buffer (50 mM, pH 8.5). mPEG5k-succinimidyl 
carbonate was synthesized as described in the literature [1]. The reaction mixture was 
purified by size exclusion chromatography using a Sephadex G-25 resin in a PD-10 
column with DPBS as the eluent. Fractions containing PEGylated Ang II were pooled and 
further purified by ultrafiltration using a 5 KDa molecular weight cut-off Amicon Ultra-
15 filter unit. Final purity and conjugate concentration were determined using RP18-
HPLC: The HPLC system consisted of a Shimadzu LC-10ATVP pump (Shimadzu, 
Duisburg, Germany), a Shimadzu SIL-10ADVP autosampler connected to a Shimadzu 
SPD-10A UV-Vis detector. A Luna® 5 µm C18(2) 100 Å 250 x 4.60 mm LC column 
(Phenomenex, Aschaffenburg, Germany) was used as separation column. The peptides 
were analyzed based on a linear acetonitrile–trifluoroacetic acid (TFA)–water gradient 
with a flow rate of 1 mL/min. Elution was obtained by using the following gradient of 
solvents A (0.1 % (v/v) TFA in water) and B (0.1 % (v/v) TFA in acetonitrile): 75:25 (A:B) 
to 30:70 in 20 min and reequilibration to 90:10 in the following 7 min. The column was 
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operated at 35 °C. The peptide and its PEG conjugate were detected at 275 nm. The 
affinity of the conjugate was measured with an intracellular calcium mobilization assay 
using fura-2AM. 
 
Figure S2: PEGylation of angiotensin II (A) RP18-HPLC analysis of Ang II and its PEGylated counterpart 
showing the absence of unreacted Ang II. (B) Upon PEGylation, the peptide’s affinity dropped 4.5-fold 
to 320 ± 42 nM 
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Abstract 
The major risk factor for primary open-angle glaucoma is increased intraocular pressure 
stemming from elevated outflow resistance in the trabecular meshwork (TM) region. 
Integrins play a pivotal role in the TM by influencing its biological properties and growth 
factor signaling. Pathologic changes in the TM are partially mediated by growth factors 
like connective tissue growth factor (CTGF). Specific targeting of TM cells could play a 
critical clinical role by increasing the therapeutic efficacy of nanoparticles, e.g. for 
nonviral gene delivery. Quantum dots with cyclo(RGDfC) covalently immobilized to their 
surface effectively targeted cultured TM cells and were rapidly and efficiently endocytosed 
by binding to αvβ3 and αvβ5 integrins. Compared to the integrin-overexpressing U87-MG 
cell line, the association of RGD-modified nanoparticles with the TM cells was 
significantly higher. Binding and uptake into TM cells was receptor-mediated and 
suppressible with free peptide. Soluble cyclic RGD peptides effectively attenuated CTGF-
mediated effects and inhibited CTGF signaling. Due to their antagonism for αvβ3 and αvβ5 
integrins, these cyclic RGD pentapeptides effectively ameliorated the CTGF-induced 
effects and strongly promoted specific nanoparticle association. Thus, cyclic RGD 
peptides are powerful multifunctional ligands for both addressing nanomaterials to the 
TM and interfering with pathologic CTGF signaling upon arrival. 
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1 Introduction 
Primary open angle glaucoma (POAG) is the second leading cause of blindness in the 
world [1] and is characterized by the degeneration of optic nerve axons. The main risk 
factor for POAG is increased intraocular pressure (IOP) due to abnormally high aqueous 
humor outflow resistance in the trabecular outflow pathways. In the trabecular outflow 
pathways, such resistance to flow is generated by the juxtacanalicular tissue (JCT) and 
Schlemm’s canal (SC) endothelium. The causative factors for altered outflow resistance 
appear to be increased contractility of TM cells together with an accumulation of 
extracellular matrix (ECM) in the JCT region [2]. The molecular signaling pathways that 
modulate TM contractility and ECM synthesis in the TM are not yet completely 
understood; however, transforming growth factor (TGF)-β signaling pathways are 
involved in the pathogenetic changes in POAG [3–6]. Recent studies have indicated that 
the action of TGF-β2 on TM is dependent on connective tissue growth factor (CTGF) as a 
downstream mediator [7]. CTGF belongs to the CCN (CYR61/CCN1, CTGF/CCN2, 
NOV/CCN3) family, which consists of six matricellular regulatory proteins [8,9], and is 
strongly and constitutively expressed in the TM [10]. Additionally, CTGF expression is 
markedly upregulated in glaucomatous SC cells compared to the SC cells of healthy 
donors [11]. A therapeutic approach to prevent further pathologic changes within the TM 
could be the inhibition of TGF-β/CTGF signaling pathways: CTGF mainly mediates its 
effects by binding to integrins in various cell types, especially to αvβ3 and αvβ5 integrins. 
Therefore, attenuation of CTGF-dependent effects by blocking specific integrins could 
represent a promising therapeutic approach for POAG patients. 
Although several potent IOP-reducing drugs exist on the market [12], they are commonly 
formulated as eye drop solutions which must be frequently applied [13]. However, due to 
poor patient adherence and improper application technique, anti-glaucoma eye drops 
often do not elicit the desired therapeutic effects [14]. For this reason, gene therapy has 
been intensely researched for glaucoma therapy as a long-term intervention alternative 
[15,16]. Although initial gene therapy efforts utilizing viral vectors experienced early 
success [17], nonviral vectors have not gained traction, due to their low transfection 
efficiency and tissue specificity [18]. 
One way to at least partially overcome these disadvantages is the attachment of targeting 
moieties to a nonviral vector’s surface [19]. A prominent example involves use of the Arg-
Gly-Asp (RGD) motif, which has been successfully deployed in the context of nonviral 
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vector-based cancer therapy [20]. Notably, RGD peptides antagonize αvβ3 and αvβ5 
integrins, which are readily expressed by cells of the TM [21]. Although linear RGD 
peptides have been tested for their influence on IOP [22,23] they have not yet been 
evaluated as targeting moieties for delivering nanoparticles to the TM. We consider RGD 
peptides to be of high potential in this application for two reasons: first, since RGD 
peptides have an inherent influence on matrix-cell interactions due to their capability to 
compete and disrupt cell-matrix contacts [24]. Second, after integrin binding, they have 
demonstrated the ability to rapidly induce receptor-mediated endocytosis [25]. Both 
features provide clear incentives for using RGD peptides as targeting ligands. 
Here, we investigate the feasibility of targeting TM cells with nanoparticles whose surface 
is coated with cyclic RGD peptides. Compared to their linear counterparts, cyclic RGD 
peptides exhibit a 100-fold increased integrin binding affinity [26]. As a model 
nanoparticle platform, highly fluorescent quantum dots (Qdots) were used to enable 
precise tracking of nanoparticles in the cellular environment. To the best of our 
knowledge this is the first in vitro study that uses ligand-coupled nanoparticles for active 
targeting of TM cells, which are among the key actors in the pathogenesis of POAG. 
Furthermore, due to the intrinsic pharmacological effects of the RGD peptides on integrin 
receptors, we investigated their influence on connective tissue growth factor (CTGF)-
induced fibrosis in TM cells. 
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2 Materials and Methods 
2.1 Materials 
Cyclo(-Arg-Gly-Asp-D-Phe-Cys) [cyclo(RGDfC)] was purchased from Bachem 
(Bubendorf, Switzerland). Prior to use, cyclo(RGDfC) was reduced with tris(2-
carboxyethyl)phosphine (TCEP) to cleave any inter-peptide disulfide bonds. 0.4 mg/mL 
cyclo(RGDfC) was incubated with 6 mg/mL TCEP for 1 h under vigorous shaking. 
Human recombinant connective tissue growth factor (CTGF) was isolated from 
transfected HEK293 cells as previously described [7]. Unless stated otherwise all 
chemicals were obtained from Sigma Aldrich (Taufkirchen, Germany) in analytical grade 
and used without further purification. Ultrapure water was obtained from a Milli-Q water 
purification system (Millipore, Billerica, MA, USA).  
2.2 Cell culture 
Human trabecular meshwork (HTM) cells were isolated from the eyes of four human 
donors (donors ranged in age from 34 to 76 years) according to previously published 
protocols [27] and maintained in F10-HAM medium supplemented with 10 % fetal calf 
serum (FCS). TM cells in the third to fifth passage were seeded in 35 mm Petri dishes at a 
density of 4.0 x 105 cells/well. Confluent TM cells were deprived of serum for 24 h, and 
then incubated in fresh serum-free medium containing 50 ng/mL CTGF, 10-6 M 
cyclo(RGDfC) or 50 ng/mL CTGF in combination with 10-6 M cyclo(RGDfC). Treated 
TM cells were then harvested for protein and RNA analyses. 
Human glioblastoma U87-MG cells (ATCC No. HTB-14) were a kind gift from Dr. 
Armin Buschauer (Faculty of Pharmacy and Chemistry, University of Regensburg) and 
were maintained in minimal essential medium containing Earl’s salts (EMEM) and 
supplemented with 10 % FCS. HTM and U87-MG cells were both grown in a 5 % CO2 
atmosphere at 37 °C. In addition, an immortalized SV40-transformed HTM cell line 
(HTM-N) was used. This cell line was provided by Iok-Hou Pang and Louis DeSantis 
(Alcon Research Laboratories, Fort Worth, TX), and was cultured according to previously 
published protocols [28,29]. Methods for securing human tissues were humane, included 
proper consent and approval and complied with the Declaration of Helsinki. 
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2.3 Quantum dot modification with cyclo(RGDfC) 
160 pmol Qdots® 655 ITK™ amino PEG (Life Technologies, Carlsbad, CA, USA) were 
activated with 160 nmol sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (sulfo-SMCC) (Thermo Fisher, Waltham, MA, USA) by gentle shaking in 
borate buffer at pH 8.50 (50 mM) for 1 h at room temperature. The maleimide-activated 
Qdots were purified from unreacted sulfo-SMCC by size exclusion chromatography using 
a Sephadex G-25 resin in a PD-10 column (1.45 x 5.0 cm) (GE Healthcare, Munich, 
Germany). Dulbecco’s phosphate buffered saline (DPBS) at pH 7.4, consisting of 1.5 mM 
KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl and 138 mM NaCl, was used as eluent. Collected 
fractions containing thiol-reactive Qdots were pooled. Next, 16 nmol of reduced 
cyclo(RGDfC) were added to the maleimide-activated Qdots and reacted for 1 h to yield a 
stable thioether bond. Unreacted maleimides were quenched with a 1000-fold molar 
excess of 2-mercaptoethanol relative to Qdots for 30 min. By using a 100 kDa molecular 
weight cut-off Amicon Ultra-4 filter unit (Millipore, Billerica, MA, USA) the reaction 
mixture was purified to remove a large portion of unreacted cyclo(RGDfC) and 2-
mercapoethanol. Qdots were further purified by size exclusion chromatography as 
described above. Last, a final ultrafiltration step was performed to concentrate the Qdots. 
The cyclo(RGDfC)-Qdot concentration was calibrated by fluorescence measurements 
using a FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg, 
Germany), an excitation wavelength of 450 nm and an emission wavelength of 650 nm. 
2.4 Flow Cytometry  
HTM and U87-MG cells were seeded into 24-well plates (Corning, Corning, NY, USA) at 
a density of 100,000 cells/well. After cells had been allowed to grow for 96 h (HTM cells) 
or 48 h (U87-MG), they were washed with DPBS. Nanoparticle solutions of non-targeted 
and c(RGDfC)-targeted Qdots were prepared in binding buffer at a concentration of 
10 nM. Binding buffer for nanoparticle uptake experiments was composed of 20 mM Tris, 
150 mM NaCl, 2 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 and 0.1 % bovine serum albumin 
at pH 7.4 [25]. Cells were incubated with the pre-warmed solutions at 37 °C. After 1 h, the 
nanoparticle solutions were removed and cells were vigorously washed and subsequently 
trypsinized for 5 min. Then, Leibovitz’s medium (Life Technologies, Carlsbad, CA, USA) 
containing 10 % FCS was added to the cells, which were subsequently centrifuged (5 min, 
200 g) and resuspended in DPBS. After a final centrifugation step (5 min, 200 g), cells 
were resuspended in ice-cold DPBS and analyzed for Qdot fluorescence using a 
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FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Qdot 
fluorescence was elicited by using an argon-ion laser at 488 nm; emission was captured 
using a 661/16 nm bandpass filter. The resulting data was processed using WinMDI 2.9 
(The Scripps Research Institute, San Diego, CA, USA). The fluorescence histogram was 
used to calculate the geometrical mean, for which only intact cells were gated. 
2.5 Confocal microscopy  
HTM cells were seeded into 8-well µ-slides (Ibidi, Martinsried, Germany) at a density of 
10,000 cells/well. After cells had been allowed to grow for 120 h, nanoparticle binding was 
assessed. Cells were washed with DPBS and pre-warmed nanoparticle solutions in binding 
buffer were pipetted onto the cells. After incubation for 1 h at 37 °C, Qdot solutions were 
removed and cells washed with pre-warmed DPBS. Cells were analyzed in Leibovitz’s 
medium. Nanoparticle binding to HTM cells was analyzed using a 63x Plan-Apochromat 
(NA 1.4) oil immersion objective with a Zeiss Axiovert 200 microscope equipped with an 
LSM 510 laser-scanning device (Zeiss, Jena, Germany). Using an argon-ion laser, Qdots 
were excited at 488 nm and fluorescence emission was recorded after filtering with a 
650 nm longpass filter. The focal plane was adjusted to 1.1 µm. For image acquisition 
AIM 4.2 software (Zeiss, Jena, Germany) was used. Images were processed using ImageJ 
(NIH, Bethesda, MD, USA, http://imagej.nih.gov/ij). 
2.6 RNA analysis 
Total RNA was isolated from 35 mm Petri dishes using TriFast™ (Peqlab, Erlangen, 
Germany) as described by Chomczynski and Sacchi [30] and according to the 
manufacturer’s recommendations. cDNA was prepared from total RNA using the 
qScript™cDNA Synthesis Kit (Quanta Biosciencies, Gaithersburg, USA) according to the 
manufacturer’s instructions. Real-time reverse transcribed (RT)-PCR was performed 
using the Bio-Rad iQ5 Real-time PCR Detection System (Bio-Rad, München, Germany). 
PCR was run for 40 cycles with 10 s melting at 95 °C and 40 s of annealing and extension 
at 60 °C. Primer pairs (table 1) for CTGF, fibronectin, GNB2L and α-smooth muscle actin 
were purchased from Life Technologies (Darmstadt, Germany) and extended over exon-
intron boundaries. RNA that was not reverse transcribed served as negative control for 
real-time RT-PCR. The accuracy of the amplicons was verified by performing a melting-
curve analysis after amplification. For relative quantification of the experiments, GNB2L 
was used as a housekeeping gene. Quantification was performed using Bio-Rad iQ5 
Standard Edition (Version no. 2.0.148.60623, Bio-Rad). 
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Table 1 
Primer pairs used for real-time RT-PCR 
Type Sequence Position 
Temperature 
(°C) 
Human CTGF 
5’-CTCCTGCAGGCTAGAGAGC-3’ 
5’-GATGCACTTTTTGCCCTTCTT-3’ 
884-977 
59 
60 
Human GNB2L 
5’-GCTACTACCCCGCAGTTCC-3’ 
5’-CAGTTTCCACATGATGATGGTC-3’ 
170-241 
59 
60 
Fibronectin 
5’-CCCTGATTGGAAGGAAAAAGA-3’ 
5’-ATGAAGATTGGGGTGTGGAA-3’ 
6217-
6284 
60 
60 
Human α-smooth 
muscle actin (α-
SM-actin) 
5’-CTGAAGTACCCGATAGAACATGG-3’ 
5’-TTGTAGAAAGAGTGGTGCCAGAT-3’ 
252-328 
59 
60 
2.7 Western blot analysis 
Protein extracts were obtained by directly lysing cells in RIPA lysis buffer containing 
150 mM NaCl, 1 % NP-40, 0.5 % deoxycholic acid and 0.1 % SDS in a 50 mM Tris buffer 
at pH 8. Isolated protein content was measured via the bicinchoninic acid (BCA) kit 
(Interchim, Montluçon Cedex, France). After an electrophoretic separation via SDS-
PAGE, proteins were transferred to polyvinylidene fluoride membranes (Roche, 
Mannheim, Germany). Western blots were probed using rabbit anti-fibronectin (1:1000, 
Dako, Hamburg, Germany) and rabbit anti-(p-)extracellular signal-regulated kinase-1 
(1:1000, Cell Signaling Technology, Danvers, MA, USA) primary antibodies, followed by 
horseradish peroxidase-coupled donkey anti-rabbit (1:2000; Santa Cruz, Heidelberg, 
Germany). Chemiluminescence was detected on an LAS 3000 imaging workstation 
(Raytest, Straubenhardt, Germany) with LuminataTM Forte Western HRP 
chemiluminescent substrate (Millipore, Billerica, MA. USA). The intensity of the bands 
detected by Western blot analysis was determined using appropriate software (AIDA 
Image analyzer software, Raytest). Obtained signals were normalized by detection and 
quantification of α-tubulin. 
2.8 Statistics 
To assess the statistical significance of cell culture data, Student’s t-tests were carried out. 
FACS data was analyzed by two-way ANOVA using SigmaPlot 12.2 (Systat Software, San 
Jose, CA, USA). Levels of statistical significance were set as indicated.  
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3 Results 
3.1 Cyclo(RGDfC)-coated nanoparticles bind primary HTM cells 
To target nanoparticles to HTM cells, amine-bearing quantum dots were functionalized 
with the αvβ3 specific ligand cyclo(Arg-Gly-Asp-d-Phe-Cys) (cyclo[RGDfC]) in a two-step 
reaction (Fig. 1). As recently shown with transmission electron microscopy 
imaging [25,31], this conjugation strategy neither alters the size distribution nor the 
nanoparticle dispersity. The successful conjugation of cyclic RGD peptides to 
nanoparticles was demonstrated by investigating Qdot binding to glioblastoma U87-MG 
cells, using flow cytometry for detection. PEGylated but non-targeted nanoparticles 
exhibited weak association with U87-MG cells whereas binding of cyclo(RGDfC)-
modified particles was 10-fold higher (Fig. 2). When cells were incubated with integrin-
targeted Qdots and a surplus of free cyclic RGD peptide, the mean fluorescence was 
significantly decreased, proving the receptor-mediated nature of the nanoparticle binding. 
Similarly, primary HTM cells were incubated with PEGylated and RGD-targeted 
nanoparticles and analyzed for their fluorescence. When normalized relative to cell 
autofluorescence, HTM cells accumulated a significantly higher amount of nanoparticle 
fluorescence than U87-MG cells; this effect was also reversed in the presence of excess 
cyclic RGD peptide (Fig. 2). Notably, cyclo(RGDfC)-targeted Qdots did not interact with 
immortalized HTM cells (HTM-N), in stark contrast to the impressive binding we 
observed with primary HTM cells.  
 
Figure 1: Scheme for immobilization of cyclo(RGDfC) peptides on PEGylated quantum dots. After 
introduction of thiol-reactive maleimide groups onto the Qdot surface, the thiol moiety of 
cyclo(RGDfC) is reacted with the activated Qdots in a Michael-type addition reaction. Unreacted 
maleimide groups are quenched with 2-mercaptoethanol.  
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3.2 HTM cells rapidly endocytose cyclo(RGDfC)-Qdots 
Since cyclo(RGDfC)-modified nanoparticles showed a strong association with primary 
HTM cells, we asked whether the colloids were taken up into the cells after integrin 
binding. To investigate this, HTM cells were incubated with non-targeted or 
cyclo(RGDfC)-Qdots for 1 h. After removal of non-bound Qdots and thorough washing, 
nanoparticle internalization was visualized by confocal laser scanning microscopy. This 
data clearly illustrates that ligand-modified Qdots were efficiently endocytosed into HTM 
cells (Fig. 3). The cyclo(RGDfC)-Qdot fluorescence was visible in vesicle-like structures 
throughout the cytoplasm, whereas only cell nuclei seemed to be free of nanoparticle 
fluorescence. Co-incubation of cells with cyclo(RGDfC)-Qdots and a surplus of 
cyclo(RGDfC) peptide completely abolished intracellular fluorescence, underscoring the 
αvβ3 integrin-mediated nature of nanoparticle entry into the cell. Conversely, non-
targeted Qdots adhered only sparsely to the cell surface, exhibiting weak nonspecific 
binding.  
 
Figure 2: Flow cytometry data for HTM and U87-MG cells incubated with non-targeted and cyclo(RGD)-
targeted nanoparticles. Non-targeted Qdots show only minor association to the tested cell lines, 
whereas targeted Qdots effectively bind primary HTM and U87-MG cells but not immortalized HTM 
cells. With a surplus of free cyclo(RGD) peptide, the nanoparticle binding can be displaced. Levels of 
statistical significance are indicated as: (**) p < 0.01 compared to non-targeted Qdots; (†) p < 0.01 
compared to cyclo(RGDfC)-Qdots on U87-MG cells; (#) p < 0.01 vs. cyclo(RGDfC)-Qdots. Data is 
expressed as mean ± standard deviation (n=3).  
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3.3 Cyclic RGD peptides ameliorate CTGF-induced fibrosis 
After we verified that cyclo(RGDfC)-targeted nanoparticles bind αvβ3 integrins on HTM 
cells and are rapidly endocytosed, we investigated whether or not the targeting moiety, the 
soluble cyclo(RGDfC) peptide, has intrinsic pharmacological effects on the cells of the 
TM. With the help of qRT-PCR and Western blots, regulation of extracellular matrix 
proteins like fibronectin and important cell signaling proteins on HTM cells was 
determined at the level of both mRNA and protein. Upon treatment with 50 ng/mL 
CTGF, mRNA levels of fibronectin (1.63 ± 0.23 fold, p < 0.05) and α-smooth muscle actin 
(α-SM-actin, 1.81 ± 0.53 fold, p < 0.05) were significantly upregulated (Fig. 4). CTGF 
expression was also significantly increased (1.38 ± 0.28 fold, p < 0.01) upon treatment 
with exogenous CTGF. 
 
Figure 3: Confocal microscopy pictures of primary HTM cells incubated with targeted or non-targeted 
Qdots. Non-targeted Qdots show only weak cellular association. In contrast, cyclo(RGDfC)-Qdots are 
readily taken up by the cells and trafficked into vesicle-like structures. With a surplus of free 
cyclo(RGDfC) peptide, nanoparticle uptake is tremendously decreased, clearly underscoring the 
receptor-mediated nature of this endocytosis. Arrowheads depict cell nuclei, which were free of Qdot 
fluorescence.  
To investigate the influence of the RGD peptide alone, HTM cells were treated with the 
cyclo(RGDfC) peptide at a concentration of 10-6 M. Expression of CTGF (1.24 ± 0.44 fold, 
p > 0.05) and fibronectin (1.27 ± 0.42 fold, p > 0.05) mRNA were slightly elevated 
compared to the control, but not in a statistically discernible manner (Fig. 4), whereas α-
SM-actin mRNA was significantly elevated (1.47 ± 0.47 fold, p < 0.05). However, when 
cells were co-treated with 50 ng/mL CTGF and 10-6 M cyclo(RGDfC), mRNA expression 
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of CTGF (1.02 ± 0.42 fold), fibronectin (0.98 ± 0.40 fold) and α-SM-actin (1.11 ± 0.21 
fold) was significantly lowered compared to the CTGF treatment alone and ultimately 
‘reset’ to the level of the untreated control cells (Fig. 4).  
 
Figure 4: qRT-PCR data for CTGF, fibronectin and α-SM-actin from HTM cells after incubation with 
CTGF, cyclo(RGDfC) or both. Levels of statistical significance are indicated as: (*) p < 0.05 compared 
to control; (**) p < 0.01 compared to control; (#) p < 0.05 compared to CTGF treatment; (n.s.) p > 0.05 
compared to control. Data is expressed as mean ± standard deviation.1 
In a next step we investigated the influence of CTGF and cyclo(RGDfC) on 
phosphorylation of the extracellular regulated kinase 1/2 (ERK1/2) and on fibronectin 
expression in HTM cells via Western blotting. Similar to the results obtained by qRT-
PCR, CTGF treatment significantly increased phosphorylation of ERK1/2 (1.78 ± 0.43 
fold, p < 0.05) and synthesis of fibronectin (2.36 ± 0.30 fold, p < 0.01). Cyclo(RGDfC) 
treatment alone did not result in a significant increase of either pERK1/2 (0.81 ± 0.15 fold, 
p > 0.05) nor fibronectin (1.48 ± 0.62 fold, p > 0.05). When HTM cells were 
simultaneously incubated with CTGF and cyclo(RGDfC), the effects induced by CTGF 
were effectively inhibited by cyclo(RGDfC). ERK1/2 phosphorylation and fibronectin 
synthesis were both significantly lowered to 0.74 ± 0.13 and 0.98 ± 0.45 compared to the 
expression levels of CTGF-treated HTM cells.  
4 Discussion 
Conjugation of αvβ3-specific ligand cyclo(RGDfC) to fluorescent Qdots enabled the 
nanoparticles to efficiently associate with HTM cells. As demonstrated by flow cytometry, 
binding of cyclo(RGDfC)-targeted Qdots to HTM cells was significantly higher than Qdot 
                                                      
1 qRT-PCR data for CTGF, fibronectin and α-SM-actin from HTM cells was obtained and analyzed at the 
Department for Human Anatomy and Embryology (University of Regensburg) by Rudolf Fuchshofer & 
colleagues. 
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binding to U87-MG glioblastoma cells. This is remarkable since U87-MG is a cancer cell 
line that has one of the highest cellular αvβ3 integrin expression levels, with over 100,000 
receptors per cell [32]; for this reason, they are regularly used as a benchmark for RGD-
targeted nanomaterials [33,34]. This pronounced binding of cyclo(RGDfC)-targeted 
Qdots to primary HTM cells signifies the importance of αvβ3 and αvβ5 integrins for the 
TM. Nanoparticle binding to an immortalized, SV40-transformed HTM cell line (HTM-
N) was in stark contrast to the primary HTM cells; cyclo(RGDfC)-Qdots did not show 
higher binding than the non-targeted Qdot control. Similar observations have been made 
by Gagen et al. using immunofluorescence measurements. In their experiments, an 
immortalized TM cell line had no measurable αvβ3 expression, in contrast to cultured but 
non-immortalized cells [21]. Presumably due to immortalization, continued cultivation 
and absence of the physiological environment, αvβ3 integrin expression is drastically 
downregulated in these cells. This also shows that cyclo(RGDfC)-targeted Qdots 
exclusively bind cells expressing αvβ3 integrins. As recently demonstrated, the association 
to αvβ3 negative cells is negligible [25,35]. This is of paramount importance, since the off-
target neural retinal cells show neither αvβ3 nor αvβ5 integrin expression in a healthy 
state [36,37] and would, therefore, be unlikely to exhibit unwanted binding and 
internalization of RGD-functionalized nanoparticles. However, the retinal pigment 
epithelium (RPE), the cell layer that constitutes the outer blood-retinal barrier and that is 
responsible for maintenance of the photoreceptors does show αvβ5 expression on its apical 
side [38] and thus may be an off-target accumulation site if the RGD-functionalized 
nanoparticles are able to cross the inner limiting membrane. Furthermore, it has been 
shown that glial cells can express integrin αvβ3 following injury [36], which would result in 
an off-target site for RGD-targeted nanomaterials in an injured state. 
Confocal microscopy experiments revealed that not only did targeted Qdots bind TM 
cells, but they were also rapidly and efficiently endocytosed. Efficient uptake into target 
cells is known to be a critical determinant of overall efficacy for nonviral vectors [39]. 
Commonly, this uptake is promoted by polycationic carrier polymers such as 
polyethyleneimine, poly-L-lysine or poly(amido amine) dendrimers [40]. At physiological 
pH, their amines are protonated and carry a cationic charge that electrostatically interacts 
with the negatively charged cell membrane, inducing cell uptake [41]. However, the 
polycationic nature of these polymers and lipids also pose inherent toxicity problems; 
these multiple positive charges have the potential to induce apoptosis in a wide range of 
cells [42]. Although cell penetrating peptides such as TAT peptides have been investigated 
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for TM cell targeting [43], their mode of action is much more nonspecific than that of 
RGD-mediated receptor binding [44,45]. As a result, cells without integrin expression 
would also endocytose nanoparticles, ultimately reducing the colloid’s TM availability and 
increasing the risk of undesirable off-target effects. Recently, viral vectors have been 
recombinantly modified to display RGD units on their surface with the aim of increasing 
their tropism at the anterior eye. For adenoviral carriers the RGD motif was incorporated 
into the fiber knob [46] whereas for adenovirus-associated viruses the RGD peptide was 
incorporated into the capsid protein [47]. However, because the non-RGD-modified viral 
vectors were already capable of entry into the TM, RGD modification yielded no 
significant advantage. Besides gene delivery, the nanoparticle-mediated uptake into the 
cell we demonstrate here could also immensely increase the intracellular concentration of 
conventional drug molecules with otherwise poor membrane permeability. Therefore, 
efficient endocytosis into TM cells with low toxic side effects could be one main 
advantage of both RGD-targeted nonviral nucleic acid vectors and nanoparticles loaded 
with drug molecules.  
In a next step, we analyzed functional aspects of the cyclic RGD peptide. As integrin αvβ3 
has been shown to be a potential receptor for CTGF in different cell types [48,49] we 
investigated the influence of the cyclic peptide on CTGF signaling in TM cells. CTGF is of 
interest in POAG as it acts as a critical downstream mediator of TGF-β2 in HTM cells [7] 
– it is found in high concentrations in the aqueous humor of POAG patients [3–6] – and 
because of its increased expression levels in glaucomatous Schlemm's canal endothelial 
cells [11]. CTGF is suggested to play a pivotal role in the formation of increased outflow 
resistance by inducing expression of extracellular matrix proteins like fibronectin and by 
enhancing the contractile properties of TM cells [50]. Wallace and colleagues showed that 
in vitro treatment with a humanized monoclonal anti-CTGF antibody attenuated the 
ECM expression in TM cells after incubation with aqueous humor of POAG patients [51]. 
In our experiments, CTGF-induced effects were significantly halted and reset to control 
expression levels when TM cells were co-incubated with cyclic RGD peptides and CTGF. 
Previously, we were able to show that CTGF activates MAPK signaling pathway by 
increasing the phosphorylation state of ERK1/2 [50]. Elevated pERK1/2 levels lead to 
increased extracellular matrix synthesis in HTM cells [52]. Notably, co-treatment of HTM 
cells with cyclic RGD peptide and CTGF significantly halted pERK1/2 up-regulation. This 
is in agreement with studies by Tan et al., in which a cyclic RGD peptide inhibited CTGF-
induced ERK phosphorylation in chondrosarcoma cells [53]. The reduced pERK1/2 levels 
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were associated with significantly reduced fibronectin synthesis in comparison to CTGF-
treated HTM cells. The potent anti-fibrotic effects of RGD peptides have also previously 
been demonstrated for choroidal neovascularization [54] and liver fibrosis [55,56]. 
Notably, minuscule concentrations of cyclic RGD peptides are known to be potentially 
agonistic for the αvβ3 integrin [57], which could hinder CTGF inhibition if RGD-
nanoparticles are highly diluted at the anterior eye. 
 
Figure 5: Western blot data for pERK1/2 and fibronectin. (A) Treatment with 50 ng/mL CTGF significantly 
increased pERK1 protein after a 3 h incubation period. When co-incubated with 1 µM cyclo(RGDfC), 
pERK1/2 expression was reduced to basal levels. Incubation with cyclo(RGDfC) and without CTGF 
did not influence pERK1/2 expression. (B) Similarly, fibronectin expression was dependent on CTGF 
stimulation. Again, co-treatment with cyclo(RGDfC) inhibited CTGF-induced protein expression. 
Levels of statistical significance are indicated as: (*) p < 0.05 compared to control; (**) p < 0.01 
compared to control; (#) p < 0.05 compared to CTGF treatment; (n.s.) p > 0.05 compared to control. 
Data is expressed as mean ± standard deviation. Equal loading was ensured by detection of α-tubulin.2  
CTGF comprises four structural modules: an amino-terminal insulin-like growth-factor 
(IGF) binding domain, a Willebrand type c (VWC) domain followed by a 
thrombospondin-1 (TSP-1) domain, and a carboxy-terminal cysteine knot (CT) domain 
[58]. Although no specific receptors for CTGF have been identified so far [59], several 
studies have shown that CTGF mediates effects such as adhesion, migration and most 
importantly extracellular matrix protein deposition through activation of integrins [60]. 
                                                      
2 Western blot data for pERK1/2 and fibronectin was obtained and analyzed at the Department for Human 
Anatomy and Embryology (University of Regensburg) by Rudolf Fuchshofer & colleagues. 
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Due to the lack of RGD motifs in the CCN family of matricellular proteins, to which 
CTGF belongs, binding to integrins is thought to be non-RGD-dependent [61]. 
Furthermore, the specific integrin(s) that interact with CTGF are dependent upon cell 
type [62]. Although non RGD-dependent, CTGF’s activation of integrin αvβ3 takes place 
via its fourth module and can be inhibited by linear RGD-containing peptides, as shown 
in hepatic stellate cells [63]. Besides RGD peptides, an αvβ3 integrin-neutralizing antibody 
has also been shown to modulate the effects of CTGF, markedly attenuating CTGF-
induced motility of breast cancer cells [48]. Due to their antagonism for αvβ3 and αvβ5 
integrins, cyclic RGD pentapeptides effectively ameliorate the CTGF-induced fibrotic 
effects in vitro and can be utilized to precisely address nanoparticles to the TM. 
5 Conclusions 
With our present work we provide compelling in vitro evidence for the potential of cyclic 
RGD peptides as powerful targeting moieties for addressing nanoparticles to TM cells. 
Nanoparticles coated with cyclo(RGDfC) peptides showed strong and specific receptor-
mediated uptake into TM cells, whereas cyclic RGD peptides ameliorated CTGF-
mediated matrix production and stress fiber formation. Thus, cyclic RGD peptides 
attached to nonviral vectors could not only increase transfection specificity but also 
effectively attenuate fibrotic events. 
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Summary 
It was more than 100 years ago when Paul Ehrlich coined the idea of the ‘Magic Bullet’, a 
personalized and tailored drug that precisely targets diseased cells in the human body and 
leaves healthy cells untouched [1]. Among many examples that resemble this concept, 
targeted delivery of nanoparticles to specific tissues is often designated as the most 
promising one [2]. Active targeting, which is addressing nanoparticles to individual 
tissues, is usually achieved by conjugating ligand molecules to the colloidal surface. 
Moreover, since multiple ligand molecules can be attached to the particle corona, highly 
sophisticated multivalent material-cell interactions are imaginable. Although they add 
another layer of complexity to the system, they may ultimately determine a particle’s fate. 
A prominent example in which nanoparticle formulations have gained much interest 
recently is the treatment of pathologic neovascularizations in the posterior eye segment. 
Their outstanding features, which include the encapsulation of drugs, the accumulation in 
areas of increased vascular permeability or the controlled release of active ingredients, has 
prompted immense research efforts for the intravitreal but also systemic application. In 
addition, certain nanomaterials exhibit unique anti-proliferative and anti-oxidative effects 
that could impressively expand and improve the current therapeutic arsenal (Chapter 1). 
However, although there are tremendous efforts going into the design and development 
of nanoparticle formulations, the actual amount of novel formulations entering clinical 
trials or being approved is very limited [3]. A potential pitfall that could reduce 
nanoparticle applicability is the loss of nanoparticle targeting efficacy due to ligand 
affinity decrease, which can be a consequence of ligand attachment to the nanoparticle 
polymer corona. EXP3174, a non-peptide angiotensin receptor blocker, underwent a 580-
fold decreased receptor binding affinity after conjugation to a PEG chain. When 
multivalently presented on a nanoparticle surface, initially lost affinity was rapidly 
regained, which was a consequence of the nanoparticle’s capability to bind several 
receptors simultaneously (Chapter 3). However, for this to happen, a sufficiently high 
receptor density is required. Owing to the weak affinity of a monovalent nanoparticle-cell 
interaction compared to the multivalent interaction, the colloids gained the ability to 
differently target cells depending on their receptor expression levels. For this reason, 
Chapter 8 – Summary and conclusion 
206 
EXP3174-targeted Qdots strongly associated with NCI-295R cells that showed a high 
AT1R expression, but not with HeLa cells with a low receptor expression. The receptor’s 
physiological ligand angiotensin II is a potent growth factor and of critical importance for 
neovascularizations in the posterior eye segment. Hence, the type-1 receptor in the ocular 
vasculature is a logical target for nanoparticles that are capable of blocking the receptor 
over an extended period of time. EXP3174-Qdots specifically accumulated in the retinal 
and choroidal vessels but not in off-target tissue such as the kidney, which was attributed 
to the multivalent ligand display. Remarkably, the nanoparticle’s blood circulation time 
did not suffer from ligand attachment but, in contrast, was improved (Chapter 4). 
Since the semiconductor Qdots were mainly used as reporter particles in the preceding 
studies due to their outstanding fluorescence properties, the multivalent binding and 
blocking of AT1 receptors was transferred to drug-polymer-conjugates as potential 
therapeutic agents. EXP3174-modified multi-arm PEGs and generation 5 PAMAM 
dendrimers both blocked AT1R receptors with nanomolar affinity. Due to their unique 
microarchitecture PAMAM dendrimers retained a 6-fold higher receptor binding affinity 
than the branched PEGs, whose lowered affinity was presumably due to hydrophobic 
interactions between EXP3174 and the polymer. Both conjugates showed no measurable 
in vitro cytotoxicity, which was impressively in stark contrast to the unmodified PAMAM 
dendrimers (Chapter 5).  
Compared with antagonist-modified nanoparticles which are not immediately taken up 
but rest at the cell membrane, agonist-modified colloids are promptly endocytosed into 
the cell after receptor activation. However, as tested with calcium mobilization 
experiments the instant cell uptake did not impede the formation of multivalent 
nanoparticle-cell interactions for angiotensin II-targeted Qdots, as the agonist-targeted 
colloids exhibited a 30-fold higher affinity than the free ligand. In a cell binding model the 
ligand-modified Qdots exclusively interacted with receptor expressing cells. The resulting 
receptor-mediated endocytosis occurred via clathrin-coated pits and was inhibitable with 
receptor antagonists. Interestingly, although the immediate uptake did not suppress 
multivalent binding formation, the multivalency was lower than observed for antagonist-
modified nanoparticles (Chapter 6).  
The trabecular meshwork, a sponge-like tissue in the iridocorneal angle of the eye is 
responsible for aqueous humor drainage and thus pivotal key player in the pathogenesis 
of primary open-angle glaucoma. Nanoparticles coated with cyclic RGD peptides and 
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targeted towards integrin receptors were rapidly and massively endocytosed into human 
trabecular meshwork cells. The association to the cultured trabecular meshwork cells was 
significantly higher than the association to the prominent αvβ3 integrin-overexpressing 
glioblastoma cell line U87-MG. As demonstrated by real-time PCR and western blotting, 
the cyclic RGD peptide mitigated connective tissue growth factor-induced fibrotic events 
such as matrix deposition and stress fiber formation. The experimental data convincingly 
illustrated why cyclic RGD peptides are powerful targeting moieties when the aim is to 
address nanoparticles, e.g. for gene delivery, specifically to the trabecular meshwork 
(Chapter 7). 
Conclusion 
The present work unveiled the immense potential of multivalent nanoparticle-cell 
interactions and promising applications thereof. Not only can nanoparticle multivalency 
be utilized to differentially target organs, tissue and cells based on divergent receptor 
expression levels, but it can also be used to amplify cell-specific targeting. The difference 
in multivalent behavior between antagonistic and agonistic nanoparticles targeting the 
AT1 receptor was clearly evident and a result of different receptor responses upon ligand 
binding. In this regard, especially the binding of antagonistic nanoparticles to angiotensin 
receptors of retinal and choroidal blood vessels and thus blockade of these receptors holds 
great potential for tissue-specific attenuation of pathologic neovascularizations. In a 
similar fashion, blockade of integrin receptors by cyclo(RGDfC)-coated nanoparticles and 
cell-specific delivery of therapeutic agents to the trabecular meshwork is a promising 
strategy to enhance glaucoma treatment options that currently appear on the horizon.  
Taken together, the newly gained understanding of nanoparticles and their multivalent 
interactions with cells has significant potential to carve out new paths for treating severe 
diseases of the anterior and posterior eye segment. 
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Abbreviations 
AGEs advanced glycosylation end products 
AMD age-related macular degeneration 
Ang II angiotensin II 
ARB angiotensin receptor blocker 
α-SM-actin α-smooth muscle actin 
AT1R angiotensin II receptor type 1 
ATCC American Type Culture Collection 
AuNP gold nanoparticles 
BAB blood-aqueous barrier 
bFGF basic fibroblast growth factor 
BM Bruch’s membrane 
BRB blood-retinal barrier 
BSA bovine serum albumin  
CC choriocapillaris 
cDNA complementary DNA 
CLSM confocal laser scanning microscopy 
CNV choroidal neovascularization 
CTGF connective tissue growth factor 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DHA docosahexaenoic acid 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethyl sulfoxide 
DPBS Dulbecco’s phosphate buffered saline 
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DR diabetic retinopathy 
DXR doxorubicin 
EC50 half maximal effective concentration 
EDC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
EGF endothelial growth factor 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
EMEM Eagle's minimal essential medium 
EPR enhanced permeation and retention 
ER endoplasmic reticulum 
ERK extracellar-signal regulated kinase 
FA fluorescein angiography 
FCS fetal calf serum 
FDA US Food and Drug Administration 
FITC fluorescein isothiocyanate 
FGF fibroblast growth factor 
FWHM full width at half maximum 
G generation 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GNB2L guanine nucleotide binding protein beta polypeptide 2-like 1 
GPCR G protein-coupled receptor 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HIF-1α hypoxia-inducible factor 1α 
HPLC high performance liquid chromatography 
HTM human trabecular meshwork 
HUVEC human umbilical vein endothelial cells 
IC50 half maximal inhibitory concentration 
ICAM-1 intracellular adhesion molecule-1 
ICP-MS inductively coupled plasma mass spectrometry 
ID initial dose 
IFP interstitial fluid pressure 
IGF insulin-like growth factor 
IgG immunoglobulin G 
IOP intraocular pressure 
INL inner nuclear layer 
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IS inner segments  
IV intravenous 
IVT intravitreal 
JCT juxtacanalicular tissue  
LDL low density lipoproteins 
MES 2-(N-morpholino)ethanesulfonic acid 
MPS mononuclear phagocyte system 
mRNA messenger RNA 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
MVE multivalent enhancement  
MW molecular weight 
NMRI Naval Medical Research Institute 
NP nanoparticle 
OIR oxygen-induced retinopathy 
OPL outer plexiform layer  
ONL outer nuclear layer 
OS outer segments 
PAMAM poly(amido amine) 
PDGF platelet-derived growth factor 
pDNA plasmid DNA 
PDR proliferative diabetic retinopathy 
PDT photodynamic therapy 
PECAM platelet endothelial cell adhesion molecule 
PEDF pigment epithelium-derived factor 
PEG poly(ethylene glycol) 
PI propidium iodide  
PLA poly(lactic acid) 
PLGA poly(lactid-co-glycolide) 
PO peroral 
POAG primary open angle glaucoma 
ppb parts per billion 
PRP panretinal photocoagulation 
Qdots quantum dots 
RGD arginine-glycine-aspartate peptide 
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RPII RNA polymerase II  
RNV retinal neovascularization 
ROP retinopathy of prematurity 
ROS reactive oxygen species 
RPE retinal pigment epithelium 
RP-HPLC reverse phase high performance liquid chromatograpy 
RT room temperature 
SC Schlemm’s canal 
SDS sodium dodecyl sulfate 
SEC size exclusion chromatography 
sulfo-NHS N-hydroxysulfosuccinimide 
shRNA small hairpin RNA 
siRNA small interfering RNA 
SPR surface plasmon resonance 
TEM transmission electron microscopy 
TFA trifluoroacetic acid 
TGF transforming growth factor 
TM trabecular meshwork 
VEGF vascular endothelial growth factor 
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